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Propositions 
1. Foam cell formation in mesenteric lymph nodes of Angptl4-/- mice after high fat 
feeding is uncoupled from peritoneal ascites and acute inflammation. 
(this thesis) 
 
2. Safe targeting of ANGPTL4 against dyslipidaemia may lie in the partial but not full 
repression of this protein.  
(this thesis) 
 
3. Based on evidence at the cellular and molecular level, the harmful effects of trans 
fats are over-exaggerated. 
 
4. Classification of fatty acids into saturated, cis- and trans-unsaturated fatty acids 
downplays the specificity and unique properties of every individual fatty acid. 
 
5. Definition of a biological cell as “the basic unit of life” is an oversimplification of 
the complexity that a cell displays in the lab. 
 
6. “Science communication to non-scientific audience” should be made a mandatory 
course at the Masters’ and PhD level. 
 
7. An expert is the person who has had ample time to right his wrongs. 
 
8. In several parts of Africa today, a biomedical research scientist is a luxury. 
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Classification of fatty acids 
Fats are a class of lipids that consist of biomolecules such as phospholipids, cholesterol 
and triglycerides. The triglyceride component of fats is hydrolysable and consists of 
three fatty acid molecules that are esterified to glycerol. Therefore, fats are efficient 
energy substrates and fuel stores in the body. Fats are also important for insulating 
internal body organs, for maintaining normal core body temperature and for the 
absorption and storage of fat-soluble vitamins such as Vitamins A, D, E and K. The types 
of fatty acids that constitute a triglyceride are important for determining its functional 
and physiological properties [1]. 
Fatty acids consist of chains of hydrophobic hydrocarbons with a terminal carboxylic 
acid functional group. Fatty acids can be essential or non-essential. Essential fatty acids 
cannot be synthesized endogenously and must be consumed via the food. Linoleic and 
linolenic acids are essential fatty acids. Almost all other fatty acids can be synthesized 
endogenously from linoleic and linolenic acids or from non-fatty acid precursors and are 
therefore non-essential [2,3]. Fatty acids are also categorised as saturated or unsaturated. 
Saturated fatty acids do not contain a double bond because all carbon atoms in the chain 
are fully bonded to hydrogen atoms. Palmitic and stearic acids are common saturated 
fatty acids and are found mostly in meat, butter, lard, and palm oil. Unsaturated fatty 
acids possess one or more double bonds and are mostly from plant sources. Unsaturated 
fatty acids with only one double bond are distinguished as mono-unsaturated fatty acids 
(MUFAs). Oleic acid is the most commonly consumed MUFA and it is rich in olive oil, 
peanut oil, avocado and other nut-based oils. The presence of two or more double bonds 
categorizes an unsaturated fatty acid as a poly-unsaturated fatty acid (PUFA). PUFAs 
can further be divided into omega-3 or omega-6 depending on the position of the double 
bond relative to the last (omega) carbon at the methyl end.  Alpha-linolenic acid (ALA) 
is an omega-3 PUFA contained richly in linseed and hempseed oils, whereas 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are omega-3 PUFAs 
found in microalgae and fish. Linoleic and arachidonic acids are examples of omega-6 
PUFAs and are common in poultry, cereals and nuts. These MUFAs and PUFAs belong 
to the more common cis-unsaturated fatty acids because the hydrogen atoms around all 
double bonds point in the same plane. However, less abundant trans-unsaturated fatty 
acids also exist. In trans fatty acids, the hydrogen atoms that surround one or more of the 
double bonds point in opposite directions [1,4]. 
 
 General Introduction 
 
 
9 
 
In general, most MUFAs and PUFAs are known to have beneficial effects on human 
health but saturated and trans fatty acids have been implicated in several human diseases 
such as obesity, insulin resistance, diabetes, cardiovascular diseases and cancer [5–7]. 
Trans fatty acids 
Trans fat is a term that is used to describe triglycerides that are rich in trans fatty acids. 
Trans fatty acids are unsaturated fatty acids that contain at least one double bond 
surrounded by trans-configurated hydrogen atoms. Trans fatty acids are less abundant in 
human diets compared to their cis isoforms. 
The artificial synthesis of trans fatty acids became commercialized after Dr Peter 
Normann patented its industrial production over a century ago [8]. Such artificial trans 
fatty acids are products of partial hydrogenation of vegetable oils in the presence of a 
chemical catalyst. This industrial process converts liquid PUFA-rich vegetable oil into 
solid trans fatty acid-rich fats. Foods that are high in trans fatty acids have the benefit of 
easier packaging, improved texture, improved taste and increased shelf life. Food 
products such as margarine, shortenings, crackers, cookies, and deep fried foods are all 
rich in industrial trans fatty acids [9]. Industrial production aside, relatively small 
amounts of trans fatty acids are produced by intestinal microbes of ruminants. These 
trans fatty acids are often referred to as natural or ruminant trans fatty acids and are 
present in the meat and dairy products of these animals. Elaidic acid is the most abundant 
industrial trans fatty acid in the diet and represents about 80% of total trans fatty acids 
consumed by humans, whereas trans-vaccenic acid is the most abundant natural trans 
fatty acid [9,10].  
A number of epidemiological and clinical studies have shown a strong association 
between trans fatty acid intake and coronary heart disease [11–13]. It is now known that 
a 2% increase in energy resulting from trans fatty acid consumption increases the risk of 
heart disease by 23% [14]. Based on these findings, Denmark was the first country to 
ban the consumption of foods that contain industrial trans fatty acids [15]. Today many 
other countries have laws that restrict or completely ban food companies from 
incorporating trans fatty acids into food products [16–20]. Across Europe, the European 
Union (EU) never took any legislative action in order to remove trans fats from the food 
supply. Instead, the European food industries voluntarily committed themselves to 
reduce the trans fatty acid content of foods to a maximum of 2% of the total fat content. 
While the overall trans fatty acid content of foods has dropped, the lack of legislation 
has prevented many food manufacturers, mostly concentrated in Eastern Europe, from 
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taking action. The residual presence of trans fat in the EU food supply should drive 
legislators to consider additional public health approaches to further reduce trans fat 
intake in Europe, including imposing legal limits on trans fat content in foodstuffs, 
mandatory and voluntary trans fat labelling, and voluntary food reformulation pledges. 
In October 2018, the EU solicited input on a new proposal that would set a maximum 
limit of 2% for trans fat content in foodstuffs. Food which does not comply to the new 
regulation may continue to be placed on the market until April 1 2021.These efforts have 
resulted in a substantial decline in total trans fatty acid intake [21]. However, many other 
countries do not have such policies or regulations against trans fat consumption. 
Additionally, a complete elimination of dietary trans fat is impossible due to existence 
of natural trans fatty acids. 
Trans fat and cholesterol metabolism 
Cholesterol is a lipophilic sterol biomolecule that forms a structural component of animal 
cell membranes and is important for maintaining cell fluidity, division, survival, and 
function. It is also a precursor for the synthesis of steroid hormones, bile acids, and 
vitamin D [22]. Notwithstanding its importance, an excessive amount of cholesterol in 
plasma and tissues is implicated in cardiovascular diseases and must therefore be tightly 
regulated [23]. Cholesterol is obtained from exogenous and endogenous sources. 
Exogenous cholesterol is obtained from the diet, absorbed through the small intestine, 
and packaged into chylomicron particles for onward secretion. Endogenous cholesterol 
is synthesized mainly in the liver, packaged into lipoprotein particles (VLDL) and 
secreted into the circulation [24]. Circulating VLDL gives rise to LDL after removal of 
apolipoproteins C and E, and hydrolysis of the triglyceride content of VLDL by 
lipoprotein lipase and hepatic lipase. The resulting  LDL particles composed mainly of 
apolipoprotein B (apoB), cholesterol and cholesteryl esters are the major determinant of 
plasma cholesterol levels [25,26]. Through reverse cholesterol transport, circulating 
cholesterol that are contained in HDL particles are taken up by the liver for bile acid 
synthesis or excretion through faeces [27]. Clinical studies have shown that elevated 
levels of non-HDL cholesterol or apoB-containing lipoproteins such as LDL, VLDL and 
their remnant particles are associated with higher risk of cardiovascular diseases [28,29].  
In the early 1990s, a ground-breaking study conducted in Wageningen showed that 
industrial trans fatty acids significantly increase plasma levels of total and LDL 
cholesterol but decrease levels of HDL cholesterol in healthy individuals [30–32]. This 
raised serious concerns about the safety of dietary trans fatty acids. In the same study, 
saturated fatty acids also increased levels of LDL cholesterol but showed no effect on 
 General Introduction 
 
 
11 
 
HDL cholesterol compared to cis-unsaturated fatty acids [30]. This led to the conclusion 
that in comparison to saturated fatty acids, industrial trans fatty acids likely have stronger 
deleterious consequence on cardiovascular health. Subsequently, a number of clinical 
and pre-clinical studies have attempted to investigate the underlying mechanisms for the 
reported harmful effects of trans fatty acids [33–36]. However, it is still unclear which 
molecular and cellular processes mediate the effects of trans fatty acids. This has fuelled 
our research interest to investigate the molecular mechanisms of trans fatty acids. 
Transcriptional regulators of cellular lipid metabolism   
A number of transcription factors have been studied for their role in cellular lipid 
metabolism. These transcriptional factors include peroxisome proliferator-activated 
receptors (PPARs), sterol regulatory element binding proteins (SREBPs), liver X 
receptor (LXR), carbohydrate-responsive element-binding protein (ChREBP), farnesoid 
X receptor (FXR) and NF-E2–related factor-2 (NRF2) [37].  
In this thesis, we found that industrial trans fatty acids regulate the transcriptional activity 
of SREBP2. Also, we purposely investigated the response of Angptl4-deficient mice to 
diets rich in industrial trans fatty acids. Since ANGPTL4 is direct target of PPARs, the 
focus in the subsequent sections will be on SREBP and PPARs for their direct relevance 
to the research contained in this thesis. 
Sterol regulatory element binding proteins (SREBPs) 
SREBPs are transcription factors that regulate lipid metabolism through transcriptional 
regulation of genes involved in fatty acid and cholesterol synthesis. Three isoforms of 
SREBPs have been identified and characterised: SREBP1a, SREBP1c and SREBP2 [38–
40]. All three isoforms of SREBP are localised intracellularly in the endoplasmic 
reticulum membrane as inactive precursors. SREBP1c is much strongly activated by 
anabolic hormones such as insulin, while  SREBP2 activation is strongly induced by low 
levels of intracellular cholesterol [41]. Therefore SREBP2 preferentially induces the 
expression of genes for cholesterol synthesis, SREPB1c prominently upregulates the 
expression of fatty acid synthesis genes whereas SREBP1a is less-specific towards 
inducing either cholesterol or fatty acid synthesis genes [42,43]. In response to low levels 
of cholesterol, the sterol sensor protein, SREBP-cleavage activating protein (SCAP) 
initiates activation of SREBPs by transporting SREBPs to the Golgi apparatus. In the 
Golgi apparatus, SREBP is cleaved sequentially by Site-1 and Site-2 proteases to 
produce the active forms. The active SREBP enters the nucleus and binds to the specific 
loci called SREBP-response element (SRE) that are located at the promoter regions of 
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target genes. This results in transcriptional activation and mRNA expression of SREBP 
target genes involved in cholesterol and fatty acid synthesis [42,43]. Typically, SREBP 
activation promotes mRNA expression of cholesterol biosynthesis genes such as HMG-
CoA reductase (HMGCR), HMG-CoA synthase (HMGCS), and mevalonate kinase 
(MVK), as well fatty acid biosynthesis genes such as fatty acid synthase (FASN), ATP-
citrate lyase (ACYL) and acetyl-CoA carboxylase (ACC) [44,45]. 
Peroxisome proliferator activated receptors (PPARs) 
PPARs are nuclear receptors and serve as transcriptional regulators of genes involved in 
fatty acid metabolism. They are activated in response to binding specific ligands. PPARs 
exist in 3 isoforms; PPAR-alpha (PPARα), PPAR-gamma (PPARγ) and PPAR-
beta/delta (PPARβ/δ). PPARα is strongly expressed in the liver, but also in the brown 
adipose tissue. PPARγ is most highly expressed in both white and brown adipose tissue, 
large intestines and in macrophages, while PPARδ is strongly expressed in skeletal and 
cardiac muscles as well as many other tissues [46–48]. Activation of PPARs can be 
achieved nutritionally through fatty acids, physiologically through fasting, and 
pharmacologically through high-affinity agonists such as fenofibrate, Wy14643 and 
rosiglitazone [49–51]. Activated PPARs form a heterodimer with the Retinoid-X 
receptors in order to bind to a unique sequence called PPAR response element (PPRE) 
located in or around target genes [52,53]. The target genes of PPARs are involved in 
numerous biological pathways related to nutrient and energy metabolism [54,55]. 
Specifically, several target genes of PPAR are known to be directly involved in lipid 
metabolism, one of which encodes Angiopoietin-like 4 (ANGPTL4) [47,56]. 
Angiopoietin-like 4 (ANGPTL4) 
ANGPTL4 is a member of the angiopoietin-like family of proteins that includes seven 
additional members numbering ANGPTL1 to 8. The Angptl4 gene encodes a protein of 
406 amino acids that is approximately 50 kDa in size. ANGPTL4 was discovered in 2000 
as a target gene of PPAR following a fasting study in PPARα-null and wild-type mice 
and was therefore named as fasting-induced adipose factor (FIAF) [57]. The ANGPTL4 
gene consists of 7 exons and 6 introns, with a PPAR-response element (PPRE) located 
within intron 3 [58]. ANGPTL4 is ubiquitously expressed in the adipose tissue, liver, 
kidney, intestine, cardiac and skeletal muscles, as well as in macrophages [56,57,59]. 
The ANGPLT4 protein is made up of an N-terminal coiled-coiled domain and a C-
terminal fibrinogen-like domain that are connected by a linker region. It is well 
established that ANGPTL4 has a major impact on lipid metabolism via its N-terminal 
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domain. Less is known about the role of C-terminal portion of ANGPTL4. A number of 
studies have shown that C-terminal or full length ANGPLT4 is involved in various 
biological processes such as angiogenesis [60,61], wound healing [62], tumorigenesis 
[63–65] and kidney function [66].  
The N-terminal domain of ANGPLT4 directly regulates circulating levels of plasma 
triglycerides by inhibiting the enzyme lipoprotein lipase (LPL) [67–69]. LPL functions 
as an extracellular lipase that hydrolyses triglycerides contained in circulating 
triglyceride-rich lipoproteins such as chylomicrons and VLDL. The resultant free fatty 
acids are taken up by the underlying tissues for storage or as energy substrates [70,71]. 
Non-functional LPL due to inhibition by ANGPLT4 results in increased levels of 
circulating triglycerides. Therefore, ANGPTL4 plays an important role in maintaining 
systemic triglyceride homeostasis under different physiological, nutritional, and clinical 
conditions [72,73]. In humans, a loss-of-function mutation in ANGPTL4 leads to a 
reduction in levels of plasma triglycerides with an associated reduced odds of developing 
coronary artery disease [74,75]. Therefore, current research is investigating the potential 
targeting of ANGPTL4 as a strategy against dyslipidaemia and associated cardiovascular 
diseases. 
Outline of thesis  
The research contained in this thesis has two overarching aims: (1) to probe the 
mechanisms of cellular lipid metabolism with a focus on trans fatty acids and (2) to 
further characterize the lipid-sensitive ANGPTL4 protein for its role in lipid metabolism 
and the potential of targeting ANGPTL4 for correcting cardiometabolic disorders. 
Chapter 1 is a general introduction and explanation of the key terms and concepts of 
this thesis. Chapter 2 presents a contemporary review of existing literature on the 
molecular effects of trans fatty acids. In Chapter 3, we have compared the physiological 
response of mice to diets enriched in either trans-unsaturated, cis-unsaturated or 
saturated fatty acids. At the molecular level, we investigated the effects of elaidate, oleate 
and palmitate as representatives of trans-unsaturated, cis-unsaturated and saturated fatty 
acids, respectively, using murine and human cell lines. In Chapter 4, we have studied 
the response of Angptl4-/- mice to the different types of dietary fat as used in Chapter 3. 
We were specifically interested in the response of Angptl4-/- mice to diets rich in trans 
fatty acids. We complemented the mice findings with in vitro experiments in murine 
macrophages. In Chapter 5 of this thesis, we investigated the clinical potential of 
targeting ANGPTL4 by studying the effects of fasting and a high saturated fat diet in 
ANGPTL4-hypomorph mice with complete deletion of the C-terminal domain of 
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ANGPTL4, and a partial expression of the N-terminal LPL-inhibiting domain. 
Additionally, Chapter 5 also investigates the influence of ANGPTL4 on lipid uptake 
by macrophages. Chapter 6 contains a collaborative research project that investigated 
the role of muscle specific inflammation on whole body insulin sensitivity in mice. 
Chapter 7 is a general discussion of the major outcomes of these studies, 
recommendations for future studies and a final conclusion.  
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Abstract 
Studies in humans have established a positive association between intake of industrial 
trans fatty acids and the development of cardiovascular diseases. The strength of the 
association is such that several countries have enacted laws that restrict the incorporation 
of industrial trans fatty acids in food products. However, trans fatty acids cannot be 
completely eliminated from the human diet since they are also naturally present in meat 
and dairy products of ruminant animals. Moreover, bans on industrial trans fatty acids 
have not yet been instituted in all countries. The epidemiological and clinical evidence 
against trans fatty acids by far overshadows mechanistic and molecular insights that may 
explain how these trans fatty acids achieve their damaging effects. In this review, the 
cellular and molecular studies on trans fatty acids are compiled in an attempt to improve 
our understanding of the molecular mechanisms that underlie their deleterious effects. 
In doing so, effects of trans fatty acids will be juxtaposed against those of cis-unsaturated 
and saturated fatty acids. This review will also carefully explore the argumentation that 
natural trans fatty acids from ruminants have contrasting effects to artificial trans fatty 
acids from industrial sources. Overall, a number of in vivo and in vitro studies 
demonstrate that industrial trans fatty acids promote inflammation and ER stress 
although to a much lower extent compared to saturated fatty acids, whereas cis-
unsaturated fatty acids are protective against ER stress and inflammation. Also, 
industrial trans fatty acids promote storage of fat in the liver at the expense of fat tissue 
compared to cis-unsaturated and saturated fatty acids. In cultured liver and adipocyte 
cells, industrial trans fatty acids but not cis-unsaturated or saturated fatty acids stimulate 
the cholesterol synthesis pathway by activating SREBP2-mediated gene regulation. The 
effects of trans fatty acids on inflammation, ER stress and cholesterogenesis appear to 
be specific to industrial but not ruminant trans fatty acids. Clearer insight into the 
molecular mechanisms of action of trans fatty acids may create new therapeutic windows 
for the treatment of diseases characterised by disrupted lipid metabolism. 
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Introduction 
Trans fatty acids are unsaturated fatty acids that contain one or more unconjugated 
double bond in the trans configuration. The term trans fats is used to describe 
triglycerides that are rich in trans fatty acids. The majority of trans fatty acids are 
generated during industrial processing through partial hydrogenation of vegetable oils 
rich in poly-unsaturated fatty acids. Foods containing these industrially produced 
artificial trans fatty acids carry several benefits including improved texture, better taste, 
and enhanced longevity [1–3]. The enhanced shelf life prompted heightened use and 
consumption of trans fatty acids during the first and second world wars, when food was 
in short supply. In 1957, twelve years after World War II, a study by Dr. Fred 
Kummerow showed that lipid extracts of specimens from 24 human subjects who died 
of heart disease contained up to 12.2% trans fatty acids in their adipose tissue, 14.4% in 
liver, 9.3% in heart tissue, 8.8% in aortic tissue and 8.8% in atheroma [4]. Subsequent 
studies such as conducted by Thomas and colleagues showed that the level of trans fatty 
acids in adipose tissue of persons who died of coronary heart disease was significantly 
higher compared to persons who died of other causes [5,6]. In 1990, Mensink and Katan 
firmly demonstrated the plasma cholesterol-raising effect of trans fatty acids in human 
volunteers [7]. Several years later, Willett and colleagues found that in the Nurses’ health 
study, after adjustment for age and total energy intake, intake of trans fatty acids was 
positively associated with risk of coronary heart disease [8]. Also, in a case-control 
study, Thomas had found that in the fat tissue of subjects who died of ischemic heart 
disease, the content of  trans palmitoleic acid was significantly higher compared with the 
fat tissue of subjects who died of unrelated causes [9]. The studies that strongly 
connected the intake of trans fatty acids with cardiovascular derailment were initially 
abhorred by players in the margarine industry. However, this later fuelled more research 
into the pro-atherogenicity of trans fatty acids. Collectively, these studies strongly 
suggest a causal relationship between trans fatty acid consumption and the development 
cardiovascular diseases in humans [8,10–14]. In response to this finding, a number of 
countries enacted laws that either restrict or completely ban food companies from 
incorporating trans fatty acids into their food products. Whereas in many countries food 
items such as margarine, crackers, bakery products, cookies and deep fried foods were 
previously loaded with industrial trans fatty acids, nowadays the levels of trans fatty 
acids in these foods are very low, which has resulted in a substantial decline in the intake 
of industrial trans fatty acids in many countries [15–24]. However, trans fatty acids 
cannot be completely removed from human diets as ruminant trans fatty acids exist. 
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These trans fatty acids, which include vaccenic acid and rumenic acid, are generated 
through bio-hydrogenation of poly-unsaturated fatty acids in the guts of ruminant 
animals and are therefore present in meats and dairy products [25–27]. In addition, 
industrial trans fatty acids persist in our food supply because laws aimed at banning 
industrial trans fatty acids have not yet been instituted in every country. 
Because the health concerns connected to the consumption of industrial trans fatty acids 
could be mitigated by removing them from foods, there has been little incentive for basic 
researchers to probe mechanistic insights related to trans fatty acids. The end result is a 
marked imbalance between the vast amount of epidemiological data on trans fatty acids 
and health outcomes and the limited understanding of the molecular mode of action of 
trans fatty acids. By collating the cellular and molecular studies on trans fatty acids, this 
review aims to improve our understanding of the molecular mechanisms underlying the 
deleterious effects of trans fatty acids. To achieve this objective, some parallels will be 
drawn between the literature on trans fatty acids and other relevant types of fatty acids. 
In addition, this review will carefully dissect the argumentation that ruminant trans fatty 
acids have contrasting effects to artificial trans fatty acids produced during industrial 
processing. 
Chemistry of trans fatty acids 
Trans fatty acids are defined by the presence of one or more trans unconjugated double 
bonds in their aliphatic hydrocarbon chain. In the trans configuration, the two hydrogen 
atoms around the double bond point towards opposite planes, whereas in the cis 
configuration, these hydrogen atoms point in same direction. In comparison to the cis 
form, the trans double bond produces a more extended fatty acid-carbon chain due to 
greater bond angle, giving rise to a straight chain tertiary structure akin to that of 
saturated fatty acids (Figure 1) [2,28]. Differences in tertiary structure affect crystalline 
packaging, which in turn influences physicochemical properties such as the melting 
point. For example, the 18-carbon cis oleic acid is liquid at room temperature, with a 
melting point of 14 oC. By contrast, elaidic acid, which is the trans geometric isomer of 
oleic acid, has a much higher melting point at 45 oC and is solid at room temperature. 
For comparison, the fully saturated stearic acid has a melting pint of 69 oC [29]. As 
discussed below, evidence exists to show that beyond affecting their geometric 
isomerisation and physicochemical properties, the cis-trans configuration of fatty acids 
has a major influence on the physiological properties after consumption in humans. 
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Figure 1. Structure of the geometric isomers of C18 fatty acids showing elaidic acid with trans double 
bond, oleic acid with cis double bond and fully saturated stearic acid. 
Trans fatty acid effect on molecular players of heart disease 
Although the majority of studies performed on trans fatty acids are observational, a 
substantial number of experimental studies have been performed. These studies vary 
from studies in cultured cells and animal models to human clinical trials. A number of 
these studies have provided evidence that certain trans fatty acids influence the 
regulation of physiological processes such as lipid metabolism, inflammation, oxidative 
stress, endoplasmic reticulum (ER) stress, autophagy, apoptosis and even the gut 
microbiota. The dysregulation of some of these biological pathways by trans fatty acids 
has been invoked as a potential underlying mechanism that contributes to the negative 
effects of trans fatty acids on cardiometabolic health [30–32]. 
Plasma cholesterol and lipoprotein profile 
Elevated levels of plasma cholesterol are a risk factor for cardiovascular disease. 
Cholesterol is transported in the blood mainly as part of low-density lipoproteins (LDL) 
and high-density lipoproteins (HDL). Smaller amounts of cholesterol are also contained 
in the triglyceride-rich chylomicrons, very low-density lipoproteins (VLDL), and their 
remnant particles. Increased levels of non-HDL cholesterol or apolipoprotein B (apoB)-
containing particles are associated with increased risk of cardiovascular diseases [33–
35]. 
Several studies have examined the effect of trans fatty acids on plasma cholesterol levels 
and lipoprotein dynamics. Randomized controlled trials carried out at Wageningen 
University in the 1990s showed that a diet rich in trans fatty acids from partially 
hydrogenated sunflower oil significantly increased the serum concentration of total and 
Trans-unsaturated elaidic acid 
Saturated stearic acid 
Cis-unsaturated oleic acid 
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LDL cholesterol but decreased HDL cholesterol in comparison with cis-unsaturated or 
saturated fatty acid-rich diets [7,36]. In a separate randomized controlled trial conducted 
in 32 healthy men and women, trans fatty acid intake from partially hydrogenated 
soybean oil decreased serum HDL cholesterol levels but had no effect on LDL 
cholesterol and triglyceride levels in comparison with a saturated fat diet [37]. In another 
study conducted in 50 normocholesterolemic men, intake of a trans fatty acid rich diet 
significantly increased plasma levels of total and LDL cholesterol with no significant 
effect on HDL cholesterol and triglyceride levels [38]. In providing some mechanistic 
insights, Mauger and colleagues have reported that the atherogenicity of trans fatty acids 
may lie in part in their ability to reduce LDL particle size in a dose-dependent manner 
[39]. Matthan and colleagues have likewise shown in hypercholesterolemic women that 
the deleterious lipoprotein profile caused by trans fatty acid intake is partly explained by 
increased apoA1 and decreased apoB100 catabolism [40]. Interestingly, a limited 
number of studies did not find a significant deleterious effect of trans fatty acid intake 
on plasma lipid levels [41,42]. These discrepant results are potentially due to the use of 
a different reference or control diet. Additionally, differences in amounts of trans fatty 
acids consumed may account for some of the conflicting findings, as the effect of trans 
fatty acids on plasma lipids seems proportional to intake [43]. Overall, it can be 
concluded that the positive association between trans fatty acid intake and cardiovascular 
risk is likely at least partly explained by the unfavorable effect of trans fatty acids on 
plasma LDL cholesterol and the overall lipoprotein profile. 
Inflammation 
Inflammation is characterized by pain, swelling, redness, heat, and loss of function. It is 
the dominant response of body tissues to various types of harmful stimuli, including 
radiation, physical stress, and harmful chemicals. In addition, inflammation can be 
induced by microbial infection and tissue damage and as such is an essential mechanism 
of the innate immune response [44,45]. Sterile inflammation describes inflammation that 
occurs in the absence of an infection and is a symptom of numerous chronic diseases and 
pathologies, including atherosclerosis. Indeed, in addition to being a lipid-driven 
process, atherosclerosis is primarily an inflammatory disease characterized by the 
accumulation of macrophage foam cells in the vascular wall, triggering the secretion of 
numerous inflammatory mediators and leading to the recruitment of other immune cells 
[46]. One mechanism by which trans fatty acids may promote atherogenesis is by 
activating inflammation [32]. In randomized controlled trials, diets that contained trans 
fatty acids increased plasma levels of inflammatory markers such as C-reactive protein 
(CRP), TNFα, IL-6, IL-1β, and MCP-1 in healthy men [47], in subjects with moderate 
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hypercholesterolemia [48], and in overweight women [49]. Furthermore, in a cross-
sectional study in patients with heart disease, levels of trans fatty acids in red blood cell 
membranes, which is a marker for intake, were positively associated with several 
inflammatory markers [50].  
Due to ethical constraints and other challenges connected with human studies, 
mechanistic probing into the pro-inflammatory effects of trans fatty acids has been 
conducted in animal models and in vitro experiments. Two separate studies in the 
atherosclerosis-prone LDL-receptor knockout mice shed some light on the molecular 
properties of trans fatty acids obtained from partially hydrogenated soybean oil. In both 
studies, the industrial trans fatty acids not only increased plasma levels of total and LDL 
cholesterol but also increased levels of plasma inflammatory cytokines as well as 
cytokines released into culture medium from primary macrophages when compared to a 
PUFA-rich diet [51,52]. Secondary to the induction of inflammation, the mice on the 
trans fatty acid diet showed increased accumulation of activated macrophages in the 
enlarged atherosclerotic lesions located in the aortic intima [51,52]. Another animal 
study reported that ad libitum feeding of C57BL/6 mice with a diet supplemented with 
partially hydrogenated vegetable oil resulted in a hepatic necro-inflammatory phenotype 
characterised by a marked increase in hepatic TNFα expression [53]. The pro-
inflammatory effect of trans fatty acids seems robust and transcends specific animal 
models. In PPARα deficient mice as well as in mice with full body or liver-specific 
knockout of 11β-HSD1, trans fatty acid-enriched diets enhanced activation of NF-kB 
[54] and increased hepatic expression of Tnfa, Mcp1, osteopontin and macrophage 
markers [54,55]. At the cellular level, the activation of the transcription factor NF-kB by 
the industrial trans elaidic and linoelaidic acids but not cis-unsaturated linoleic acid was 
demonstrated in human microvesicular endothelial cells (Figure 2). In this study, the 
authors found that the profound activation of NF-kB signalling by industrial trans fatty 
acids is a consequence of enhanced IkBα phosphorylation, which subsequently leads to 
elevated levels of IL6 and TNFα [56]. In a recent study, Hirata and colleagues showed 
that in comparison to both control and oleic acid, elaidic acid stimulated apoptotic cell 
death in RAW264.7 macrophages through hyperactivation of the apoptosis signal-
regulating kinase 1 (ASK1)-p38 mitogen-activated protein (MAP) kinase pathway that 
resulted in increased inflammation [57]. 
Whereas the above studies point to pro-inflammatory effects of trans fatty acids, a 
number of other studies have reported neutral or anti-inflammatory effects of certain 
trans fatty acids. We recently showed in ANGPTL4 deficient C57Bl/6 mice that a diet 
rich in trans fatty acids from partially hydrogenated soybean oil did not induce 
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inflammation compared to a diet high in saturated fatty acids. Mice deficient in 
ANGPTL4—an endogenous inhibitor of lipoprotein lipase—have a unique phenotype 
characterized by the development of a massive acute phase response upon consumption 
of a diet rich in saturated fatty acids. The saturated fatty acid-enriched diet markedly 
increased plasma levels and hepatic expression of serum amyloid A, haptoglobin and 
lipocalin, whereas  the trans fatty acid-enriched diet did not [58]. Studies in RAW264.7 
macrophages showed that certain trans fatty acids such as elaidic acid have a neutral 
effect or modestly decrease inflammatory markers, whereas saturated fatty acids such as 
palmitic and stearic acid increase mRNA expression and protein levels of inflammatory 
and apoptotic markers [58]. Accordingly, whether trans fatty acids should be classified 
as pro-inflammatory may depend on the reference, e.g. no treatment, cis unsaturated fatty 
acids, or saturated fatty acids. Notwithstanding the considerations, experimental data 
from clinical studies, animal and cell culture experiments suggest that the deleterious 
effects of trans fatty acids may be partly mediated by activating inflammation. 
 
 
Figure 2: Proposed molecular mechanisms of trans fatty acids. 
Abbreviations: TFA, trans fatty acid; UPR, unfolded protein response; ER, endoplasmic reticulum; ATF6, 
Activating transcription factor 6; ATF4, Activating transcription factor 4; XBP1s, X-box binding protein 1, spliced 
form; NF-κB, nuclear factor kappa-B; p-IκB phosphorylated Ikappa B; TNFa, tumor necrosis factor-alpha; IL6, 
interleukin 6; IL1b, interleukin 1 beta; ROS, reactive oxygen species 
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Endoplasmic reticulum (ER) stress, Reactive oxygen species (ROS) production and 
Oxidative stress 
At the cellular level, environmental, physiological and pathological insults can generate 
varying degrees of stress, such as ER and oxidative stress, which negatively affect cell 
function. The ER is a cellular organelle that plays important functions in calcium 
homeostasis, lipid metabolism, protein synthesis and post-translational modifications. 
Stress to the ER impairs ER function and results in activation of the unfolded protein 
response (UPR). The UPR comprises a signalling cascade that promotes cell survival but 
can also lead to apoptotic cell death if the stress persists [59]. Meanwhile, ROS are highly 
reactive chemical species that are generated during various biochemical processes. In 
low and controlled amounts, ROS serve important signalling functions and initiate 
certain biological processes, such as cell proliferation and inflammation. However, high 
levels of ROS due to imbalance between ROS production and antioxidant defence can 
result in oxidative stress and subsequent damage to lipids, DNA and  protein [60,61]. 
Certain fatty acids, especially when present in excessive amounts, are known to be 
injurious to cells due to their modulatory effects on ER stress, ROS production, and 
oxidative stress [31]. In the study of the molecular mechanism of trans fatty acids, ER 
and oxidative stress have been invoked as potential mediators of the harmful effects of 
trans fatty acids (Figure 2). In coronary artery disease patients, a correlation was found 
between plasma levels of trans fatty acids and the severity of the disease. In these 
patients, antioxidant enzymes such as erythrocyte glutathione peroxidase and superoxide 
dismutase activities were significantly decreased concomitant with increases in oxidative 
stress and lipid peroxidation [14]. A number of animal studies and cell culture 
experiments have further examined the role of ER stress and oxidative stress as 
mechanistic mediators of the effects of trans fatty acids. A number of animal studies and 
cell culture experiments have further examined the impact of ER stress and oxidative 
stress. In a mouse model of hyperlipidaemia, a diet containing elaidic acid but not oleic 
acid increased atherosclerotic lesion size [62]. The mice fed elaidic acid showed 
significant increases in superoxide production and the expression of NADPH oxidase in 
the aortic vessel wall. The authors recapitulated the in vivo findings in cultured smooth 
muscle cells incubated with elaidic acid to further underscore the role of ROS and 
oxidative stress as mediators of trans fatty acid-induced atherosclerosis [62]. In C57Bl6/J 
mice [63] and Wistar rats [64], the presence of industrial trans fatty acids in the diet 
resulted in hepatic lipotoxicity characterized by an increase in oxidative stress and a 
decrease in antioxidant activity of catalase, superoxide dismutase, and glutathione 
peroxidase.  
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Events in the endothelial lining of blood vessels are known to be important in the 
pathogenesis of vascular diseases. In human umbilical vein endothelial cells, both elaidic 
and linoelaidic acid increased ROS production in a dose-dependent manner through 
increased activity of caspase 3 prior to apoptosis induction [65]. Furthermore, in human 
microvascular endothelial cells, elaidic and linoelaidic trans fatty acids increased 
superoxide production leading to vascular inflammation through enhanced NF-kB 
signalling [56]. One study explored the possible mechanisms behind the neurotoxic 
effects of elaidic acid in neuroblastoma cell line. It was found that along with increased 
ER stress, elaidic acid induced ROS production and decreased activity of antioxidants, 
which resulted in  oxidative damage and apoptosis [66]. By contrast, in RAW264.7 
macrophages, elaidic acid showed similar inability to induce ER stress as oleic acid. 
Whereas palmitic acid potently induced ER stress characterized by enhanced mRNA and 
protein expression of several stress markers including CHOP and XBP1(s), elaidic acid 
had only modest to no effects [58]. Taken together, there is evidence that compared to 
cis-unsaturated fatty acids, trans fatty acids may promote oxidative stress and to a lesser 
extent ER stress, which may contribute to their deleterious effects.  
Autophagy 
Autophagy refers to self-cannibalism. Specifically, autophagy describes an adaptive 
response to stress during which organelles and other intracellular components are 
degraded in the lysosome as a way of recouping energy substrates for cell survival and 
maintenance of cell integrity. Nutrient shortage, sub-lethal damage and adaption to 
changing environmental conditions are important triggers of autophagy. Autophagy 
involves a complex signalling cascade comprising essentially of phagophore formation, 
conjugation of autophagy related proteins (ATGs), microtubule-associated protein 
1A/1B-light chain 3 (LC3) processing and association with the phagophore membrane, 
the capture of targets for degradation, fusion between autophagosomes and lysosomes, 
and the proteolytic degradation of engulfed targets by lysosomal proteases [67,68]. Few 
studies have investigated fatty acids in general as triggers of autophagy and even less so 
for trans fatty acids [69]. One study conducted in primary cardiac myofibroblasts showed 
that trans-vaccenic and elaidic acid induce apoptosis secondary to autophagy induction 
[70]. Compared to non-treated control, both trans fatty acids stimulated autophagosme 
formation, LC3-β lipidation, LC3-II formation and ATG5-12 accumulation concomitant 
with elevated levels of cleaved caspases 9, 3, 7 and enhanced translocation of Bax to the 
mitochondria [70]. This study highlighted trans fatty acids as potent stressors to 
myofibroblasts culminating in pre-mature apoptosis. A recent study, however, reported 
contrasting results in U2OS cells that stably expressed different biosensor markers of 
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autophagy, unfolded protein response, and golgi stress. In these cells, the trans fatty acids 
elaidic and trans-vaccenic acid inhibited autophagy induced by saturated fatty acids [71]. 
The suggestion was raised that the lipotoxicity of trans fatty acids may reside in their 
ability to inhibit cytoprotective stress response induced by saturated fatty acids [71]. So 
far, it is rather difficult to make tangible conclusions from these few and seemingly 
incoherent studies. Additional work is needed to clarify the exact role of trans fatty acids 
in autophagy and its implication on cardiometabolic health.  
Gut microbiota 
The human gut contains trillions of bacteria that are categorized into over 1,000 species. 
These microbes are important for shaping the intestinal immune response and for the 
degradation of complex polysaccharides, leading to the production of metabolites such 
as short chain fatty acids (SCFAs) [72,73]. Studies of the gut microbial populations have 
revealed an association between changes in gut microflora and certain human diseases 
such as obesity, inflammatory bowel disease, diabetes, cardiovascular diseases and 
cancer [74–77]. It is now known that a harmonious symbiotic relationship between the 
resident gut microbes is important to maintain good health. A disturbance in harmony 
and biodiversity due to external factors such as diet can promote the outgrowth of 
pathogenic or opportunistic subpopulation. In humans and mice, diets rich in certain 
types of fatty acids have been suggested to alter metabolic health due in part to a 
reorganisation of certain species of the gut microbiome [78,79]. A recent study 
specifically investigated the effect of a diet enriched with industrial trans fatty acids from 
partially hydrogenated soybean oil on the gut microbiota in C57BL/6 mice. Compared 
to a control diet that contained no trans fatty acids, the trans fatty acid-enriched diet not 
only resulted in liver steatosis and intestinal inflammation, but also increased relative 
abundances of ‘harmful’ Proteobacteria and Desulfovibrionaceae, and decreased 
abundances of ‘beneficial’ bacteria that belong to Bacteroidetes, Lachnospiraceae, and 
Bacteroidales S24-7 [80]. Studies on trans fatty acid regulation on gut microbiota are 
very few. Accordingly, whether the gut microbiota have a causal role in mediating the 
effects of trans fatty acids on cardiometabolic disorders is unclear and requires further 
investigation. 
Molecular effects of trans fatty acids on liver 
The liver serves as the hub of lipid metabolism. In the liver, an intricate balance exists 
between the uptake, storage, synthesis, and oxidation of lipids in order to maintain local 
and systemic lipid homeostasis. Aberrant hepatic lipid metabolism can lead to 
dyslipidaemia and non-alcoholic fatty liver disease (NAFLD), both of which are 
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important risk factors for cardiovascular disorders [81,82]. A number of studies have 
shown that the liver bears the brunt of trans fatty acid-mediated pathology. In mice, the 
intake of diets rich in industrial trans fatty acids has been shown to promote liver damage, 
characterised by elevated levels of plasma alanine aminotransferase activity and 
increased plasma levels of acute phase proteins including serum amyloid A and 
haptoglobin [53,83–85]. Furthermore, histological staining of liver slices have showed 
profound fat accumulation in mice fed diets rich in industrial trans fatty acids as well as 
histological indications of NASH and cirrhosis [53,54,86,87]. In a number of animal 
studies, the steatotic liver phenotype was associated with increased expression of genes 
involved in lipogenesis, including Fasn, Acaca, and Srebp1 [54,84,87]. In a recent study 
in Chapter 3 of this thesis, we found that a diet rich in industrial trans fatty acids markedly 
increased the ratio of liver to gonadal fat mass, plasma alanine aminotransferase activity, 
and plasma acute phase proteins in comparison with diets enriched in cis-unsaturated 
and saturated fatty acids. Additionally, the diet rich in industrial trans fatty acids 
increased steatosis, hepatic cholesterol levels, and fibrosis markers, suggesting enhanced 
NAFLD. 
In conjunction with these studies in mice, several studies have examined the effect of 
elaidic acid on lipid metabolism in human and murine hepatoma cells. It was found that 
elaidic acid stimulated SREBP1c-dependent lipid synthesis in human Huh-7 cells 
through enhanced expression SREBP target genes [88]. Nielsen and colleagues applied 
an integrated lipidomics, transcriptomics and proteomics approach in human HepG2 
cells to demonstrate that elaidic acid, but not oleic or palmitic acid, potently enhanced 
expression of key enzymes involved in cholesterol and fatty acid biosynthesis. Relative 
to oleic acid, elaidic acid upregulated SREBP2 expression along with several other 
cholesterogenic genes such as HMGCo-A reductase, squalene epoxidase and mevalonate 
kinase [89]. We recapitulated the findings of Nielsen and colleagues in murine Hepa1-6 
hepatocytes and showed an unequivocal role of SREBP2 in mediating the effect of trans 
fatty acids on lipid/cholesterol metabolism (Chapter 3 of this thesis). Specifically, we 
found that elaidic acid potently upregulates the expression of genes involved in 
cholesterol synthesis and induces the expression and activity of SREBP2. Silencing of 
Srebp2 by siRNA-mediated knockdown abrogates the cholesterogenic effect of elaidic 
acid. The Srebp2 activation by elaidic acid is likely due to lowered levels of intracellular 
free cholesterol since cholesterol is a negative regulator of the SREBP signalling 
pathway. A previous study reported that elaidic acid is a high affinity substrate for the 
esterification of cholesterol into cholesterol esters [90], which might explain why elaidic 
acid reduces levels of intracellular free cholesterol. In support of this hypothesis, elaidic 
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acid was shown to increase the expression of the cholesterol esterification enzyme, Sterol 
O-acyltransferase 1 (Soat1) [89]. In our hands, although elaidic acid significantly 
lowered levels of free cholesterol, there was no concomitant increase in levels of 
cholesterol ester. Furthermore, silencing of Soat1 did not abrogate the induction of 
cholesterol synthesis genes by elaidic acid. Accordingly, enhanced cholesterol 
esterification likely does not explain the increase in SREBP2 activity by elaidic acid. 
Rather, elaidic acid appears to decrease the sensitivity of SCAP to cholesterol (Chapter 
3 of thesis). Overall, the cholesterogenic effect of elaidic acid can at least partly be 
ascribed to its ability to reduce the levels of intracellular free cholesterol and decrease 
the sensitivity of SCAP to cholesterol. This anabolic effect of elaidic acid may contribute 
to the deleterious effect of industrial trans fatty acids on lipid metabolism. 
Molecular effect of trans fatty acids on adipose tissue  
White adipose tissue is the principle organ responsible for the storage of excess energy 
and fat. Compared to the liver, fewer studies have reported the effects of trans fatty acids 
on adipose tissue. Most human studies that have investigated the effects of trans fatty 
acids on adipose tissue have focussed on conjugated linoleic acids (CLAs). CLAs are a 
distinct class of naturally occurring trans fatty acids that require a full review on its own, 
as done elsewhere [91,92] and therefore will only be discussed briefly here. In the United 
States, 10E,12Z CLA is marketed commercially as a natural weight loss supplement due 
to its reported ability to reduce adipose tissue mass [93,94]. Notwithstanding their 
potential health benefits, a number of studies have revealed that intake of CLAs may 
cause negative side effects such as increasing plasma markers of inflammation and 
oxidative stress [93], liver damage [95], and inflammation in macrophages [96]. In mice, 
diets that contain 10E,12Z CLA remarkably reduced fat mass yet at the same time 
promoted hyperinsulinemia, adipose tissue inflammation, and liver damage [97–100]. In 
3T3-L1 adipocytes, 10E,12Z CLA enhanced lipid utilization by stimulating lipolysis and 
fatty acid oxidation, thereby impairing triglyceride storage [101]. The increased lipid 
oxidation was associated with increased mitochondrial ROS production and a 
proinflammatory response, characterised by increased expression of Mcp-1 and Il-6 
[101].  
Apart from CLAs, a diet enriched with elaidic acid reduced fat tissue mass in LDL-
receptor knockout mice along with an increase in liver mass and liver steatosis [87]. 
Consistent with these findings, in Chapter 3 of this thesis, we show that feeding wild-
type C57BL6/J mice a high fat diet rich in industrial trans fatty acids reduced adipose 
tissue mass but increased liver mass compared with isocaloric diets rich in cis-
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unsaturated or saturated fatty acids. The decrease in adipose tissue mass was 
accompanied by a strong upregulation of genes involved in fatty acid and cholesterol 
synthesis in both gonadal and inguinal fat tissue depots [102]. The evidence from these 
studies suggests that diets rich in trans fatty acids cause preferential fat accumulation in 
the liver at the expense of fat tissues. The fat tissue seems to compensate for this anomaly 
by stimulating de-novo lipogenesis. What molecular mediators account for preferential 
fat trafficking to the liver is unknown. These intriguing observations warrant further 
investigation, as any mechanistic insight gained could be utilised to redirect fat towards 
specific tissues under different physiological states to avert ectopic fat accumulation and 
potentially diminish NAFLD. 
Molecular effects between industrial and ruminant trans fatty acids  
Public health policies that are meant to restrict consumption of trans fatty acids are 
rendered less efficient due to the existence of ruminant trans fatty acids. As previously 
mentioned, trans fatty acids can be of industrial or ruminant origin. The concentration of 
industrial trans fatty acids in partially hydrogenated vegetable oils can be as high as 60%, 
with elaidic acid as main trans fatty acid [27,103]. Trans-vaccenic acid is the most 
abundant ruminant trans fatty acid and represents 50-80% of total ruminant trans fatty 
acid intake [26,104]. Previous understanding that all trans fatty acids have similar 
pathophysiological effects has proven less accurate in light of evidences emerging from 
studies that discriminated between industrial and ruminant trans fatty acids. In a meta-
analysis by Brendsten and colleagues, only intake of industrial but not ruminant trans 
fatty acids showed a positive association with coronary heart disease [25]. In LDL-
receptor knockout mice, elaidic acid enhanced the progression of atherosclerosis by 
stimulating inflammation and oxidative stress, whereas trans-vaccenic acid decreased 
aortic atherosclerotic plaque formation [62]. It can be hypothesized that the different 
position of the trans double bonds in elaidic and trans-vaccenic acid may lead to 
differences in fatty acid signalling, cellular transport, and incorporation into cell 
membranes [105]. 
A number of in vitro studies also underscore the different properties of industrial and 
ruminant trans fatty acids. In HepG2 cells, elaidic acid increased protein levels of 
enzymes involved in cholesterol synthesis and transport, whereas trans-vaccenic acid 
showed no such effect [106]. Similarly, in Hepa1-6 and 3T3-L1 adipocytes, elaidic acid 
distinctly induced the expression of cholesterol and fatty acid synthesis genes in contrast 
to trans-vaccenic acid. Also, Hirata and colleagues showed that elaidic and lionelaidic 
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acids but not trans-vaccenic acid induce inflammation and superoxide production in 
human microvascular endothelial cells [56].  
In spite of the reported contrasting effects of industrial and ruminant trans fatty acids, 
other studies report no such differences [107]. In a quantitative review of the existing 
literature, Brouwer and colleagues concluded that trans fatty acids raise the ratio of 
plasma LDL to HDL cholesterol independent of their ruminant or industrial origin [108]. 
In a randomized controlled study in healthy men, ruminant and industrial trans fatty acid 
diets had similar effects on plasma lipoproteins by significantly increasing levels of 
plasma LDL-cholesterol and lowering levels of plasma HDL-cholesterol [109]. Studies 
in cultured macrophages suggest that industrial and ruminant fatty acids behave similarly 
with respect to cytotoxicity and inflammation. In RAW264.7 macrophages, both elaidic 
acid and trans-vaccenic acid induced apoptotic cell death and inflammation [57]. In a 
separate study in RAW264.7 macrophages, palmitate potently induced gene markers of 
inflammation and ER stress, which could not be reproduced with either industrial and 
ruminant trans fatty acids [58]. 
Taken together, evidence from both pre-clinical and clinical studies shows that industrial 
and ruminant trans fatty acids have differential effects, depending on the biological 
pathway and clinical outcome measures under investigation. It is conceivable and indeed 
suggested that the proposed positive effects of ruminant trans fatty acids could be due to 
a relatively lower intake compared to industrial trans fatty acids [25]. Nonetheless, the 
underlying mechanisms for such reported differences are still unclear. From a 
biochemical perspective, the differences in the source and slight change in the position 
of the trans double bond may not justify the separate classification of industrial and 
ruminant fatty acids. However, there are numerous examples of bioactive molecules in 
which a slight change in molecular structure has a profound impact on the biological 
properties. Indeed, the position of the trans double bond could impact the extent to which 
fatty acids are taken up, sensed, metabolised, and incorporated into cellular organelles 
and membranes. Such potential mechanisms are still poorly delineated and warrant 
further investigation. 
Conclusion 
Epidemiological studies have indicated that intake of industrial trans fatty acids is 
associated with increased risk of cardiovascular disease. Clinical studies in humans have 
shown that this association is likely explained by an increase in total and LDL cholesterol 
levels and a decrease in HDL cholesterol levels by industrial trans fatty acids. Pre-
clinical studies in mice and cultured cells have partly clarified the molecular mechanisms 
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of action of trans fatty acids. In cultured cells, trans fatty acids stimulate inflammation, 
ER stress, and oxidative stress, although less potently than saturated fatty acids. Besides 
impacting on inflammation and stress-related pathways, trans fatty acids have a profound 
influence on lipid metabolism. In mice, industrial trans fatty acids promote the 
preferential storage of fat in the liver at the expense of fat tissue. Studies in cultured liver 
cells indicate that industrial trans fatty acids stimulate the cholesterol synthesis pathway 
by activating SREBP2-mediated gene regulation.  
Overall, the reported distinct effects of industrial and ruminant trans fatty acids in vitro 
and in vivo prevents the grouping of all trans fatty acids as a single entity. From an 
evolutionary perspective, certain animals have conserved the ability to endogenously 
synthesize certain types of trans fatty acids, rendering it unsurprising that such ruminant 
trans fatty acids may carry certain benefits. Presently, there is still limited understanding 
of the mechanism of action of trans fatty acids. Accordingly, further mechanistic studies 
are required to fully clarify both defined and undefined properties of industrial and 
ruminant trans fatty acids. Gaining deeper understanding of the molecular mechanism of 
action of trans fatty acids may create new therapeutic windows for the treatment of 
diseases characterised by disrupted lipid metabolism. 
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Abstract 
Objective: Consumption of industrial trans fatty acids unfavourably alters plasma 
cholesterol levels and has been linked to non-alcoholic fatty liver disease (NAFLD). 
However, the molecular mechanisms underlying these deleterious effects of trans fatty 
acids are unclear. Here, we aim to investigate the molecular mechanisms of industrial 
trans fatty acids.  
Methods: To this end, in vitro experiments were conducted in Hepa1-6 and 3T3-L1 cells 
incubated with elaidate, oleate, and palmitate as model for trans-unsaturated, cis-
unsaturated and saturated fatty acids, respectively. Animal experiments were performed 
in male C57Bl/6 mice that were fed diets rich in trans-unsaturated, cis-unsaturated or 
saturated fatty acids for 7 weeks, after which plasma, liver, and adipose tissues were 
collected and analysed. 
Results: Transcriptomics analysis of 3T3-L1 adipocytes and Hepa1-6 cells indicated that 
elaidate but not oleate or palmitate potently induced expression of genes involved in 
cholesterol biosynthesis. Induction of cholesterogenesis by elaidate in Hepa1-6 cells was 
mediated by an increase in SREBP2 and dependent on SCAP, yet independent of LXR 
and UBXD8. Elaidate decreased intracellular free cholesterol levels and repressed the 
anti-cholesterogenic effect of exogenous cholesterol. Despite activating the SREPB2 
pathway, elaidate decreased abundance of the LDL receptor in an SREBP2-independent 
and SCAP/SREBP1-dependent manner. In mice, the trans-unsaturated diet markedly 
increased the ratio of liver to gonadal fat mass, plasma alanine aminotransferase activity, 
and plasma acute phase proteins relative to the cis-unsaturated and saturated diets. 
Additionally, the trans-unsaturated diet increased steatosis, hepatic cholesterol levels, 
and fibrosis markers, suggesting enhanced NAFLD. 
Conclusion: Elaidate induces cholesterogenesis via activation of the SCAP-SREBP 
axis, likely by lowering intracellular free cholesterol and attenuating cholesterol-
dependent repression of SCAP translocation. This pathway potentially underlies the 
increase in liver cholesterol and NAFLD by industrial trans fatty acids. 
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Introduction 
Trans fatty acids are unsaturated fatty acids with at least one double bond in the trans 
configuration. Compared to the more common cis-unsaturated fatty acids, trans-
unsaturated fatty acids are less flexible and maintain a straight chain carbon backbone, 
similar to saturated fatty acids [1,2]. Most of the trans fatty acids consumed by humans 
are industrially produced by partial hydrogenation of vegetable oils and are present in 
deep fried foods, pastries, cookies, margarine, and popcorns. A small proportion of trans 
fatty acids are synthesized naturally in the gut of ruminants by bacterial bio-
hydrogenation and are present in meat and dairy products of cattle, goat and sheep [3–
5]. Partially hydrogenated vegetable oils and trans fatty acids are used by the food 
industry because they confer a combination of beneficial properties to food products, 
including a long shelf life and a pleasant mouthfeel. In response to growing evidence 
linking intake of trans fatty acids to coronary heart disease, most food manufacturers and 
retailers have largely removed trans fatty acids from their products. The 2018 Dutch 
Nutrition Survey indicated that nowadays, trans fatty acids only provide approximately 
0.3% of the daily energy requirement, as opposed to 5-10% several decades ago. 
In a landmark study in 1990, Mensink and Katan demonstrated the plasma cholesterol-
raising effect of trans fatty acids in human volunteers [6]. Specifically, they found that 
trans fatty acids raise plasma LDL cholesterol and reduce plasma HDL cholesterol levels. 
Following this important finding, multiple epidemiological studies found strong positive 
associations between consumption of industrial trans fatty acids and the onset and 
progression of coronary heart disease [7–10]. A recent meta-analysis convincingly 
established  that intake of trans fatty acids is positively associated with all-cause 
mortality, total coronary heart disease, and coronary heart disease mortality [11].  
In addition to coronary heart disease, trans fatty acids have also been connected with 
other diseases, including non-alcoholic fatty liver disease [12–14]. Indeed, several 
studies have shown that feeding mice a diet rich in industrial trans fatty acids enhances 
liver steatosis and features of NASH [15–19]. The increase in liver triglycerides was 
associated with elevated expression of lipogenic genes, such as Fasn, Acaca, and Srebp1. 
Remarkably, little is known about the mechanism(s) that underlie the increase in liver 
triglycerides and lipogenic gene expression in mice fed diets rich in trans fatty acids. 
Because the health concerns connected to the consumption of industrial trans fatty acids 
have been largely allayed by their removal from foods, unfortunately there has been little 
effort into trying to understand the molecular mechanisms underlying the detrimental 
effects of trans fatty acids. In a recent study, we found that the industrial trans fatty acid 
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elaidate and the saturated fatty acid palmitate had very distinct effects on markers of 
inflammation and the unfolded protein response in murine RAW264.7 macrophages. In 
addition, it was observed that elaidate upregulated the expression of putative target genes 
of sterol regulatory element binding proteins (SREBPs) [20], an observation that was 
further confirmed in studies in human hepatoma HepG2 and Huh7 cells [21,22]. 
SREBPs, consisting of SREBP1 and SREBP2, are basic helix-loop-helix–leucine zipper 
(bHLH-Zip) transcription factors involved in the regulation of cellular lipid metabolism 
[23–25]. SREBP1 preferentially induces genes involved in fatty acid synthesis, while 
SREBP2 is more specific for genes involved in cholesterol biosynthesis [26,27]. 
SREBPs are synthesized as inactive precursors and held in a tripartite complex with 
SREBP cleavage–activating protein (SCAP) and INSIGs in the endoplasmic reticulum 
(ER) membrane. In response to low cholesterol levels, INSIG dissociates and the SCAP-
SREBPs complex is translocated to the Golgi apparatus for proteolytic activation. The 
resulting active N-terminal SREBP enters the nucleus, where it binds to sterol regulatory 
elements in the promoter regions of target genes [27–31]. Although both cholesterol and 
fatty acids are products of SREBP signalling, regulation of SREBP by fatty acids is 
relatively poorly delineated compared to regulation by cholesterol. Evidence has been 
presented that poly-unsaturated fatty acids decrease SREBP1 mRNA levels [32–34], 
stimulate SREBP1 decay [35], inhibit proteolytic processing of SREBP1 via binding to 
the auxiliary protein UBXD8 [36,37], and antagonize the activity of the liver X receptor, 
which is a potent inducer of SREBP1 gene transcription [38,39]. How elaidate causes 
activation of the SREBP pathway remains unclear. 
Here, we set out to better understand the mechanism of action of industrialized trans fatty 
acids. To that end, we pursued two independent experimental strategies. On the one hand, 
we conducted in vitro experiments in hepatocyte and adipocyte cell lines treated with 
individual fatty acids, and on the other hand, we fed mice diets enriched in trans-
unsaturated fatty acids, cis-unsaturated fatty acids, and saturated fatty acids, and 
analyzed the hepatic phenotype. 
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Materials and Methods 
Animal treatment 
Animal studies were performed using 4 to 6-month-old pure-bred male mice on a 
C57Bl/6 background. For the long-term experiment, the mice were randomly assigned 
to three groups (n = 8 mice per group). For 7 weeks, each group was fed a high-fat diet 
rich in trans-unsaturated (Trans), cis-unsaturated (Cis) or saturated (Saturated) fatty 
acids (modified TestDiet 58V8; TestDiet LTD, London). Detailed composition of test 
diets is provided in Supplemental Table 1. Fat sources were from partially hydrogenated 
soy oil for the Trans diet, canola and palm olein oil for the Cis diet, and cocoa butter for 
the Saturated diet. Total fat content in all three diets was 45% energy percent. 
Bodyweight and food intake were measured weekly. Following the diet intervention, 
mice were anesthetized with isoflurane, blood collected via orbital puncture and 
euthanized by cervical dislocation. Tissues for RNA and protein analysis were 
immediately frozen in liquid nitrogen and stored at -80°C. Tissues for histological 
analysis were fixed in 4% paraformaldehyde and later embedded in paraffin. For the 
short-term experiment, the mice were randomly assigned to the three diet groups (n = 10 
mice per group). The mice were fasted from 12.00 to 18.00 hrs, after which they were 
given access to one of the three diets. The mice were euthanized the next day between 
9.00 and 11.00 hrs as described above. The animal studies were approved by the Local 
Animal Ethics Committee at Wageningen University (2014096.d and 
AVD104002015236: 2016.W-0093.006). 
FA profiling of test diets by gas chromatography-flame ionization detection 
The Folch technique was used to extract the fat component in the test diets as previously 
described [40]. In summary, a 2:1 mixture of chloroform to ethanol was used to isolate 
fats from diets. Water was then added to obtain a biphasic system, with the fat present in 
the lower chloroform phase. The extracted fats were measured gravimetrically after 
purification followed by saponification with methanolic NaOH and methylation with 
boron trifluoride to obtain fatty acid methyl esters. The methyl esters were then 
fractionated by gas chromatography, detected by flame ionization, and calculated as a 
fraction of the total amount. 
Measurement of plasma parameters 
Blood samples collected into EDTA-coated tubes were centrifuged at 10,000 g for 15 
min at 4oC to obtain plasma. Plasma levels of non-esterified fatty acids (NEFA) and 
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glycerol were measured using kits from HUMAN Diagnostics (Wiesbaden, Germany) 
according to manufacturer’s protocol. Plasma cholesterol and glucose were also 
quantified using kits from Diasys Diagnostics Systems (Holzheim, Germany) according 
to manufacturer’s protocol. Plasma serum amyloid A (SAA) (Tridelta Development 
LTD, Ireland) and haptoglobin (Abcam, Cambridge) were measured using ELISA 
development kits with slight modifications to manufacturer’s protocol. Plasma alanine 
aminotransferase (ALT) activity (Abcam, Cambridge, UK) and insulin (Crystal Chem, 
Downers Grove, IL) were measured also using dedicated kits. 
Liver H & E staining 
Histology of mice liver samples was performed by Haematoxylin and eosin (H&E) 
staining. In summary, paraformaldehyde-fixed liver tissues were processed using ethanol 
and xylene before being embedded into paraffin blocks. Thin liver sections at 5 µm 
thickness were made using a microtome onto superfrost glass slides and incubated at 
37oC overnight. The liver slices were then stained for 10 min in Mayer haematoxylin 
solution and for 10 sec in eosin Y solution. The slides were then observed under a light 
microscope and representative images taken. 
Liver collagen staining 
Collagen staining of the liver was performed using the Fast Green FCF/Sirius Red 
staining. In brief, frozen livers were sectioned at 5 µm, mounted on glass slides and left 
to air dry for 30 min at room temperature. The slides were then fixed in 4% 
paraformaldehyde for 30 min, washed thrice (1 min each) in absolute ethanol and rinsed 
briefly with demi water. The tissues were then stained in collagen dye (0.1% fast green 
FCF, 0.1% direct Red 80 in saturated picric acid solution, Sigma) in a 37 OC incubator 
for 90 min. The tissues slices were then rinsed with demi water for 3 to 4 times until the 
water was clear, dehydrated with absolute ethanol thrice (30 sec each) and in xylene 
twice (5 min each). The slides were air dried and mounted with Depax mounting 
medium. Pictures were taken by light microscope. 
Liver triglyceride measurement  
To measure liver triglycerides, 2% liver homogenates were made in a buffer composed 
of 10 mM Tris, 2 mM EDTA and 25 mM sucrose at pH 7.5 by homogenising in a Tissue 
Lyser II (Qiagen, Hilden, Germany). Liver triglyceride content was then quantified using 
Triglyceride liquicolormono from HUMAN Diagnostics (Wiesbaden, Germany) according 
to manufacturer’s instructions.  
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Liver cholesterol measurement 
Total cholesterol in liver was quantified by gas chromatography-mass spectroscopy (GC-
MS) as previously described [41]. In brief, a procedure involving extraction, 
centrifugation and purification steps were used to isolate cholesterol from 200 mg liver 
samples using KOH, water and hexane as solvents. The extracts along with calibration 
standards were dissolved in dimethyl formamide (DMF), which also served as mobile 
phase prior to injection into the GC. The chromatogram that were generated were 
analysed as total cholesterol content in the mice liver samples. 
RNA isolation and quantitative real-time PCR 
Total RNA was isolated from mice tissues, Hepa1-6, Huh7 or 3T3-L1 cells using TRIzol 
reagent (Invitrogen, Bleiswijk, The Netherlands) and in the case of the mice tissues, 
homogenised in TRIzol using a Tissuelyser II (Qiagen, Venlo, The Netherlands). 
Following RNA isolation, 1000 ng of RNA was used to synthesize cDNA by reverse 
transcription using First strand cDNA synthesis kit (Thermo Fisher-Scientific, 
Schaumburg, IL) in accordance with manufacturer’s protocol. Changes in gene 
expression were then determined using a quantitative real-time PCR detection system 
(Bio-Rad) by using SensiMix (Bioline, GC Biotech, Alphen aan den Rijn, The 
Netherlands). Gene expression values were normalized to the 36b4 housekeeping gene. 
Primer sequences for measured genes are listed in Supplemental Table 2. 
Cell culture, 3T3-L1 differentiation and siRNA knockdown 
Cell culture: Hepa1-6 (# CRL-1830) and 3T3-L1 pre-adipocytes (# CL-173) were 
obtained from ATCC (Manassas, VA, USA). Huh-7 cells was a gift from Nicole de Wit 
(Wageningen University). The cells were cultured in Dulbecco's modified Eagle medium 
(DMEM) media supplemented with 10% fetal bovine serum, 100 U/mL penicillin and 
1000 µg/mL streptomycin (Lonza, Verviers, Belgium) in a humidified chamber at 37oC 
with 5% CO2.  
3T3-L1 differentiation: During differentiation, the pre-adipocytes were cultured in 6-
well plates. Two-days post-confluence, the cell culture media was changed to induction 
media (0.5 mM IBMX, 5 µg/mL insulin, 1 µM dexamethasone) for 2 days. Induction 
media was then replaced with insulin media (5 µg/mL insulin) for 3 days, after which 
the fully differentiated cells were treated with fatty acids.  
3T3-L1 co-differentiation with fatty acids: In these experiments, 3T3-L1 were 
differentiated as described above. During differentiation, the cells were co-treated with 
500 µM fatty acids.  
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siRNA-mediated silencing: Silencing of Srebp1, Srebp2, Scap, Ubxd8 and Soat1 was 
performed using Dharmacon ON-TARGETplus SMARTpool siRNAs diluted in 1x 
siRNA buffer. Hepa1-6 cells were plated at 5 x 104 cells per well into 24-well plates and 
transfected overnight with 50 nM siRNA using 2 µL per well Lipofectamine RNAiMAX 
transfection reagent (Life Technologies, Bleiswijk, The Netherlands). Transfected cells 
were subsequently treated with 500 µM fatty acids for 24 hrs. 
PLAP-reporter assay: The PLAP assay was performed to measure the processing of 
SREBP2 in the presence of fatty acids or controls. HEK293 cells were plated at 2 x 105 
cells/mL into 12-well plates and incubated overnight. The cells were then co-transfected 
overnight with 150 ng each of PLAP-conjugated SREBP2 plasmids pCMVpCMV-
SREBP2-PLAP and pcDNA4-hSCAP-MycHis in PEI transfection medium. The 
transfected cells were washed with PBS and treated for 24 hrs with 500 µM of fatty 
acids: oleate, palmitate, elaidate or vehicle control. Treatments with 50 µg/mL of β-MCD 
cholesterol (Sigma-Aldrich) and a combination of simvastatin (Calbiochem) and 
mevalonic acid (Calbiochem) at 5 µg/mL each served as negative and positive controls 
respectively. The PLAP assay was then performed by incubating cultured media with 
PNPP substrate and colorimetrically measuring the absorbance at 405 nm after 60 min 
as previously described [42]. 
Sub-cellular localisation in CHO SCAP-GFP cells: CHO SCAP-GFP cells were a 
kind gift of Prof. Espenshade and were described previously [43]. CHO SCAP-GFP cells 
were cultured at 37°C in an atmosphere of 8%–9 % CO2, a 1:1 mixture of Ham's F-12 
medium and DMEM supplemented with 5% (v/v) FCS. Briefly, cells were generated by 
transfection of SCAP-deficient SRD-13A cells with pGFP-SCAP, followed by selection 
in a 1:1 mixture of Ham's F-12 medium and DMEM supplemented with 5% newborn 
calf lipoprotein-deficient serum. pGFP-SCAP rescued the cholesterol auxotrophy of 
SRD-13A cells. CHO SCAP-GFP cells were incubated for 24 hours with 500 µM 
elaidate or control. The cells were analysed by microscopy for subcellular localisation 
of SCAP. 
Fatty acid preparation and treatment 
All fatty acid stocks were initially reconstituted in absolute ethanol. Sub-stocks of fatty 
acids at 25 mM were prepared in filter-sterilised KOH at 70 mM. Complete DMEM 
supplemented with fatty acid-free BSA (Sigma-Aldrich, St. Louis, MO) were filter 
sterilised, and incubated for 30 min with fatty acids to complex BSA to fatty acids. Ratio 
of BSA to fatty acids were approximately 1:2. Vehicle control treatments only contained 
equivalent mixture of ethanol and KOH. During treatment, Hepa1-6, Huh7 or 3T3-L1 
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cells were seeded at 2 x 105 cells/mL and incubated overnight, followed by treatment 
with 500 µM concentration of fatty acids for 24 hrs. Treatment with any other fatty acids 
were performed similarly. Differentiated 3T3-L1 cells were incubated with 1 mM final 
concentrations of fatty acids. 
Elaidate treatment in presence of LXR agonist or exogenous cholesterol 
To investigate the role of LXR, elaidate-treated Hepa1-6 cells were co-incubated for 24 
hrs with 1 µM of GW3965 (Sigma), an LXR agonist. To investigate the effect of elaidate 
in the presence of elevated cholesterol, Hepa1-6 cells were co-incubated with elaidate in 
the presence of 500 µM of water-soluble cholesterol (Sigma). 
Intracellular cholesterol and cholesterol ester quantification by HPLC 
For intracellular cholesterol and cholesterol ester measurement, 4 x 105 cells per well 
were plated into 6-well plates. After overnight incubation cells were treated with 500 
µM of elaidate or control for 24 hours. The cells were then washed three times with ice-
cold PBS and scraped into cold methanol. Cholesterol and cholesterol esters were 
extracted using a single-phase extraction. A define amount of internal standards 
consisted of 0.5 nmol of cholesterol ester (CE(14:0)) and 1 nmol cholesterol-D7. The 
mixture was sonicated in a sonication bath for 15 minutes and centrifuged for 5 minutes 
at 16,000g at 4°C. The supernatant was transferred to a glass vial and evaporated. The 
Residue was dissolved in 150 µl chloroform/methanol (1:1 v/v). The analysis of 
cholesterol and cholesterol esters was performed using an HPLC-MS system consisting 
of an Ultimate 3000 binary HPLC pump, a vacuum degasser, a column temperature 
controller, an auto sampler and a Q-exactive plus mass spectrometer (Thermo Scientific, 
Waltham, MA, USA). For the cholesterol esters 5 µl of the lipid extract was injected 
onto a "normal phase column" LiChrospher 2x250-mm silica-60 column, 5 µm particle 
diameter (Merck, Darmstadt, Germany) as previously described [44]. For the 
quantification of cholesterol 5 µl of the same lipid extracted was inject onto a "reverse 
phase column" Acquity UPLC HSS T3, 1.8 µm particle diameter (Waters, Milford 
Massachusetts, USA) and measured as previously described 
(https://doi.org/10.1016/j.chroma.2014.08.088). 
Oil red O staining of lipid droplets  
Oil red-O staining was performed in 3T3-L1 pre-adipocytes co-differentiated with fatty 
acids. A stock of oil red O (Sigma) was prepared by dissolving 0.5 g in 500 ml of 
isopropanol. Working concentrations were made by dissolving stock concentrations with 
water (3 stock : 2 water) and filtered. Treated cells were washed twice with PBS, 
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followed by fixation with 4% formalin for 30 min. The cells were then washed twice 
with PBS and incubated with oil red-O dye for 20 min. The stained cells were washed 3 
times with ddH2O after which cells were visualised under a light microscope and pictures 
taken. 
Western immunoblotting  
Protein expression was determined by western immunoblotting following siRNA 
knockdown of specific genes and elaidate treatment in Hepa1-6 cells using standard 
protocols. In summary, proteins were isolated with RIPA lysis buffer containing protease 
inhibitors and quantified by Pierce BCA protein assay (ThermoScientific, USA) 
according to manufacturer’s protocol. Proteins were prepared and 20 µg were loaded 
onto SDS-PAGE gels, transferred onto PVDF membranes and probed for specific 
proteins. Primary antibodies for SREBP1 (Millipore, #MABS1987), SREBP2 
(Millipore, #MABS1988), ACSS2 (Cell Signalling; #3658S), HMGCR (ATCC CRL-
1811, IgG-A9, undiluted hybridoma supernatant), LDLR (Biovision, #3839-100) and 
Actin (Merck, MAB1501) were diluted in 5% milk in TBS-T. Secondary antibodies anti-
rabbit IgG-HRP were diluted at 1:5000 in 5% milk. 
Microarray analysis  
Microarray analysis was performed on liver samples from the mice fed the 3 different 
diets as well as on Hepa1-6 hepatoma and differentiated 3T3-L1 adipocyte cells 
incubated with different fatty acids. RNA was purified with RNeasy Minikit columns 
(Qiagen) and analysed for quality with RNA 6000 Nano chips on the Agilent 2100 
bioanalyzer (Agilent Technologies, Amsterdam, The Netherlands). One microgram of 
RNA was used for cDNA synthesis using the First Strand cDNA synthesis kit (Thermo 
Scientific). Purified RNA (100 ng) was labeled with the Ambion WT expression kit 
(Invitrogen) and hybridized to an Affymetrix Mouse Gene 1.1 ST array plate (mouse 
liver, Hepa1-6 cells) or 2.1 ST array plate (3T3-L1 adipocytes) (Affymetrix, Santa Clara, 
CA). Hybridization, washing, and scanning were carried out on an Affymetrix GeneTitan 
platform. Scans of the Affymetrix arrays were processed using packages from the 
Bioconductor project. Arrays were normalized using the robust multi-array average 
method [45,46]. Probe sets were defined by assigning probes to unique gene identifiers, 
e.g., Entrez ID [47]. For the Hepa1-6 and 3T3-L1 cells, the total gene set (24,973 probe 
sets) was filtered to only include genes with mean signal > 20, yielding 10,379 and 
11,504 genes, respectively. Microarray data were submitted to the Gene Expression 
Omnibus (accession number pending). 
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Statistical analysis 
Results are presented as mean ± SEM  for animal experiments and mean ± SD for in 
vitro experiments. Statistical analyses were performed using Student’s paired T-tests or 
by one-way ANOVA followed by a Turkey’s post-hoc multiple comparison test 
(GraphPad Software, Inc., La Jolla, USA).  P < 0.05 was considered statistically 
significant.  
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Results 
Elaidate induces a cholesterogenic gene profile in Hepa1-6 and differentiated 3T3-
L1 adipocytes 
To better characterize the molecular pathways activated by industrial trans fatty acids in 
liver and fat cells, we determined the effects of elaidate on whole genome gene 
expression in mouse hepatoma  Hepa1-6 cells and mouse 3T3-L1 adipocytes. For 
comparison, cells were also treated with oleate and palmitate as representative cis-
unsaturated, and saturated fatty acid, respectively. Using a fold-change cut-off of >1.5, 
thirty-one genes were commonly induced by elaidate in Hepa1-6 cells and 3T3-L1 
adipocytes (Fig 1A). Pathway analysis of the 31 genes by Enrichr showed strong 
overrepresentation of pathways related to cholesterol synthesis (Fig 1B). Specifically, of 
the 31 commonly induced genes, 11 genes are involved in the mevalonate and cholesterol 
synthesis pathway, including Mvd, Fdft1, Insig1, Dhcr7, Lss  (Fig 1C). In contrast to 
elaidate, oleate downregulated genes involved in cholesterol synthesis, which was most 
obvious in the Hepa1-6 cells, while palmitate showed an intermediate effect (Fig 1C). 
QPCR confirmed the induction of cholesterogenic genes in 3T3-L1 adipocytes (Fig 1D) 
and Hepa1-6 cells (Fig 1E), which was further verified in undifferentiated and 
differentiating 3T3-L1 cells (Supplemental Fig 1). Since the gene expression changes 
were most robust in the Hepa1-6 cells, we used Hepa1-6 cells for further investigation 
into the cellular mode of action of elaidate. 
Cholesterogenic effect of elaidate is dependent on SREBP and SCAP 
The expression of cholesterogenic genes is under control of the transcription factors 
SREBP2 and to a lesser extent SREBP1. Accordingly, we examined the effect of elaidate 
on the expression of Srebp1 and Srebp2, as well as on additional target genes. Compared 
to control, elaidate significantly upregulated the expression of Srebp2 and target genes 
involved in cholesterol synthesis, including Hmgcr, Acss2, Pmvk, Mvd, Fdft1, Ldlr and 
Sqle  (Fig 2A). Elaidate did not induce expression of Srebp1. In fact, elaidate 
downregulated Srebp1c (Fig 2A), and had minimal effect on the expression of SREBP1c 
target genes involved in fatty acid synthesis (Supplemental Fig 2). Consistent with the 
transcriptomics data, oleate downregulated the expression of the cholesterogenic genes, 
while palmitate showed a modest to no effect relative to control (Fig 2A). Similar effects 
of elaidate on cholesterogenic genes were observed in human Huh7 hepatoma cells (Fig 
2B). 
Industrial trans fatty acids promote NAFLD and cholesterogenesis 
 
 
61 
 
 
Figure 1. Elaidate induces a cholesterogenic expression profile in differentiated 3T3-L1 and 
Hepa1-6 cells. Transcriptomics analysis was performed on differentiated 3T3-L1 treated with 1 
mM fatty acids and Hepa1-6 cells treated with 500 µM fatty acids for 24 hours. Genes with mean 
signal above 20 were selected. (A) Venn diagram showing number of upregulated genes by 
elaidate by at least 1.5-fold.  (B) Pathway analysis by Enrichr of the 31 genes commonly 
upregulated by elaidate in differentiated 3T3-L1 and Hepa1-6 cells. (C) Heatmap showing relative 
expression profile of the 31 genes in differentiated 3T3-L1 and Hepa1-6 cells after treatment with 
elaidate, oleate or palmitate. (D-E) Relative mRNA expression by qPCR of cholesterol synthesis 
genes in 3T3-L1 adipocytes (D) and Hepa1-6 cells (E).  mRNA expression was normalized to 
36b4. Data are mean ± SD; *p < 0.05 relative to control. 
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Figure 2. Induced expression of cholesterogenic genes in murine and human hepatoma cells 
by elaidate. (A) mRNA expression of cholesterogenic genes in Hepa1-6 cells treated with 
elaidate, oleate or palmitate at 500 µM for 24 hours. (B) mRNA expression of cholesterogenic 
genes in Huh7 cells treated with elaidate, oleate or palmitate at 500 µM for 24 hours. mRNA 
expression was normalized to 36b4. Data are mean ± SD; *p < 0.05 relative to control. 
Guided by these results, we probed the role of SREBP1 and SREBP2 in mediating the 
induction of cholesterogenic genes by elaidate using siRNA. The siRNA-mediated 
silencing of Srebp1 and Srebp2 completely abrogated the induction of cholesterogenic 
genes by elaidate (Fig 3A), supporting a role of SREBPs. Interestingly, expression of 
Srebp2 was not only reduced by siRNA-mediated silencing of Srebp2, but also by 
silencing of Srebp1 (Fig 3A). Nevertheless, the observation that elaidate increased 
Srebp2 mRNA but not Srebp1 mRNA suggests that in these cells the induction of 
cholesterogenic genes by elaidate is likely mediated by SREBP2. 
SREBP-dependent gene regulation requires SCAP for translocation to the Golgi. SCAP 
serves as a chaperone protein that facilitates the transport of SREBP to the Golgi 
apparatus for proteolytic processing and activation. Similar to the effect of 
Srebp1/Srebp2 silencing, silencing of Scap abrogated the induction of SREBP target 
genes by elaidate, indicating that the effects of elaidate require a functional SCAP-
SREBP axis (Fig 3B). The role of the SREBP/SCAP pathway in the regulation of 
cholesterogenesis by elaidate was further investigated at the protein level. Specifically, 
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elaidate increased the levels of activated SREBP1 and 2, as well as the protein levels of 
SREBP targets HMGCR and ACSS2 (Fig 3C). Copying the mRNA data, knockdown of 
either isoforms of Srebp or Scap abolished the induction of ACSS2 and HMGCR by 
elaidate. Further in line with the mRNA data, silencing of Srebp1 resulted in the absence 
of SREBP2, yet the opposite was not the case. 
 
Figure 3.  Elaidate induces cholesterogenic gene expression via SREBP2 and SCAP. (A) 
mRNA expression of cholesterogenic genes in Hepa1-6 cells treated with elaidate and siRNA 
against Srebp1 or Srebp2. (B) mRNA expression of cholesterogenic genes in Hepa1-6 cells treated 
with elaidate and siRNA against Scap. (C) Immunoblot for SREBP1, SREBP2, HMGCR and 
ACSS2 in Hepa1-6 cells treated with elaidate and siRNA against Srebp1, Srebp2 or Scap. β-Actin 
served as loading control. (D) Relative SREBP2 activity by PLAP reporter assay in HEK293 cells. 
Simvastain/mevalonic acid (Sim/Mev) at 5 µg/mL served as a positive control. (E) Immunoblot 
for LDLR in Hepa1-6 cells treated with elaidate and siRNA against Srebp1, Srebp2 or Scap. β-
Actin served as loading control. (F) mRNA expression of cholesterogenic genes in Hepa1-6 cells 
treated with elaidate and siRNA against Ubxd8. (G) mRNA expression of LXR and SREBP target 
genes in Hepa1-6 cells treated with elaidate or 1 µM of the LXR agonist GW3695. mRNA 
expression was normalized to 36b4. Data are mean ± SD; *p < 0.05 relative to control; #p < 0.05 
relative to elaidate treatment with non-targeted siRNA (siNT + Elaidate). 
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To further demonstrate that elaidate enhances the processing and activation of SREBP2, 
we performed a PLAP-reporter assay in HEK293, an assay that allows monitoring of 
translocation and subsequent processing of SREPB to its activate form [42]. In this assay, 
elaidate significantly enhanced the processing of SREBP2 to an extent comparable to 
that observed with statins (Fig 3D). By contrast, oleate decreased SREBP2 activity. 
Overall, our data suggest that the stimulatory effect of elaidate on cholesterogenic gene 
expression is mediated by the SREBP-SCAP pathway via SREBP2. 
Intriguingly, despite upregulating Ldlr mRNA, elaidate did not affect LDLR protein (Fig 
3E). Furthermore, elaidate reduced LDLR protein in Hepa1-6 cells treated with Srebp2 
siRNA but not Srebp1 or Scap siRNA (Fig 3E). These data suggest that, in addition to 
inducing cholesterogenic gene expression, elaidate has a suppressive effect on LDLR 
protein levels, which is independent of SREBP2 and dependent on SREBP1 and SCAP.  
Cholesterogenic effect of elaidate is independent of UBXD8 and LXR 
Having established that elaidate requires an intact SCAP-SREBP axis, we evaluated two 
potential mechanisms by which this fatty acid may stimulate SREBP signalling. First, 
we considered the possibility that elaidate requires UBXD8 for its activity, as previous 
studies have proposed this protein to serve as a sensor for unsaturated fatty acids [36]. 
UBXD8 is an ER membrane-associated protein that promotes SREBP processing by 
degrading INSIG1, an inhibitor of SREBP-SCAP translocation. However, as shown in 
Figure 3F, Ubxd8 mRNA was not affected by elaidate, nor did silencing of Ubdxd8 affect 
the induction of cholesterogenic genes by elaidate, suggesting that the induction is 
independent of UBXD8 (Fig 3F). Alternatively, we hypothesized that elaidate may 
inhibit activity of the Liver X receptors (LXR), which regulate Srebp1c expression and 
which are reported to be inhibited by poly-unsaturated fatty acids [48]. To test this idea 
we treated Hepa1-6 cells with the LXR agonist GW3965. LXR activation markedly 
induced the expression of the established LXR target genes Abca1, Abcg1, and Srebp1c, 
whereas elaidate suppressed these genes (Fig 3G). In turn, elaidate strongly induced 
cholesterogenic genes, whilst GW3965 had minimal to no effect. The above data do not 
support a role of UBXD8 and LXR in the activation of the SREBP-SCAP pathway by 
elaidate.  
Elaidate alters intracellular cholesterol metabolism 
To gain further insight into the mechanism behind the cellular effect of elaidate, we 
determined  fluxes and metabolism of intracellular cholesterol. In the ER, cholesterol 
binds to SCAP to inhibit SREBP transport to the Golgi [49,50]. A previous study showed 
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that elaidate upregulates SOAT1, the enzyme that catalyses cholesterol esterification 
[21]. Accordingly, we hypothesized that elaidate constitutively turns on SREBP 
signalling by promoting the esterification of cholesterol, thereby decreasing intracellular 
free cholesterol levels. While elaidate significantly reduced intracellular free cholesterol 
levels (Fig 4A), levels of cholesterol esters remained unaltered (Fig 4B). Furthermore, 
siRNA-mediated knockdown of Soat1 did not abrogate the ability of elaidate to 
upregulate the expression of SREBP2 target genes (Fig 4C), indicating that the activation 
of the SCAP-SREBP pathway by elaidate is not dependent on cholesterol esterification. 
 
Figure 4. Elaidate alters intracellular cholesterol metabolism in Hepa1-6 cells. (A-B) 
Intracellular levels of free cholesterol (A) and esterified cholesterol (B) in Hepa1-6 cells treated 
with elaidate at 500 µM for 24 hours. (C) mRNA expression of cholesterogenic genes in Hepa1-
6 cells treated with elaidate and siRNA against Soat1. (D) SCAP localisation in SCAP-GFP 
expressing CHO cells treated with elaidate or control. (E) mRNA expression of cholesterogenic 
genes in Hepa1-6 cells treated for 24 hours with 500 µM elaidate and/or 500 µM of exogenous 
cholesterol. (F) mRNA expression of cholesterogenic genes in Hepa1-6 cells treated with 500 µM 
of elaidate or other trans fatty acids. mRNA expression was normalized to 36b4. Images are 200x 
magnification. Data are mean ± SD; *p < 0.05 relative to control; #p < 0.05 relative to elaidate or 
elaidate treatment with non-targeted siRNA (siNT + Elaidate); §p < 0.05 relative to cholesterol 
treatment. 
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Next, we considered the possibility that elaidate directly influences SCAP translocation. 
To test this, we studied CHO cells that stably produce SCAP-GFP [43]. In these cells, 
treatment with elaidate did not change the cellular distribution of SCAP (Fig 4D). 
Alternatively, elaidate may modulate cholesterol sensing by SCAP. To test this notion, 
we increased intracellular levels of cholesterol by delivering exogenous cholesterol, 
either in the absence or presence of elaidate. As expected, elaidate induced 
cholesterogenic gene expression, while exogenous cholesterol had a marked suppressive 
effect on the same set of genes (Fig 4E). In the presence of elaidate, exogenous 
cholesterol still significantly reduced cholesterogenic gene expression, suggesting that 
elaidate does not completely abolish the cholesterol-sensing ability of SCAP. However, 
compared to the cholesterol-only condition, adding elaidate significantly upregulated 
cholesterogenic gene expression, suggesting that elaidate desensitizes SCAP to 
cholesterol (Fig 4E). Taken together, these results suggest that elaidate activates the 
SREBP/SCAP pathway through complementary mechanisms that include lowering 
intracellular free cholesterol levels and desensitizing SCAP to cholesterol. 
Finally, we examined whether the stimulatory effect of elaidic acid on cholesterogenic 
genes can be generalized to dietary trans fatty acids as a group. Remarkably, elaidate has 
distinct effects from natural trans fatty acids. Whereas the industrially-produced elaidate 
upregulated cholesterol synthesis genes, natural trans fatty acids such as trans-vaccenate, 
conjugated linoleate, and palmitelaidate did not show such an effect (Fig 4F). In fact, if 
anything, these naturally occurring trans fats mildly decreased expression of these genes. 
Our data thus indicate that elaidate, but not ruminant trans fatty acids, activate the 
SREBP-SCAP pathway in cultured hepatoma cells. 
Trans fat feeding causes lipoatrophy and hepatomegaly in mice 
In a separate set of studies, we aimed to investigate the effects of industrial trans fatty 
acids on the liver in vivo. To that end, male C57Bl/6 mice were randomly assigned to 
one of 3 calorically equivalent diets enriched in different types of fatty acids: a Trans 
diet, a Cis diet, or a Saturated diet. The Trans diets consisted of 30-35% trans-unsaturated 
fatty acids originating from partially hydrogenated soybean oil (Fig 5A, Supplemental 
Table 3). The Cis diet contained equivalent amount of saturated fatty acids as the Trans 
diet, but with cis mono- and poly-unsaturated fatty acids replacing the trans-unsaturated 
fatty acids. The Saturated diet contained about 60% saturated fatty acids, but with 
equivalent amounts of cis mono- and poly-unsaturated fatty acids as the Trans diet. 
Overall, about 60-65% of the fatty acid composition was similar between the three diets, 
with the remaining 35-40% being taken up by either trans-unsaturated fatty acids, cis-
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unsaturated fatty acids or saturated fatty acids  (Fig 5A). Food intake (Fig 5B) and body 
weight (Fig 5C) were not significantly different between the 3 groups of mice. In 
comparison to the mice fed the Saturated and Cis diet, the mice fed the Trans diet had a 
significantly higher relative liver weight (Fig. 5D), but significantly lower relative 
gonadal fat weight (Fig 5E). Consequently, the ratio of liver to gonadal fat weight was 
approximately 2-fold higher in the mice fed the Trans diet (Fig 5F). No significant 
differences in plasma levels of cholesterol, glycerol, non-esterified fatty acids, glucose, 
and insulin were observed between the Trans group and the Cis and Saturated groups 
(Fig 5G). 
 
Figure 5. Anthropometric measurements and plasma metabolites in mice fed the different 
high fat diets for 7 weeks. (A) Profile of relative content of different fatty acids in the test diets. 
TFA, trans-unsaturated fatty acids; PUFA, poly-unsaturated fatty acids; cisMUFA, cis mono-
unsaturated fatty acids; SFA, saturated fatty acids. (B) Average weekly food intake during the 7-
week diet intervention. (C) Final body weights. (D) Relative liver weight. (E) Relative weight of 
gonadal white adipose tissue (gWAT). (F) Ratio of liver to gWAT weight. (G) Plasma levels of 
cholesterol, glycerol, non-esterified fatty acids (NEFA), glucose, and insulin. Data are mean ± 
SEM; N=8 mice/group; *p < 0.05 relative to Trans group. 
Trans fat feeding promotes non-alcoholic fatty liver disease 
Remarkably, plasma alanine aminotransferase activity was significantly higher in the 
Trans group than in the Cis and Saturated groups, suggesting enhanced liver damage (Fig 
6A). In addition, plasma levels of the acute phase proteins haptoglobin (Fig 6B) and 
serum amyloid A (Fig 6C) were markedly higher in the mice fed the Trans diet. 
Furthermore, hepatic triglycerides and cholesterol levels were higher in the Trans group 
compared to the Saturated group (Fig 6D and E). Supporting the quantitative triglyceride 
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analysis, H&E staining revealed enhanced steatosis in the livers of mice fed the Trans 
diet in comparison with mice fed the Saturated and Cis diets (Fig 6F). 
 
Figure 6. Increased liver damage, steatosis and fibrosis in mice fed the Trans diet. (A) Plasma 
levels of alanine aminotransferase (ALT) activity. (B-C) Plasma levels of the acute phase proteins 
haptoglobin (B) and serum amyloid A (C). (D-E) Quantification of hepatic content of cholesterol 
(D) and triglycerides (E). (F) Representative images of liver steatosis by haematoxylin & eosin 
staining. (G) Top 20 upregulated gene sets in livers of mice fed the Trans diet, determined by gene 
set enrichment analysis. Gene sets were ranked according to normalized enrichment score. (H) 
Expression profile of genes within the gene set Assembly of Collagen Fibrils. (I) Representative 
images of collagen staining using Fast Green FCF/Sirius Red. Images are 200x magnification. 
Data are mean ± SEM; N=8 mice/group; *p < 0.05 relative to Trans group. 
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Figure 7. Reduced cholesterogenic gene expression in livers of mice fed the Trans diet. (A) 
Top 20 downregulated gene sets in livers of mice fed the Trans diet for 7 weeks, determined by 
gene set enrichment analysis. Gene sets were ranked according to normalized enrichment score. 
(B) Expression profile of genes within the gene set Cholesterol Biosynthesis. (C) Relative mRNA 
expression by qPCR of cholesterol synthesis genes in the liver of mice fed the 3 different types of 
diets. (D-E) Strong negative correlation between hepatic cholesterol levels and liver expression 
of the cholesterol synthesis genes Fdft1 (D) and Msmo1 (E) in the mice fed the Trans diet. (F-G) 
Relative mRNA expression of fatty acid synthesis genes (F) and cholesterol synthesis genes (G) 
in the gonadal adipose tissue of mice fed the 3 different types of diets. (H) mRNA expression of 
cholesterogenic genes in liver of mice fed overnight with the Trans, Cis or Saturated diets. mRNA 
expression was normalized to 36b4. Data are mean ± SEM. N=8 mice/group for the chronic 
feeding study and N=10 mice/group for the overnight feeding study. *p < 0.05 relative to Trans 
group. 
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To further characterize the hepatic phenotype in the three groups, we performed 
transcriptomics analysis. Gene set enrichment analysis showed elevated expression of 
collagen formation pathways and fatty acid degradation pathways in the mice fed the 
Trans diet (Fig 6G). The higher expression of collagen-related genes in the Trans group 
compared to the Cis and Saturated group is visualized in Fig 6H. Consistent with the 
transcriptomic results, hepatic collagen staining was more pronounced in the mice fed 
the Trans diet (Fig 6I), further supportive of a more marked NAFLD phenotype. 
Interestingly, gene set enrichment analysis showed decreased expression of the 
cholesterol synthesis pathway in the mice fed the Trans and Cis diet compared to the 
Saturated fat (Fig 7A, B), which was confirmed by qPCR (Fig 7C). The expression of 
cholesterol synthesis genes was highly negatively correlated with hepatic cholesterol 
levels, suggesting that cholesterogenic gene expression is mainly determined by hepatic 
cholesterol levels (Fig 7D, E). In contrast to liver, in gonadal adipose tissue the 
expression of genes involved in lipogenesis (Fig 7F) and cholesterogenesis (Fig 7G) was 
markedly higher in the Trans group than in the Cis and Saturated group. This lipo- and 
cholesterogenic effect of the Trans diet was recapitulated in the inguinal adipose tissue 
depot (Supplemental Fig 3). Taken together, these data show that the Trans diet led to 
more advanced NALFD as compared to the Cis and Saturated diet, as shown by elevated 
alanine aminotransferase activity, elevated triglyceride and cholesterol levels, and 
increased expression of fibrosis-related genes.  
Since lower cholesterogenic gene expression in the liver after chronic high fat feeding 
seemed to be mainly driven by higher hepatic cholesterol levels, we determined the acute 
effect of the different diets on hepatic gene expression. To this end, we fed mice 
overnight with the Trans diet, the Cis diet, or the Saturated diet. Interestingly, 
cholesterogenic gene expression was markedly higher in the mice fed the Trans diet 
compared to mice fed the Cis diet (Fig 7H). In addition, the expression of cholesterogenic 
genes was highly similar between the Saturated and the Trans group, suggesting that in 
vivo the acute effects of industrial trans and saturated fatty acids are similar. 
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Figure 8: Graphical abstract: Potential mechanism of elaidate. Elaidate activates the SREBP 
signalling pathway by reducing the sensitivity of SCAP to cholesterol and lowering the levels of 
intracellular cholesterol.   
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Discussion 
The major outcomes of our studies are: 1) in vivo, a diet enriched in industrial trans fatty 
acids promotes NAFLD when compared with a diet enriched in cis-unsaturated and 
saturated fatty acids. Specifically, we find that feeding mice a diet enriched in industrial 
trans fatty acids enhances liver steatosis and fibrosis, and raises hepatic triglyceride 
levels, hepatic cholesterol levels, and plasma alanine aminotransferase activity in 
comparison with diets enriched in cis-unsaturated or saturated fatty acids. 2) in vitro, the 
industrial trans fatty acid elaidate, but not ruminant trans fatty acids, stimulates the 
cholesterol synthesis pathway in liver cells via activation of the SCAP/SREBP2 axis, 
presumably by lowering intracellular free cholesterol and desensitizing SCAP  to 
cholesterol.  
Using an integrated transcriptomics, lipidomics, and proteomics approach in HepG2 
cells, it was previously shown that elaidate induces the expression of several genes 
involved in fatty acid and cholesterol synthesis [21]. Here, using siRNA-mediated gene 
silencing, we show that the cholesterogenic effect of elaidate is dependent on functional 
SREBP2 and SCAP. Although silencing of Srebp1 abolished the induction of 
cholesterogenic genes by elaidate, the role of SREBP1 is probably indirect by serving as 
an important transcriptional regulator of SREBP2. Indeed, SREBP2 protein and mRNA 
were nearly equally silenced by siRNA targeting Srebp2 and Srebp1. Accordingly, the 
abrogation of the elaidate effect by Srebp1 silencing is likely due to the concomitant 
downregulation of SREBP2. This result is in line with studies that show that both 
SREBP1 and SREBP2 contain a sterol response element (SRE) in their respective 
promoter regions, which mediates upregulation of the two isoforms in a feed-forward 
manner [51,52]. Also, the reduction in protein levels of SREBP1 and SREBP2 after 
SCAP knockdown agrees with a previous study that reported profound reductions in 
mRNA and protein levels of SREBP1 and SREBP2 in mice with liver-specific deletion 
of SCAP, due in part to the abrogation of the feed-forward mechanism that enables 
SREBPs to regulate their own expression. [53]. 
It is well established that the SREBP/SCAP pathway is controlled by fatty acids. 
Evidence indicates that (poly)-unsaturated fatty acids inhibit SREBP1-induced 
lipogenesis in the liver by suppressing SREBP1 mRNA levels and inhibiting proteolytic 
processing of SREBP1. The direct target of (poly)-unsaturated fatty acids was proposed 
to be UBXD8, an ER membrane–bound protein that facilitates the degradation of INSIG-
1, which normally sequesters the SCAP-SREBP complex in the ER and prevents its 
activation [36,37]. Our data indicate that activation of the SREBP/SCAP pathway by 
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elaidate is independent of UBXD8. Our data also indicate that the effect of elaidate is 
distinct from that of oleate. Whereas oleate suppressed the expression of cholesterogenic 
genes in Hepa1-6 and 3T3-L1 cells, elaidate had the opposite effect. Apparently, the 
configuration of the double bond in 9-octadecenoic acid dramatically alters its signalling 
properties in liver and other cells. The effect of palmitate was intermediate between that 
of oleate and elaidate in Hepa1-6 cells, and diverges from elaidate in 3T3-L1 cells, 
supporting our previous report that in macrophages, elaidate and palmitate have distinct 
signalling properties [20].  
As already indicated, elevated levels of intracellular free cholesterol serves as a negative 
feedback regulator of SREBP signalling. When intracellular cholesterol levels drop, the 
interaction between SREBP-SCAP and INSIG1 is released, triggering the movement of 
SREBP-SCAP to the Golgi, where SREBP becomes activated [54,55]. We found that 
elaidate significantly reduced intracellular free cholesterol levels, likely accounting for 
the activation of the SREBP/SCAP pathway. One possible explanation for the lower free 
cholesterol levels is enhanced cholesterol esterification. Although Soat1 has been 
reported to be induced by elaidate [21], silencing of Soat1 did not abrogate the 
cholesterogenic effects of elaidate, nor did elaidate increase intracellular levels of 
cholesterol ester, ruling out enhanced cholesterol esterification as key underlying 
mechanism. Besides lowering intracellular free cholesterol, elaidate partially but 
significantly repressed the strong anti-cholesterogenic effect of exogenous cholesterol, 
suggesting that elaidate decreases the sensitivity of SCAP to cholesterol. Overall, our 
data  suggest that elaidate activates the SREBP signalling through complementary 
mechanisms that include lowering intracellular free cholesterol levels and desensitizing 
SCAP to cholesterol. 
Previously, Koppe and colleagues showed that compared to diets high in saturated fatty 
acids, a diet high in industrial trans fatty acids markedly increased plasma alanine 
aminotransferase activity in AKR/J mice, suggesting enhanced liver damage [56]. 
Furthermore, studies in different mouse strains revealed that diets rich in industrial trans 
fatty acid from partially hydrogenated vegetable oil promote hepatic steatosis and 
fibrosis [17,57,58]. Our in vivo study, which provides the most detailed characterization 
of the effects of industrial trans fatty acids on the liver, extends these findings by showing 
that a diet enriched in trans fatty acids enhances liver steatosis and fibrosis, and raises 
hepatic triglyceride levels, hepatic cholesterol levels, plasma acute phase proteins, and 
plasma alanine aminotransferase activity. Accordingly, we now have convincing 
evidence that industrial trans fatty acids promote NALFD in mice.  
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Our study is also consistent with other studies showing that the trans fatty acid-induced 
increase in liver mass and hepatic lipid accumulation is accompanied by a decrease in 
fat tissue mass [15,59,60]. One potential explanation for the pronounced increase in the 
liver to fat ratio is that trans fatty acids may be preferentially directed towards the liver 
at the expense of fat tissue. Currently, it is unclear how this can happen. It can be 
hypothesized that lipoproteins containing triglycerides enriched in trans fatty acids may 
be less efficiently hydrolyzed by lipoprotein lipase in fat tissue. As a result, a larger 
portion of the dietary fat is taken to the liver. Unfortunately, there are no tools to 
experimentally validate this hypothesis, given the lack of radiolabelled trans fatty acids 
and triglycerides. An alternative explanation is that differences in liver to fat ratio are 
related to differences in adipose tissue lipolysis. However, plasma levels of NEFA and 
glycerol were not significantly different between the groups, suggesting that adipose 
tissue lipolysis is not different between the groups.  Although it would certainly be a 
worthwhile pursuit to tease out the processes underlying the differential in vivo 
partitioning of trans fatty acids, tools are lacking to properly address this question. 
Our studies also do not allow us to draw conclusions about whether trans fatty acids 
themselves are responsible for the enhanced NASH features or whether the effects could 
be mediated by the increase in hepatic cholesterol. Indeed, emerging evidence suggests 
that hepatic free cholesterol is a major lipotoxic molecule that plays a critical role in the 
development of NASH [61,62]. Taking into account the damaging role of cholesterol, it 
is not unreasonable to suggest an increase in cholesterogenesis may underlie the 
stimulation of NASH by industrial trans fatty acids.  
Given the major differences in experimental set-up and complexity of the treatments 
between the in vitro and in vivo studies, one should be careful to directly compare the 
outcomes of the two experimental approaches. Nevertheless, cis-unsaturated fatty acids 
seemed to behave similarly in vivo and in vitro, as the Cis diet and oleate led to lower 
cholesterogenic gene expression compared to the Saturated diet and palmitate, 
respectively. By contrast, whereas elaidate induced cholesterogenic gene expression in 
Hepa1-6 cells in comparison with palmitate, chronic feeding of the Trans diet reduced 
cholesterogenic gene expression in liver in comparison with the Saturated diet, while 
overnight feeding of the Trans diet led to similar cholesterogenic gene expression as the 
Saturated diet. Compared with oleate, elaidate induced cholesterogenic gene expression 
in vitro, and overnight feeding of the Trans diet led to higher cholesterogenic gene 
expression than the Cis diet. Intriguingly, chronic feeding of the Trans and the Cis diet 
led to similar cholesterogenic gene expression. Although caution should be exercised 
when comparing the outcomes of in vitro and in vivo approaches, it is tempting to 
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attribute the increase in hepatic cholesterol in the Trans group to activation of the 
SREBP/SCAP pathway. It can be speculated that the Trans diet initially stimulated 
hepatic cholesterogenesis, leading to the observed elevation in liver cholesterol levels, 
which in turn caused a compensatory decrease in cholesterogenic gene expression. 
Alternatively, it is possible that the increase in liver triglyceride and cholesterol levels in 
the Trans group is caused by preferential shuttling of circulating lipids to the liver. 
Epidemiological studies have found a positive association between intake of trans fatty 
acids and NAFLD [12,13]. Our and other animal studies suggest that this association 
may be causal. Currently, there is no record of a nutritional trial that investigated the 
effect of industrial trans fatty acids on intrahepatic lipid or markers of liver damage in 
humans. It is likely that these studies will never be performed due to ethical restrictions. 
Industrial trans fatty acids are best known for their ability to raise plasma LDL 
cholesterol and lower plasma HDL cholesterol levels in human volunteers [6,63,64]. Due 
to the very different lipoprotein profiles of mice and humans, effects of specific 
treatments on plasma lipid levels in mice cannot easily be extrapolated to the human 
situation. Nevertheless, we anticipated that the molecular mechanism of action of 
elaidate in liver cells might give some clues about the plasma cholesterol-modulating 
effect of trans fatty acids. The observed activation of the SREBP/SCAP pathway by 
elaidate is expected to enhance the extraction of LDL from the bloodstream by activating 
the transcription of LDLR. Indeed, elaidate significantly increases Ldlr mRNA in 
Hepa1-6 cells, which is mediated by a functional SREBP/SCAP pathway. Strikingly, 
elaidate was found to suppress LDLR protein levels, via a mechanism independent of 
SREBP2 and dependent on SREBP1. One possibility is that elaidate decreases LDLR 
protein by enhancing its degradation. Based on these data, it could be hypothesized that 
SREBP1 drives the expression of a gene that mediates the degradation of LDLR by 
elaidate. One obvious candidate would be Pcsk9. However, mRNA expression levels of 
Pcsk9 were not altered by elaidate. Additional studies are necessary to elucidate the 
mechanism accounting for the suppressive effect of elaidate on LDLR protein. 
In conclusion, we show that industrial trans fatty acids stimulate cholesterogenesis in 
vitro via activation of the SREBP/SCAP pathway. Induction of cholesterogenesis might 
explain the increase in liver cholesterol and NAFLD in mice fed a diet rich in trans-
unsaturated fatty acids. 
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 Supplemental Material 
 
Supplemental Figure 1: Elaidate induces cholesterogenic genes in 3T3-L1 cells. (A) Relative 
mRNA expression of cholesterol synthesis genes in undifferentiated 3T3-L1 fibroblasts treated 
with 500 µM of individual fatty acids for 24 hours. (B) Relative mRNA expression of cholesterol 
synthesis genes in 3T3-L1 cells that were differentiated in the presence of 500 µM of individual 
fatty acids. mRNA expression was normalized to 36b4. Data are mean ± SD. *p < 0.05 relative to 
control.  
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Supplemental Figure 2: Relative mRNA expression of target genes of SREBP1c involved in 
fatty acid synthesis in Hepa1-6 cells treated with 500 µM of individual fatty acids for 24 hours. 
mRNA expression was normalized to 36b4. Data are mean ± SD. *p < 0.05 relative to control 
condition. 
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Supplemental Figure 3: Trans diet induces lipogenic and cholesterogenic genes in inguinal 
adipose tissue. (A-B) Relative mRNA expression of fatty acid synthesis genes (A) and cholesterol 
synthesis genes (B) in the inguinal adipose tissue of mice fed Trans, Cis and Saturated diets. 
mRNA expression was normalized to 36b4. N=8 mice/group. Data are mean ± SEM. *p < 0.05 
relative to Trans group. 
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Supplemental Table 1: Composition of test diets 
Ingredients (%)  Saturated fat diet Unsaturated fat diet Trans fat diet 
Cocoa Butter  23.3060   0   0 
Canola Oil  0   13.2265   0 
Palm Olein Oil  0   7.8536   0 
Hydrogenated Soy Oil 0   0   21.0800 
Casein- Vitamin Tested 23.3060   23.3059   23.3060  
Sucrose   19.7090   19.7090   19.7090  
Maltodextrin  11.6530   11.6530   11.6530 
Dextrin   8.4830   8.4830   8.4830 
Powdered Cellulose 5.8270   5.8270   5.8270 
Soybean Oil  2.9200   2.9200   2.9200 
Potassium Citrate, 1.9230   1.9230   1.9230  
Tribasic Monohydrate 
Calcium Phosphate 1.5150   1.5150   1.5150 
AIN-76A Vitamin Mix 1.1650   1.1650   1.1650 
DIO Mineral Mix 1.1650   1.1650   1.1650 
Calcium Carbonate 0.6410   0.6410   0.6410 
L-Cystine  0.3500   0.3500   0.3500 
Choline Bitartate 0.2330   0.2330   0.2330 
FD&C Yellow 6 Lake  0.0300   0.0300     0.0300 
(orange)  
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Supplemental Table 2:  Primer sequences of genes 
Genes  Forward primer   Reverse primer    
m36B4  ATGGGTACAAGCGCGTCCTG   GCCTTGACCTTTTCAGTAAG 
mFasn  GGCATCATTGGGCACTCCTT  GCTGCAAGCACAGCCTCTCT 
mAcyl  CCAGTTAATCAAACGTCGAGGA  CTTTGGCCTTGCCGACAGT 
mScd1 TAGCCTGTAAAAGATTTCTGCAAACC CCGGAGACCCTTAGATCGA   
mScd2 TTCTCCCGAGAGCTAATGTTCT  TTCTTGCGATACGCCGTGG  
mAcss2  AAACACGCTCAGGGAAAATCA  ACCGTAGATGTATCCCCCAGG 
mPmvk  AAAATCCGGGAAGGACTTCGT  AGAGCACAGATGTTACCTCCA 
mMvd ATGGCCTCAGAAAAGCCTCAG  TGGTCGTTTTTAGCTGGTCCT 
mFdft1  TCCCACTGCTGTGTAACTTCC  TGTCTACAAATTCTGCCATCCC 
mInsig1  TGTCGGTTTACTGTATCCCTGT  GGCAAAATCTAATTTGGCACTGG 
mFdps  GGAGGTCCTAGAGTACAATGCC  AAGCCTGGAGCAGTTCTACAC 
mSrebp1a    GCCAGCCTGGCAATGTGTGA  CAGGTCACACAGGAGCAGCT 
mSrebp1c   GGAGCCATGGATTGCACATT   CCTGTCTCACCCCCAGCATA 
mSrebp2     CTGCAGCCTCAAGTGCAAAG  CAGTGTGCCATTGGCTGTCT   
mHmgcr     AGCTTGCCCGAATTGTATGTG  TCTGTTGTGAACCATGTGACTTC 
mLdlr     GCATCAGCTTGGACAAGGTGT  GGGAACAGCCACCATTGTTG  
mScap    TGGAGCTTTTGAGACTCAGGA   TCGATTAAGCAGGTGAGGTCG 
mUbxd8     GAGCAGGATCTAACTCAGGAGC CAGCAGCCTCCATGTTCCAG 
mLxra     CTCAATGCCTGATGTTTCTCCT  TCCAACCCTATCCCTAAAGCAA 
mLxrb     CGTGGTCATCTTAGAGCCAGA  GCTGAGCACGTTGTAGTGGAA 
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Supplemental Table 2 continued:  Primer sequences of genes 
Genes  Forward primer   Reverse primer    
mAbca1      AAAACCGCAGACATCCTTCAG  CATACCGAAACTCGTTCACCC 
mAbcg1       CTTTCCTACTCTGTACCCGAGG CGGGGCATTCCATTGATAAGG 
mSoat1        GAAGGCTCACTCATTTGTCAGA GTCTCGGTAAATAAGTGTAGGCG 
mSqle       ATAAGAAATGCGGGGATGTCAC ATATCCGAGAAGGCAGCGAAC 
hGAPDH     GAAGGTGAAGGTCGGAGTC  GAAGATGGTGATGGGATTTC 
hSREBP1     ACTTCCCTGGCCTATTTGACC  GGCATGGACGGGTAAATCTT 
hSREBP2      AACGGTCATTCACCCAGGTC  GGCTGAAGAATAGGAGTTGCC 
  hACSS2        CAAGTGTGTCAGTTCAGCAATG CCACAAGCTCTGGGATCATAGG 
hHMGCR      GGACCCCTTTGCTTAGATGAAA CCACCAAGACCTATTGCTCTG  
hHMGCS1     CTCTTGGGATGGACGGTATGC GCTCCAACTCCACCTGTAGG 
hMVD            GGACCGGATTTGGCTGAATG CCCATCCCGTGAGTTCCTC 
hINSIG1          CCTGGCATCATCGCCTGTT  AGAGTGACATTCCTCTGGATCTG 
hSQLE            TGACAATTCTCATCTGAGGTCCA CAGGGATACCCTTTAGCAGTTTT 
hLDLR          GACGTGGCGTGAACATCTG  CTGGCAGGCAATGCTTTGG 
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Supplemental Table  3: Detailed fatty acid profile of diets 
Fatty acids Saturated (%)   Cis-Unsaturated (%)   Trans-Unsaturated (%) 
C 14:0   0.18    0.44     0.14 
C 14:1 9t  0    0     0 
C 14:1 9c  0    0     0 
C 16:0   23.76    16.16     11.01 
C 16:1 9t  0    0     0 
C 16:1 9c  0.18    0.26     0 
C 17:0   0.28    0     0.17 
C 17:1 10c  0    0     0 
C 18:0   31.59    2.99   8.23 
C 18:1 7+8t  0.11    0   4.28 
C 18:1 9t  0    0.11   3.33 
C 18:1 11t  0    0   6.66 
C 18:1 5c+7c+12t 0    0   5.03 
C 18:1 9c+13t  30.98    49.24   23.84 
C 18:1 11c+15t  0.87    2.54   2.05 
C 18:1 12c  0    0.23   6.85 
C 18:1 13c  0    0.10   0.91 
C 18:1 15c  0    0   0.65 
C 18:2 tt  0    0   0.78 
C 18:2 ct  0    0.19   0 
C 18:2 tc  0    0.11   0 
C 18:2 cc  9.67    19.96   7.56 
C 18:3 ttt  0    0   0  
C 20:0   1.10    0.55   0.31 
C 18:3 tct  0    0   0 
C 18:3 ctt  0    0   0 
C 18:3 ctc  0    0.09   0 
C 18:3 tcc  0    0.19   0 
C 18:3 ccc  1.16    5.03   1.00 
C 20:1 11c  0    0.84   0.21 
Unspecified cis/trans 0    0   11.01   
Unknown fatty acids 0.14    1.04   6.03 
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Abstract 
Background: ANGPTL4 regulates plasma triglyceride levels by inhibiting lipoprotein 
lipase. Inactivation of ANGPTL4 decreases plasma triglycerides and reduces risk of 
coronary artery disease. Unfortunately, targeting ANGPTL4 for the therapeutic 
management of dyslipidemia and atherosclerosis is hampered by the observation that 
mice and monkeys in which ANGPTL4 is inactivated exhibit lipid accumulation in 
mesenteric lymph nodes. In mice these pathological events exclusively unfold upon 
feeding a high saturated fatty acid diet and are followed by an ultimately lethal pro-
inflammatory response and chylous ascites.  
Results: Here we show that Angptl4-/- mice fed a diet rich in trans fatty acids develop 
numerous lipid-filled giant cells in their mesenteric lymph nodes, yet do not have 
elevated serum amyloid and haptoglobin, do not exhibit ascites, and survive, unlike 
Angptl4-/- mice fed a saturated fatty acid-rich diet. In RAW264.7 macrophages the 
saturated fatty acid palmitate markedly increases markers of inflammation and the 
unfolded protein response, whereas the trans-unsaturated elaidate and the cis-unsaturated 
oleate have the opposite effect.  
Conclusion: Trans and saturated fatty acids have very distinct biological effects. 
Furthermore, lipid accumulation in mesenteric lymph nodes is uncoupled from activation 
of an acute-phase response and chylous ascites, suggesting that ANGPTL4 should not 
be fully dismissed as target for dyslipidemia. 
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Introduction 
Elevated plasma levels of LDL-cholesterol are widely accepted to accelerate the 
development of atherosclerosis. Besides LDL, elevated plasma triglycerides are 
increasingly recognized as a risk factor for coronary artery disease. More specifically, 
recent human genetic studies have pointed towards a causal role of hypertriglyceridemia 
in atherosclerosis development. Accordingly, strategies aimed at reducing 
hypertriglyceridemia in humans offer a promising therapeutic approach to lower the risk 
of coronary artery disease. Triglycerides are present in the blood as part of chylomicrons 
and very low density lipoproteins, and are hydrolysed by the enzyme lipoprotein lipase 
(LPL) [1]. Hence, enhanced hydrolysis of triglycerides by LPL attenuates 
hypertriglyceridemia and may be targeted to retard the development of coronary artery 
disease [2]. 
LPL is produced by a number of cell types including (cardio)myocytes, adipocytes, and 
macrophages, and is transported to the luminal surface of capillaries by the protein 
glycosylphosphatidylinositol-anchored HDL binding protein 1 (GPIHBP1), which also 
helps to stabilize LPL [3]. Consequently, inactivating mutations in GPIHBP1 give rise 
to hyperchylomicronemia in mice and humans [4,5]. The activity of LPL is under tight 
regulation by several proteins to ensure the homeostatic balance in triglyceride disposal 
under different nutritional and physiological states [6,7]. One of these proteins is 
Angiopoietin-like 4 (ANGPTL4). Following its discovery in 2000 [8,9], ANGPTL4 has 
been shown to post-translationally inhibit LPL activity by promoting the conversion of 
catalytically active LPL dimers into inactive monomers and by stimulating the 
intracellular degradation of LPL [10,11]. As a result, over-expression of ANGPTL4 in 
mice leads to increased plasma triglycerides, whereas the deletion of ANGPTL4 results 
in lower plasma triglycerides [12,13]. Interestingly, the loss of ANGPTL4 is able to 
correct the hypertriglyceridemia in Gpihbp1-/- mice [14], suggesting that ANGPTL4 
may interfere with an accessory transport mechanism for LPL across the endothelium 
[3]. Alternatively, the pronounced lipid lowering caused by loss of ANGPTL4 in 
Gpihbp1-/- mice may be due to enhanced entry of LPL into the bloodstream via the 
lymph [10]. 
In humans, carriers of the inactivating E40K mutation in ANGPTL4 have lower plasma 
triglyceride levels and have a reduced risk of coronary artery disease compared to non-
carriers [15,16]. Based on these observations, ANGPTL4 would seem a very attractive 
pharmacological target to decrease the risk of developing coronary artery disease. 
However, we and others have shown that inactivating ANGPTL4 in mice fed a diet high 
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in saturated fat elicits severe and ultimately lethal chylous ascites and peritonitis, which 
is preceded by enlarged mesenteric lymph nodes (MLN), the presence of lipid-filled 
giant cells, and a massive acute phase response [17]. These effects were coupled to the 
role of ANGPTL4 as LPL inhibitor in MLN macrophages, thereby preventing excessive 
fatty acid uptake and a concomitant pro-inflammatory response. The above data have 
raised serious concerns about the safety of pharmacological targeting of ANGPTL4 in 
patients. Recently, Dewey et al. reported the accumulation of lipids in MLN of several 
female monkeys treated with an anti-ANGPTL4 antibody [16]. However, it is presently 
unclear whether the accumulation of lipid in MLN forebodes a marked acute phase 
response, and is directly connected to the development of chylous ascites and peritonitis. 
In this context, it is relevant to mention that Dewey et al. did not observe any significant 
difference between E40K carriers and non-carriers in the rates of diagnosis codes for 
abdominal lymphatic disorders, as well as ascites, peritonitis, malabsorption, abdominal 
discomfort, or diarrhea [16].  
Trans fatty acids are unsaturated fatty acids that contain one or more double bonds in the 
trans configuration as opposed to the more common cis-configuration. Trans fatty acids 
are synthesized naturally in small amounts in the guts of certain ruminants and are thus 
contained in meat and dairy products of these animals [18,19]. However, most of the 
ingested trans fatty acids are synthesized artificially during food processing by partial 
hydrogenation of vegetable oils to improve the texture and longevity of foods. Numerous 
epidemiological studies have demonstrated a strong correlation between consumption of 
industrially-produced trans fatty acids and the development of cardiovascular diseases 
[20–24]. Consequently, national policies that either restrict or ban the consumption of 
trans fat-rich foods have been instituted by several countries [25–29].  
A trans double bond preserves the straight conformation of a fatty acid, whereas a regular 
cis double bond creates a kink in the fatty acid molecule. Because they have a similar 
linear structure, trans fatty acids are claimed to act like saturated fatty acids. Indeed, both 
trans and saturated fatty acids have been shown to raise plasma levels of LDL, which 
may account for the positive link between trans and saturated fatty acid consumption and 
coronary artery disease [22]. However, to what extent trans and saturated fatty acids are 
interchangeable and share the same cellular effects in vivo and in vitro is not well known. 
To further explore this question, we compared the effect of diets rich in trans or saturated 
fatty acids in Angptl4-/- mice, which as pointed out above develop a massive acute phase 
response and ultimately lethal chylous ascites upon feeding a saturated fat-rich diet. 
These studies were complemented by investigations into the effect of saturated and trans 
fatty acids in cultured macrophages. Our results indicate that: a) trans fatty acids have 
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very distinct effects from saturated fatty acids in vitro and in vivo; b) the accumulation 
of lipid in MLN is uncoupled from the hepatic acute phase response and chylous ascites 
in Angptl4-/- mice fed a diet rich in trans fatty acids.  
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Materials and Methods 
Animal Treatment 
Animal studies were conducted using pure-bred Angptl4-/- mice on a C57Bl/6 
background. Four- to six-months-old male mice were randomly assigned to 3 groups 
(n=8 per group). Each group was fed a high fat diet rich in saturated, cis-unsaturated or 
trans-unsaturated fatty acids for 7 weeks providing 45% energy percent as triglycerides 
(Modified Testdiet 58V8, TestDiet), shown in Supplemental Table 1 (Test Diet Limited, 
London). Fat sources were partially hydrogenated soy oil for the trans fat diet, canola 
and palm olein oil for the unsaturated fat diet, and cocoa butter for the saturated fat diet. 
Bodyweight and food intake were measured weekly. Blood samples were collected at 
weekly intervals by tail vein bleeding into EDTA-coated tubes. After the dietary 
intervention, mice were anaesthetized with isoflurane, followed by blood collection via 
orbital puncture. Mice were euthanized by cervical dislocation, after which tissues were 
excised. Tissues for RNA and protein analysis were immediately frozen in liquid 
nitrogen and stored at -80oC. Tissues for histological analysis were fixed in 4% 
paraformaldehyde and later embedded in paraffin. In a second study, 9 male Angptl4-/- 
and 8 male wildtype mice at 4-6 months of age were placed on the trans-fat diet for 7 
weeks purposely to confirm and to quantify foam cell formation in the MLN. These 
animal studies were approved by the Local Animal Ethics Committee at Wageningen 
University. 
Fatty acid profiling of test diets by Gas Chromatography - Flame Ionization 
Detection 
The fat component in the test diets was extracted by the Folch technique as previously 
described [30]. Briefly, the fats were extracted with a mixture of chloroform and ethanol 
(2:1 ratio). The addition of water gave a biphasic system, with the fat contained in the 
chloroform at lower phase. Following purification, the extracted fats were measured 
gravimetrically. The isolated fats were then saponificated with methanolic NaOH and 
methylated with boron trifluoride (BF3) to obtain methyl esters. The methyl esters were 
then fractionated by gas chromatography, detected by flame ionization and calculated as 
a fraction of the total amount. 
Histology 
Hematoxylin and eosin (H&E) staining of MLN was performed using standard protocols. 
In summary, the MLN were fixed in 4% paraformaldehyde, processed and embedded in 
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paraffin blocks. The tissues were then sectioned onto a superfrost glass slide at 3 μm 
with a microtome. The tissue slices were incubated overnight at 37oC. The slices were 
stained at room temperature in Mayer hematoxylin solution for 10 min and in eosin Y 
solution for 10 sec. Images were then taken with a light microscope.  
Quantification of plasma acute phase proteins, insulin, and glucose. 
Blood samples were centrifuged at 4°C for 15 min at 10,000g. Plasma was collected and 
stored at −80°C. ELISA Development kits were used to measure plasma serum amyloid 
A (Tridelta Dev. Ltd, Ireland), Haptoglobin (Abcam, Cambridge-UK) and Lipocalin-2 
(Abcam, Cambridge-UK) according to the manufacturer’s protocol. Plasma insulin and 
glucose were measured on plasma samples collected after 2 weeks of dietary 
intervention, prior to the mice getting visibly ill. Glucose (DiaSys, Germany) and insulin 
(Crystal Chem, Downers Grove, USA) were measured using dedicated kits. 
RNA isolation and quantitative real-time PCR 
Total RNA was isolated from mouse liver tissue or cultured RAW264.7 macrophages 
with TRIzol reagent (Invitrogen, Bleiswijk, the Netherlands) and a Tissuelyser II 
(Qiagen, Venlo, the Netherlands). Reverse transcription was performed using First 
strand cDNA synthesis kit (Thermo Scientific, IL, USA) according to the manufacturer’s 
protocol. Quantitative RT-PCR-amplifications were performed with iQ SYBR Green 
Supermix on a CFX384 Touch real-time PCR detection system (Bio-Rad, Hercules, CA, 
USA). Primer sequences of genes are provided in Supplemental Table 2. Expression of 
target genes were normalised to 36b4. 
Cell culture 
Murine RAW264.7 macrophages (ATCC) were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 
1000 µg/ml streptomycin (Lonza, Verviers, Belgium) in a humidified chamber at 37 oC  
with 5% CO2. 
Fatty acid preparation and treatment 
Palmitate, oleate and elaidate (Sigma-Aldrich, St Louis, MO, USA) served as models of 
saturated, cis-unsaturated and trans-unsaturated fatty acids respectively. The fatty acids 
were reconstituted in ethanol and prepared by dissolving in filter-sterilised 70 mM KOH. 
The fatty acids were coupled to FA-free BSA by 30 min incubation at 37oC in a pre-
warmed DMEM containing FA-free BSA. The final working concentrations of the FAs 
was 500 µM and the final ratio of FFA:BSA was 2:1. Vehicle control treatment was 
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prepared using an equivalent mixture of KOH and ethanol. The final concentration of 
ethanol was less than 0.1%. The RAW264.7 cells were seeded into 6-well plates at 4 x 
105 cells per well. After overnight incubation, the cells were incubated with 500 µM of 
the individual fatty acids or vehicle control for 6 hours. Treatments for experiments were 
performed in triplicates unless specified otherwise. This procedure was repeated in 
subsequent experiments with different trans fatty acids (elaidate, trans-vaccenate, 
palmitelaidate, CLA 9Z,11E and CLA 10E, 12Z) and different saturated fatty acids 
(laurate, myristate, palmitate and stearate). 
Fatty acid treatment of RAW264.7 cells in the presence of chemical inhibitors 
Palmitate-treated RAW264.7 cells were co-treated with several chemical inhibitors. 
Specifically,  RAW264.7 cells were treated with 500 µM palmitate for 6 hours, and co-
treated for the same duration with 10 µM dimethylsphingosine (DMS) (a sphingosine 
kinase inhibitor), 100 µM sulfosuccinimidyl olate (SSO) (CD36 inhibitor), 2.5 µM 
Triascin C (Acyl-CoA synthase inhibitor), 50 µM C2-ceramide (membrane-permeable 
ceramide analog), 10 µM fumonisin B1 (ceramide synthase inhibitor), 10 µM 
amidepsine A (Diglyceride acyltransferase 1 (DGAT1) inhibitor), 50 µM etomoxir 
(carnitine palmitoyl transferase 1 (Cpt1) inhibitor) or 10 µM myriocin (serine 
palmitoyltransferase 1 (SPT1) inhibitor). In a follow-up experiment, RAW 264.7 cells 
were treated with 500 µM palmitate, oleate or elaidate for 6 hours, and co-treated with 
2.5 µM Triascin C or 10 µM DMS. 
Oil red-O staining of lipid droplets 
A stock of oil red-O was prepared by dissolving 0.5 g in 500 mL of isopropanol. A 
working concentration was prepared by mixing the stock and ddH2O at a ratio of 3: 2. 
After treatment, the RAW264.7 cells were washed twice with PBS, fixed with 4% 
paraformaldehyde for 30 min and incubated with filtered oil red-O dye for 20 mins. The 
cells were then carefully washed three times with ddH2O. Pictures were taken by light 
microscope. 
Triglyceride quantification 
Following treatment, cells were washed twice with PBS. Tris-EDTA buffer (25 mM Tris, 
1 mM EDTA; pH7.5) was added to the cells and to prepared triglyceride standards 
(Instruchemie, The Netherlands). The plate was subsequently put at -80oC for 1 hour. 
The plates were allowed to thaw to room temperature, followed by the addition of 200 
µL tertiary butanol and 50 µL methanol. The plates were then put to shake at 270 rpm 
for 15 mins and allowed to evaporate on a hot plate at 60oC. Monocolor reagent 
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(Instruchemie, The Netherlands) were then added to the wells, followed by shaking for 
5 mins at 250 rpm on a plate shaker. Samples and standards were transferred to 96-well 
plates and absorbance was measured at 492 nm. Triglyceride content was normalized to 
protein content, which was quantified by the Pierce BCA protein assay 
(ThermoScientific, IL, USA) according to manufacturer’s protocol. 
Measurement of Oxidative stress 
Intracellular ROS production was measured using DCFDA Cellular ROS Detection 
Assay kit (Abcam, ab11385, Cambridge, UK) according to manufacturer’s protocol. In 
brief, RAW264.7 cells were seeded into 96-well plates at 2 × 104 cells per well. After 
overnight incubation, cells were washed with PBS and incubated with 20 μM DCFDA 
dye for 45 mins at 37°C in the dark. The cells were then washed with PBS and incubated 
for 6 hours with fatty acids or vehicle control. DCFDA oxidation by intracellular ROS 
generates a fluorescent dicholorofluorescein (DCF). Fluorescence signal was measured 
at excitation/emission wavelengths Ex485/Em538 nm with a Fluoroskan Ascent FL 
microplate reader. Six replicates were used per individual fatty acid and control 
treatment. 
Immunoblot of UPR markers 
Cell lysates were prepared with RIPA lysis buffer supplemented with protease and 
phosphatase inhibitors. Protein concentrations in lysates was quantified via Bradford 
assay (Biorad, CA, USA). Samples were boiled for 5 min in SDS-containing buffer 
before 30ug of protein lysates were loaded in a mini SDS-PAGE gel. Phos-tag gels were 
run similar to regular SDS-PAGE gels complemented with 50 μM MnCl2 (Sigma) and 
50 μM Phos-tag (NARD), and by soaking gels for 10 mins in 1 mM EDTA before 
transfer to PVDF membrane as previously described [31]. The primary antibodies which 
were diluted in 2% BSA in TBST are as follows: HSP90 (#7947, 1:5000), BiP (#1051, 
1:500), α-Tubulin (#5286, 1:2000) from Santa Cruz; IRE1α (#3294, 1:2000), PERK 
(#3192, 1:2000), cleaved caspase-3 (#9664, 1:1000) from Cell Signaling; Sel1L 
(ab78298, 1:2,000), CHOP (ab11419, 1:1000) from Abcam; Xbp1 (#9D11A43, 1:1000) 
from BioLegend; Hrd1 (kind gift from Dr. Richard Wojcikiewicz 1:200). The secondary 
antibodies which were diluted in 5% milk in TBST are anti-rabbit IgG-HRP (Biorad, 
1:5000), anti-mouse IgG-HRP (Biorad, 1:5000); and anti-goat IgG-HRP (Jackson 
ImmunoResearch, 1:5000). 
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Microarray analysis 
Microarray analysis was performed on RAW264.7 macrophages treated with either 
palmitate, oleate or elaidate (500 µM) for 6 hours. RNA was purified with RNeasy 
Minikit columns (Qiagen) and analyzed for quality with RNA 6000 Nano chips on the 
Agilent 2100 Bioanalyzer (Agilent Technologies, Amsterdam, The Netherlands). One 
microgram of RNA was used for cDNA synthesis using the First Strand cDNA synthesis 
kit (Thermo Scientific IL, USA). Purified RNA (100 ng) was labeled with the Ambion 
WT expression kit (Invitrogen) and hybridized to an Affymetrix Mouse Gene 1.1 ST 
array plate (Affymetrix, Santa Clara, CA). Hybridization, washing, and scanning were 
carried out on an Affymetrix GeneTitan platform. Scans of the Affymetrix arrays were 
processed using packages from the Bioconductor project. Arrays were normalized using 
the Robust Multi-array Average method [32,33]. Probesets were defined by assigning 
probes to unique gene identifiers, e.g. Entrez ID [34]. The total gene set (22135 
probesets) was filtered according to the Universal Probability Code method (score >0.5) 
[35], resulting in 7905 probesets , which were used to generate a scatter plot. An overall 
heatmap was generated using the 500 most variable genes based on calculation of the 
coefficient of variation. UPC-filtered genes that were induced at least 1.5 fold by 
palmitate or elaidate relative to oleate were used for Ingenuity Pathway Analysis 
(Ingenuity Systems, Redwood City, USA) Microarray data were submitted to the Gene 
Expression Omnibus (accession number SE98303). 
Lipid analysis 
Ceramide and sphingomyelin levels were determined by Liquid Chromatography 
coupled to Electrospray Ionization Tandem Mass Spectrometry (LC-ESI-MS/MS). 
RAW 264.7 macrophages from 10 cm cell culture dishes were homogenized in 400 µl 
of water using the Precellys 24 Homogenisator (Peqlab, Erlangen, Germany) at 6,500 
rpm for 30 sec. To 100 µl of homogenate 500 µl of methanol, 250 µl of chloroform and 
internal standards (127 pmol Ceramide 12:0 and 123 pmol Sphingomyelin 12:0, both 
Avanti Polar Lipids, Alabaster, AL, USA) were added. Lipid extraction was performed 
as previously described [36]. Dried lipid extracts were resolved in 300 µl of mobile phase 
solvent A (see below). LC-MS/MS analysis was performed using a normal phase 
Nucleosil NH2 column (50 mm × 2 mm ID, 3 µm particle size, 120 Å pore size, 
Macherey-Nagel, Dueren, Germany) with detection using a QTRAP 6500 mass 
spectrometer (SCIEX, Darmstadt, Germany). The LC (1260 Infinity Binary LC System, 
Agilent, Waldbronn, Germany) was operated at a flow rate of 0.75 ml/min with a mobile 
phase of acetonitrile/methanol/acetic acid 97:2:1 (v/v/v), with 5 mM ammonium acetate 
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(solvent A) and methanol/acetic acid 99:1 (v/v/v) with 5 mM ammonium acetate (solvent 
B). LC separation and MS/MS detection were performed as previously described [36]. 
Ceramide and sphingomyelin species were quantified on the basis of calibration curves 
which were calculated from LC-MS/MS measurements of serially diluted synthetic 
ceramide and sphingomyelins standards (Avanti Polar Lipids, Alabaster, AL, USA). 
Linearity and correlation coefficients of the standard curves were obtained via linear 
regression analysis. 
Statistical Analysis 
Statistical analyses were performed using one-way ANOVA followed by the Tukey HSD 
test. Data are represented as means ± SEM (animal studies) or means ± SD (cell culture 
studies).  P<0.05 was considered statistically significant.   
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Results 
Feeding Angptl4-/- mice a diet rich in saturated fatty acids but not trans- or cis-
unsaturated fatty acids results in peritonitis, chylous ascites and death.  
Angptl4-/- mice were randomly assigned to a diet rich in saturated fatty acids 
(“Saturated”), a diet rich in cis-unsaturated fatty acids (“Unsaturated”), or a diet rich in 
trans-unsaturated fatty acids (“Trans”). Different fats were blended to achieve a similar 
relative content of saturated fatty acids between the cis-unsaturated and the trans-
unsaturated diets, a similar content of cis-unsaturated fatty acids between the saturated 
and the trans-unsaturated diets, and a complete absence of trans fatty acids in the 
saturated and cis-unsaturated diets. Analysis of the fat composition of the three diets by 
gas chromatography indicated that approximately 60-65% of the total fatty acid content 
was constant among the three diets, with the remaining 35-40% of the fatty acids taken 
up by saturated fatty acids, cis-unsaturated fatty acids, or trans-unsaturated fatty acids 
(Figure 1A). The detailed fatty acid profiles of the three diets are shown in Supplemental 
Table 3.  The Angptl4-/- mice were fed the diets for 7 weeks. Consistent with our 
previous studies, Angptl4-/- mice fed the saturated fat diet developed anorexia 
characterized by decreased feed intake (Figure 1B) and a concomitant steady decline in 
body weight (Figure 1C). Six of the 8 mice in the saturated fat group became severely ill 
and showed severe lethargy, reduced responsiveness to stimuli, and abdominal 
distention. These mice had to be euthanized before the end of the 7-week period, as 
illustrated by the survival curve (Figure 1D). Upon euthanasia, Angptl4-/- mice fed the 
saturated fat diet showed an exudate of chylous ascites and fibrinopurulent peritonitis, 
as previously reported (Figure 1E). In comparison with earlier experiments, the onset of 
the development of clinical symptoms in the Angptl4-/- mice was more rapid. 
Remarkably, the observed pathologies were absent both in the Angptl4-/- mice fed the 
cis or trans-unsaturated fat diet, even after more prolonged feeding (18 weeks) and in the 
wildtype mice fed any of the three diets. 
After 2 weeks of feeding, prior to becoming visibly ill, plasma glucose levels were 
significantly lower in the Angptl4-/- mice fed the saturated fat diet compared to the other 
two groups (Figure 1F). By contrast, plasma insulin levels were the highest in the 
Angptl4-/- mice fed the trans-unsaturated fat diet.  
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Figure 1: Feeding Angptl4-/- mice a diet rich in saturated but not trans- or cis-unsaturated 
fatty acids results in peritonitis, chylous ascites and death. (A) Profile of fatty acid composition 
in the three test diets. Changes in body weight (B), average daily food intake (C), and survival (D) 
of Angptl4-/- mice fed the trans, unsaturated or saturated fat diet for 7 weeks. (E) Representative 
pictures of Angptl4-/- mice fed the saturated fat diet immediately after sacrifice, before (left) and 
after (right) removal of peritoneum. A sample of the ascites fluid collected from the peritoneum 
of a single mouse is shown at the top right. (F) Plasma levels of glucose and insulin after 2 weeks 
of feeding. Error bars represent SEM. Asterisks indicates significantly different relative to the 
trans fat group (* p< 0.05). 
Feeding Angptl4-/- mice a diet rich in saturated fatty acids but not trans- or cis-
unsaturated fatty acids causes marked elevation of acute phase proteins.  
To examine the effect of the three diets on inflammation, we measured plasma levels of 
the acute phase protein Serum Amyloid A (SAA). Strikingly, whereas Angptl4-/- mice 
fed the saturated fat diet showed a more than 50-fold increase in plasma SAA within one 
week, the mice fed the trans- and cis-unsaturated fat diet showed no increase at all 
(Figure 2A). 
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Figure 2: Feeding Angptl4-/- mice a diet rich in saturated but not trans- or cis-unsaturated 
fatty acids causes marked elevation of acute phase proteins. Angptl4-/- mice were fed the trans, 
unsaturated or saturated fat diet for 7 weeks. (A) Weekly circulating levels of serum amyloid A 
(SAA). (B) Relative hepatic mRNA level of Saa2. (C) Plasma levels of haptoglobin. (D) Relative 
hepatic mRNA level of Hp.  (E) Plasma levels of Lipocalin. (F) Relative hepatic mRNA level of 
Lcn2. mRNA expression levels were normalised against 36b4. Please note that the Angptl4-/- mice 
fed the saturated fat diet were euthanized at different time points due to the implementation of 
humane endpoints. Error bars represent SEM. Asterisks indicates significantly different relative 
to trans fat group (* p< 0.05). 
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In agreement with these data, liver mRNA levels of Saa2 at sacrifice were significantly 
elevated in the saturated fat group but not in the trans- or cis-unsaturated fat groups 
(Figure 2B). Plasma levels of haptoglobin and lipocalin, as well as liver mRNA of Hp 
and Lcn2, mirrored the SAA data, showing a marked increase in the saturated fat group 
in comparison to both the trans- or cis-unsaturated fat groups (Figure 2C-F). Overall, 
these data show that feeding Angptl4-/- mice a diet rich in trans-unsaturated fatty acids 
does not lead to chylous ascites and peritonitis, and does not provoke a massive acute 
phase response, unlike Angptl4-/- mice fed a diet rich in saturated fatty acids. 
 
Figure 3: Feeding Angptl4-/- mice a diet rich in trans or saturated fatty acids results in 
Touton giant cells in MLN.  (A) Representative photograph after H&E staining showing enlarged 
MLN in Angptl4-/- mice fed the saturated or trans fat diet but not the unsaturated fat diet. (B) 
Lower magnification (x100) images showing the relative abundance of Touton giant (foam) cells 
in the MLN of Angptl4-/- mice fed the saturated or trans fat diet but not the unsaturated fat diet. 
(C) Higher magnification (x200; insert x400) images of giant cells in MLNs of the Angptl4-/- mice 
fed the trans or saturated fat diet. Black arrows indicate giant cells. 
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Feeding Angptl4-/- mice a diet rich in trans or saturated fatty acids stimulates 
lymphadenopathy characterized by formation of giant cells. 
We have previously demonstrated that the development of chylous ascites in Angptl4-/- 
mice fed a saturated fat diet is accompanied by mesenteric lymphadenopathy as shown 
by enlarged MLN and the appearance of Touton giant cells (macrophage foam cells). 
Therefore, in this study, we performed H&E staining on the lymph nodes to examine 
giant cell formation. In agreement with our earlier studies, lipid-laden giant cells could 
be observed in the enlarged MLN of Angptl4-/- mice fed the saturated fat diet (6 positives 
out of 7 lymph nodes studied). Intriguingly, despite the absence of ascites and any 
elevation in plasma acute phase proteins, MLN were enlarged and giant cells were also 
plentiful in the Angptl4-/- mice fed the trans-unsaturated fat diet (9 positives out of 13 
lymph nodes studied) (Figure 3A, B and C). No giant cells were observed in the MLN 
of Angptl4-/- mice fed the cis-unsaturated fat diet (0 positives out of 5 lymph nodes 
studied) nor were they ever observed in wildtype mice. A summary of the observations 
in the Angptl4-/- mice fed the three diets is presented in Supplemental Table 4. These 
data show that mesenteric lymphadenopathy in Angptl4-/- mice is uncoupled from the 
hepatic acute phase response and chylous ascites. 
Palmitate but not elaidate and oleate stimulates UPR in cultured macrophages.  
The experiments in Angptl4-/- mice suggest that saturated fatty acids and trans-
unsaturated fatty acids have distinct effects on inflammation, despite both leading to 
foam cell formation. To study the mechanistic basis for these differences in inflammatory 
properties, we used RAW264.7 macrophages and incubated these cells either with a 
saturated fatty acid (palmitate), a cis-unsaturated fatty acid (oleate), or a trans-
unsaturated fatty acid (elaidate). Oil red-O staining showed that all three fatty acids 
promoted lipid droplet and foam cell formation (Figure 4A). Histological and 
biochemical analysis did not reveal any differences in lipid accumulation among the 
three fatty acids (Figure 4B). Consistent with the in vivo data, the saturated fatty acid 
palmitate had a pronounced pro-inflammatory effect, as shown by the induction of 
numerous genes involved in inflammation, including Ptgs2, Cxcl2 and Gdf15, whereas 
oleate and elaidate caused a modest yet significant decrease in inflammatory gene 
expression (Figure 5A). The differences in inflammatory properties of the fatty acids 
could not be explained by differences in activation of oxidative stress, as determined by 
measuring ROS production (Figure 5B). 
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Figure 4: Similar lipid content in RAW264.7 macrophages treated with different fatty acids. 
RAW264.7 macrophages were treated with 500 µM of individual fatty acids (palmitate, oleate or 
elaidate) or vehicle control for 6 hours. (A) Representative images of Oil red-O staining of lipid 
droplets in RAW264.7 macrophages. (B) Intracellular triglyceride quantification after fatty acid 
treatments. Error bars represent SD. Asterisks indicate statistically significant relative to vehicle 
control (* p< 0.05). 
To gain insight into the mechanism(s) underlying the differential properties of palmitate 
and elaidate, we performed whole genome expression profiling. Visualization of the 
overall gene expression data by heat map showed that the impact of palmitate on gene 
expression was very distinct from that of oleate and elaidate (Figure 5C). In turn, the 
effects of elaidate and oleate were quite similar with the exception of a cluster of genes 
involved in lipid and cholesterol synthesis. When related to oleate, palmitate caused 
much more pronounced changes in gene expression than elaidate, as shown by scatter 
plot analysis (Figure 5D). Ingenuity pathway analysis on genes induced by palmitate 
further corroborated the profound stimulation of inflammatory genes by palmitate. In 
particular, genes part of the pathway “Communication between Innate and Adaptive 
Immune Cells” were highly upregulated by palmitate (rank 6), and to a much lesser 
extent by elaidate (Figure 5E).  By contrast, the pathway “Superpathway of Cholesterol 
Biosynthesis” was specifically induced by elaidate (rank 1) (Figure 5G). Interestingly, 
the pathway “Unfolded Protein Response” was highly induced by palmitate (rank 3) 
when compared with elaidate and oleate (Figure 5F).  
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Figure 5: Differential gene expression profiles in macrophages treated with palmitate, oleate 
or elaidate. (A) Q-PCR expression of selected inflammatory markers in RAW264.7 cells after 
treatment with 500 µM fatty acids or vehicle control for 6 hours. (B) Fluorometric measurement 
of relative reactive oxygen species as marker of oxidative stress in RAW264.7 macrophages. (C) 
Heatmap of the 500 most variable genes based on the calculation of the coefficient of variation. 
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The cluster of genes deviating in the elaidate-treated cells is indicated. (D) Scatter plot of genes 
that passed the UPC filter (7905 of the 22135 probesets). The signal log ratio for the comparison 
of palmitate vs. oleate treated cells is shown along the Y-axis. The signal log ratio for the 
comparison of elaidate vs. oleate treated cells is shown along the X-axis. (E-G) Heatmaps of 
pathways that were induced by palmitate: communication between innate and adaptive immune 
cells (E) and unfolded protein response (F), or elaidate: superpathway of cholesterol biosynthesis 
(G), according to Ingenuity pathway analysis. Asterisks indicate statistically significant relative 
to vehicle control (* p< 0.05). 
Activation of the unfolded protein response (UPR) may provide a mechanistic basis for 
the pro-inflammatory action of palmitate. UPR maintains cell survival via activation of 
sensors such as protein kinase RNA-like ER kinase (PERK), activating transcription 
factor 6 (ATF6) and inositol requiring kinase 1 (IRE1), which in turn triggers the 
unconventional splicing of Xbp1 mRNA to generate the transcription factor XBP1s [37–
40]. Detailed analyses showed that palmitate increased numerous indicators of UPR, 
including XBP1 splicing (Figure 6A), IRE1α phosphorylation, PERK phosphorylation, 
XBP1 and CHOP protein levels (Figure 6B), and expression of various ER stress and 
UPR downstream effector/responsive genes (Figure 6C), which was not observed for 
oleate and elaidate. In fact, oleate and elaidate seemed to lead to a mild but significant 
reduction in UPR in general as compared to control cells, as indicated by IRE1α 
phosphorylation, Ddit3 and Grp78 mRNA levels, and Xbp1 alternative splicing. In 
addition, palmitate induced cleavage of caspase 3, concurrent with upregulation of cell 
stress markers, suggesting enhanced apoptosis (Figure 6D). None of these fatty acids 
caused the induction of ER-associated degradation proteins SEL1L and HRD1 under 
these experimental conditions (Figure 6E). To verify that the behavior of elaidate is 
representative of a broader group of trans unsaturated fatty acids, we studied the effect 
of trans-vaccenate, palmitelaidate, 9Z,11E conjugated linoleate, and 10E,12Z conjugated 
linoleate in RAW264.7 macrophages. All trans fatty acids led to a similar expression 
level of a selected group of UPR and inflammation gene markers (Figure 6F), and all 
were similarly ineffective towards inducing CHOP and XBP1 protein levels (Figure 6G), 
in clear contrast to palmitate. Aside from palmitate, the other saturated fatty acids laurate, 
myristate and stearate effectively induced UPR and inflammation marker genes as well 
as CHOP and XBP1 protein levels, with a seemingly positive correlation between the 
magnitude of induction and the length of the fatty acid chain (Figure 6H and I). These 
data show that the observed effects of palmitate and elaidate are representative of a larger 
set of saturated and trans unsaturated fatty acids, respectively. 
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Figure 6: Palmitate but not elaidate or oleate induces UPR and inflammation markers in 
RAW264.7 macrophages. RAW264.7 macrophages were treated for 6 hours with individual fatty 
acids (500 μM) as indicated.  (A)  RT-PCR of Xbp1 processing showing unspliced(u) and 
spliced(s) Xbp1 mRNA with L32 as control. (B) Immunoblot of UPR downstream effectors and 
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UPR responsive proteins using regular gels (BIP, PERK, CHOP and XBP1) and phospho-tag gels 
(IRE1α). (C) Q-PCR expression of selected UPR markers. (D) Immunoblot of cleaved caspase-3, 
an indicator of activated cell death by apoptosis. (E) Immunoblot of endoplasmic reticulum-
associated protein degradation markers. (F) Q-PCR expression of selected UPR and inflammation 
marker genes after treatment with the trans fatty acids trans-vaccenic acid, palmitelaidic acid, 
9Z,11E conjugated linoleic acid (CLA 9Z, 11E), 10E,12Z conjugated linoleic acid (CLA 10E, 
12Z), and palmitate. (G) Immunoblot of CHOP and XBP1 after treatment with different trans fatty 
acids and palmitate. (H) Q-PCR expression of selected UPR and inflammation marker genes after 
treatment with the saturated fatty acids laurate, myristate, palmitate, and stearate. (I) Immunoblot 
of CHOP and XBP1 after treatment with different saturated fatty acids. mRNA expression was 
normalised against 36b4. Error bars represent SD. Asterisks indicate statistically significant 
relative to vehicle control (* p< 0.05).  
Consistent with the results shown above, palmitate markedly raised levels of the 
lipotoxic mediator ceramide as compared to elaidate and oleate, as reflected by the total 
ceramide levels (Figure 7A) and levels of fatty-acyl subspecies (Figure 7B). To better 
delineate the differential lipotoxic effects of saturated and unsaturated fatty acids, we 
tested the effect of a number of chemical inhibitors of various pathways of intracellular 
lipid metabolism—including the ceramide pathway—on palmitate-induced UPR and 
inflammation in RAW264.7 macrophages. Whereas most compounds showed minimal 
effects, the CD36 inhibitor sulfosuccinimidyl oleate markedly suppressed the induction 
of Cxcl2 and Ddit3 by palmitate, suggesting that cellular fatty acid uptake is necessary 
for palmitate-induced lipotoxicity (Figure 7C). By contrast, the sphingosine kinase 
inhibitor dimethylsphingosine and the acyl-CoA synthetase inhibitor triascin C markedly 
augmented the induction of Cxcl2 and Ddit3 by palmitate (Figure 7C). Accordingly, we 
selected these two compounds to further dissect the differential effects of trans and 
saturated fatty acids. Interestingly, in the presence of dimethylsphingosine or triascin C, 
elaidate and oleate lowered expression of UPR and inflammation markers, indicating an 
anti-lipotoxic action (Figure 7D). This anti-lipotoxic effect was most pronounced for 
oleate but also clearly noticeable for elaidate. 
Overall, these data indicate that saturated fatty acids and trans fatty acids differentially 
affect UPR and inflammation in cultured macrophages.  
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Figure 7: Anti-lipotoxic effect of oleate and elaidate in RAW264.7 macrophages. RAW264.7 
macrophages were treated for 6 hours with individual fatty acids (500 μM) as indicated. Total 
ceramide levels (A) and levels of ceramide fatty-acyl subspecies (B) after 6-hour treatment with 
elaidate, oleate, palmitate or vehicle control. (C) Cxcl2 and Ddit3 expression in RAW264.7 
macrophages treated with palmitate or vehicle control and co-treated with the compounds 
dimethylsphingosine (DMS), sulfosuccinimidyl olate (SSO), triascin C, C2-ceramide, fumonisin 
B1, amidepsine A, etomoxir and myriocin. (D) Expression of selected UPR and inflammation 
markers in fatty acid-treated RAW264.7 cells co-treated with either triascin C (top row) or DMS 
(bottom row). mRNA expression was normalised against 36b4. Error bars represent SD. Asterisks 
indicate statistically significant relative to vehicle control (* p< 0.05). 
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Discussion 
The work presented in this paper leads to two important conclusions. First, our data show 
that lipid accumulation and the appearance of giant cells in MLN (mesenteric 
lymphadenopathy) in Angptl4-/- mice fed a high fat diet is disconnected from activation 
of the acute phase response, chylous ascites, and death. Accordingly, the development 
of mesenteric lymphadenopathy upon ANGPTL4 inactivation may be clinically silent, 
both in the short and long term, removing part of the concern associated with the use of 
ANGPTL4-inactivating antibodies as lipid-lowering therapy. Second, we demonstrate 
that the effects of saturated fatty acids and trans fatty acids are very distinct, both in vivo 
and in cultured macrophages. Hence, our data do not support the common notion that 
trans fatty acids act like saturated fatty acids. 
By virtue of their ability to inhibit LPL and raise circulating triglyceride levels, members 
of the Angiopoietin-like protein family are intensely explored as pharmacological targets 
for dyslipidemia [41–43]. Whereas the targeting of ANGPTL3 has been very successful 
[44,45]—with strategies to inactivate ANGPTL3 now having moved into clinical trial 
phase—the targeting of ANGPTL4 has been hampered by the observation that 
inactivating ANGPTL4 leads to severe clinical problems in mice fed a diet high in 
saturated fat. Specifically, inactivation of ANGPTL4 causes enhanced lipid uptake into 
macrophages in MLN, triggering foam (Touton) cell formation and a massive 
inflammatory response, which progresses into chylous ascites and ultimately death by 
peritonitis [17,46].  
Two recent genetic studies generated new interest in ANGPTL4 as lipid-lowering target 
by showing that human carriers of an inactivating mutant of ANGPTL4 have a lower 
risk of coronary artery disease than non-carriers, concomitant with a reduction in serum 
triglycerides [15,16]. However, one of these studies also found accumulation of lipids in 
the MLN in a number of the female monkeys treated with ANGPTL4-inactivating 
antibodies, copying the symptoms seen in Angptl4-/- mice fed a high saturated fat diet 
[16]. These findings raised concern about the possible side-effects of the use of 
ANGPTL4-inactivating antibodies in humans. In this paper we show that lipid 
accumulation and the appearance of lipid-laden giant cells in MLN is uncoupled from 
the activation of a massive pro-inflammatory response. In particular, we find that despite 
developing giant cells in their MLN, Angptl4-/- mice fed a diet rich in trans fatty acids 
do not have elevated plasma serum amyloid and haptoglobin levels, do not develop 
ascites, and survive, unlike Angptl4-/- mice fed a diet rich in saturated fatty acids. Our 
findings thus imply that the presence of giant cells in MLN is non-deleterious and 
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clinically silent, which, together with the reduced risk of coronary artery disease in E40K 
carriers, suggests that ANGPTL4 may still have promise as a viable therapeutic target 
for triglyceride lowering and coronary artery disease. To predict future clinical problems, 
our data also emphasize the need to closely monitor plasma levels of acute phase 
proteins, both in E40K homozygotes as well as in monkeys and patients that might be 
treated with ANGPTL4-inactivating antibodies.  
Previously, we proposed that elevated LPL activity in MLN macrophages is responsible 
for the formation of lipid-laden giant cells in Angptl4-/- mice fed a high saturated fat diet 
[17]. We hypothesized that the lipid-activated macrophages would release pro-
inflammatory cytokines into the portal circulation that activate the hepatic acute phase 
response. The data presented in this paper indicate that the formation of lipid-laden giant 
cells per se is insufficient to initiate an acute phase response, thus pointing towards an 
alternative and/or additional mechanism. Based on our in vitro studies, this mechanism 
requires uptake of fatty acids, is specifically activated by saturated fatty acids, and may 
be linked to the ceramide pathway (see below). Interestingly, Angptl4-/- mice do not 
develop lipid-laden giant cells in MLN when fed a diet rich in cis-unsaturated fatty acids, 
even though oleate was equally effective at promoting lipid accumulation in RAW264.7 
macrophages. It can be speculated that the development of lipid-laden giant cells in vivo 
may be dependent on concurrent activation of macrophage or other immune cells, which 
is triggered by saturated fatty acids (and trans-unsaturated fatty acids) but not by the 
more anti-inflammatory cis-unsaturated fatty acids.   
Because trans and saturated fatty acids have a similar linear structure, trans fatty acids 
are claimed to act like saturated fatty acids. Indeed, nutritional trials have shown that 
consumption of diets rich in saturated fatty acid and trans fatty acids both raise LDL-
cholesterol levels in human [23,47]. However, to what extent saturated and trans fatty 
acids exert the same effects at the cellular level and share the same mechanism of action 
is unclear. Our results indicate that the biological effects of saturated and trans fat in 
Angptl4-/- mice are very different. Whereas feeding a diet rich in saturated fat provoked 
a pronounced inflammatory response characterized by a huge increase in plasma levels 
of acute phase proteins, no such response was seen in Angptl4-/- mice fed a diet rich in 
trans fatty acids. Experiments in RAW267.4 macrophages confirmed the distinct 
biological effects of the saturated fatty acid palmitate as compared to the trans fatty acid 
elaidate. Specifically, whereas palmitate triggered inflammation, UPR, and apoptosis, 
elaidate induced genes involved in cholesterol synthesis. The properties of palmitate and 
elaidate were shown to be representative of a whole class of saturated fatty acids and 
trans fatty acids, respectively. 
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The observed lipotoxic properties of palmitate are in line with numerous published 
studies performed in several cell types where palmitate induced a number of stress-
related pathways such as oxidative stress, inflammation, and UPR [48–52]. Several 
physiological and pathological insults can disturb ER function, leading to the 
accumulation of unfolded proteins and causing the subsequent activation of UPR. In our 
studies in RAW264.7 macrophages, we found that palmitate treatment potently activated 
UPR and inflammatory gene expression. By contrast, elaidate and especially oleate 
suppressed UPR and pro-inflammatory gene expression, which was most evident when 
baseline levels of UPR and inflammation were raised using dimethylsphingosine or 
triascin C. These observations are consistent with existing evidence indicating that 
saturated and cis-unsaturated fatty acids are pro-lipotoxic and anti-lipotoxic, respectively 
[50,53–55]. Studies have indicated that palmitate may induce ER stress by altering the 
ER-membrane composition. Indeed, there is evidence that direct sensing of the lipid 
composition of the ER membrane contributes to the UPR [56,57]. Specifically, it has 
been suggested that saturated acyl chains are less flexible than unsaturated acyl chains 
and change the biophysical properties of the membrane to favor dimerization and 
concomitant activation of IRE1 and PERK [58,59]. If that is true, elaidate would be 
expected to mimic the properties of palmitate, which was not at all observed. Consistent 
with our observations, trans-unsaturated fatty acids did not induce ER stress or 
cytotoxicity in yeast and β cells [60,61]. The modest repressive effect of trans fatty acids 
on well-established indicators of lipotoxicity such as UPR and inflammation is both 
unexpected and interesting and presents an attractive challenge for further investigation 
into the potential specific molecular mechanisms behind the purported harmful effects 
of trans fat. Overall, these data underscore the distinct properties of saturated and trans-
unsaturated fatty acids.  
Treatment of RAW264.7 macrophages with palmitate caused a marked increase in levels 
of ceramide, which is a known lipotoxic intermediate. However, our studies using a 
ceramide analog and inhibitors of ceramide synthesis suggest that ceramide itself may 
not be responsible for the palmitate-induced lipotoxicity. The observed potentiation of 
the lipotoxic effect of palmitate by dimethylsphingosine has been observed previously 
[62], and suggests a potential role of sphingosine or sphingosine-1-phosphate. Besides 
dimethylsphingosine, the acyl-CoA synthesis inhibitor triascin C also potentiated 
palmitate-induced lipotoxicity. This result is in line with a similar study in mouse 
peritoneal macrophages treated with stearate [63], and suggest that lipotoxicity is 
mediated by free palmitate/stearate. Based on our experiments, it is not possible to 
attribute the lipotoxic effects of palmitate to a single well-defined mechanism. 
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In conclusion, our data indicate that the presence of lipid-laden giant cells in MLN is 
uncoupled from the acute phase response and chylous ascites. The probable non-
deleterious effect of foam cells in MLN of ANGPTL4 deficient mice suggests that 
ANGPTL4 should not be fully dismissed as a target for correcting dyslipidemia and 
atherosclerosis in humans. Finally, our in vitro and in vivo data strongly indicate that 
trans and saturated fatty acids have distinct biological effects, with the trans fatty acids 
leaning much more towards cis-unsaturated fatty acids than towards saturated fatty acids. 
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Supplemental Material 
Supplemental Table 1: Composition of test diets 
Ingredients (%)  Saturated fat diet Unsaturated fat diet Trans fat diet 
Cocoa Butter  23.3060   0   0 
Canola Oil  0   13.2265   0 
Palm Olein Oil  0   7.8536   0 
Hydrogenated Soy Oil 0   0   21.0800 
Casein- Vitamin Tested 23.3060   23.3059   23.3060  
Sucrose   19.7090   19.7090   19.7090  
Maltodextrin  11.6530   11.6530   11.6530 
Dextrin   8.4830   8.4830   8.4830 
Powdered Cellulose 5.8270   5.8270   5.8270 
Soybean Oil  2.9200   2.9200   2.9200 
Potassium Citrate, 1.9230   1.9230   1.9230  
Tribasic Monohydrate 
Calcium Phosphate 1.5150   1.5150   1.5150 
AIN-76A Vitamin Mix 1.1650   1.1650   1.1650 
DIO Mineral Mix 1.1650   1.1650   1.1650 
Calcium Carbonate 0.6410   0.6410   0.6410 
L-Cystine  0.3500   0.3500   0.3500 
Choline Bitartate 0.2330   0.2330   0.2330 
FD&C Yellow 6 Lake  0.0300   0.0300     0.0300 
(orange)  
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Supplemental Table 2:  Primer sequences of genes 
Genes  Forward primer   Reverse primer    
m36B4  ATGGGTACAAGCGCGTCCTG   GCCTTGACCTTTTCAGTAAG 
mGrp78  AGGACAAGAAGGAGGATGTGGG  ACCGAAGGGTCATTCCAAGTG 
mGrp94  AAACGGCAACACTTCGGTCAG  GCATCCATCTCTTCTCCCTCATC 
mXbp1  GCAGCAAGTGGTGGATTTGG  AGATGTTCTGGGGAGGTGACAAC 
mXbp1s  GAGTCCGCAGCAGGTG   GTGTCAGAGTCCATGGGA 
mDdit3  CTGGAAGCCTGGTATGAGGAT  CAGGGTCAAGAGTAGTGAAGGT 
mDdit4  CAAGGCAAGAGCTGCCATAG  CCGGTACTTAGCGTCAGGG 
mGdf15   CTGGCAATGCCTGAACAACG  GGTCGGGACTTGGTTCTGAG 
mCxcl2  CCAACCACCAGGCTACAGG  GCGTCACACTCAAGCTCTG 
mPtgs2  TTCAACACACTCTATCACTGGC  AGAAGCGTTTGCGGTACTCAT 
mErn1  ACACCGACCACCGTATCTCA  CTCAGGATAATGGTAGCCATGTC 
mHerpud1    CCTGGCTTCTCTGGCTACAC  GTCGGGACAAAAGTTCCTGA 
mHp2  GCTATGTGGAGCACTTGGTTC  CACCCATTGCTTCTCGTCGTT 
mLcn2  TGGAAGAACCAAGGAGCTGT  GGTGGGGACAGAGAAGATGA 
mSAA2  GCGAGCCTACACTGACATGA  TTTTCTCAGCAGCCCAGACT 
mTNFa  CTTCCATCCAGTTGCCTTCTTG  AATTAAGCCTCCGACTTGTGAAG 
mIL6  CAACCTCCTCTCTGCCGTCAA  TGACTCCAAAGTAGACCTGCCC 
mCD68  CCAATTCAGGGTGGAAGAAA  CTCGGGCTCTGATGTAGGTC 
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Supplemental Table  3: Detailed fatty acid profile of diets 
Fatty acids Saturated (%)   Cis-Unsaturated (%)   Trans-Unsaturated (%) 
C 14:0   0.18    0.44     0.14 
C 14:1 9t  0    0     0 
C 14:1 9c  0    0     0 
C 16:0   23.76    16.16     11.01 
C 16:1 9t  0    0     0 
C 16:1 9c  0.18    0.26     0 
C 17:0   0.28    0     0.17 
C 17:1 10c  0    0     0 
C 18:0   31.59    2.99   8.23 
C 18:1 7+8t  0.11    0   4.28 
C 18:1 9t  0    0.11   3.33 
C 18:1 11t  0    0   6.66 
C 18:1 5c+7c+12t 0    0   5.03 
C 18:1 9c+13t  30.98    49.24   23.84 
C 18:1 11c+15t  0.87    2.54   2.05 
C 18:1 12c  0    0.23   6.85 
C 18:1 13c  0    0.10   0.91 
C 18:1 15c  0    0   0.65 
C 18:2 tt  0    0   0.78 
C 18:2 ct  0    0.19   0 
C 18:2 tc  0    0.11   0 
C 18:2 cc  9.67    19.96   7.56 
C 18:3 ttt  0    0   0  
C 20:0   1.10    0.55   0.31 
C 18:3 tct  0    0   0 
C 18:3 ctt  0    0   0 
C 18:3 ctc  0    0.09   0 
C 18:3 tcc  0    0.19   0 
C 18:3 ccc  1.16    5.03   1.00 
C 20:1 11c  0    0.84   0.21 
Unspecified cis/trans 0    0   11.01   
Unknown fatty acids 0.14    1.04   6.03 
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Supplemental Table 4: Overview of clinical observations in Angptl4-/- mice fed the 
different diets 
 
    Saturated fat  Unsaturated fat  Trans fat 
Touton giant cells   Yes (6/7)  No (0/5)  Yes (9/13) 
Enlarged lymp nodes  Yes, massive  Yes, slightly  Yes, slightly 
SAA elevated  Yes   No   No 
Chylous ascites  Yes   No   No 
Weight loss   Yes   No   No 
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Abstract 
Background & Aim: ANGPTL4 regulates plasma lipids, making it an attractive target 
for correcting dyslipidemia. However, ANGPTL4 inactivation in mice fed a high fat diet 
causes chylous ascites, an acute phase response, and mesenteric lymphadenopathy. Here, 
we investigated the role of ANGPTL4 in the abovementioned pathologies using Angptl4 
hypomorphic mice. In addition, we studied the influence of ANGPTL4 on lipid uptake 
in macrophages.  
Results: Angptl4 expression in peritoneal and bone marrow-derived macrophages was 
highly induced by lipids. Recombinant ANGPTL4 decreased lipid uptake in 
macrophages, whereas deficiency of ANGPTL4 increased lipid uptake and enhanced 
lipid-induced genes. Hypomorphic Angptl4 mice with partial expression of N-terminal 
ANGPTL4 exhibited reduced fasting plasma triglyceride, cholesterol, and non-esterified 
fatty acid levels, strongly resembling Angptl4-/- mice. However, during high fat feeding, 
hypomorphic Angptl4 mice showed markedly delayed and attenuated elevation in plasma 
serum amyloid A and much milder chylous ascites than Angptl4-/- mice, despite similar 
abundance of lipid-laden giant cells in mesenteric lymph nodes.  
Conclusion: ANGPTL4 deficiency increases lipid uptake into macrophages. Compared 
with the absence of ANGPTL4, low levels of N-terminal ANGPTL4 are sufficient to 
mitigate the development of chylous ascites and an acute phase response in mice, 
whereas mesenteric lymphadenopathy is not affected. 
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Introduction 
Elevated plasma triglyceride levels are increasingly considered as an independent risk 
factor for cardiovascular diseases [1–3]. Triglycerides circulate in the blood in two major 
forms: as chylomicrons carrying the dietary triglycerides, and as very-low density 
lipoproteins carrying endogenously produced triglycerides [3,4]. The clearance of 
plasma triglycerides is primarily mediated by the action of lipoprotein lipase (LPL). This 
secretory enzyme is produced in parenchymal cells of fat tissue, skeletal muscle, and 
heart, as well as by macrophages. With the help of the endothelial protein 
glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 
(GPIHBP1), LPL is transferred from the surface of the sub-endothelial myocytes and 
adipocytes to the luminal side of the capillary endothelium. There, LPL hydrolyses the 
triglycerides contained in the triglyceride-rich lipoproteins to release fatty acids for 
uptake by the underlying tissues [5–9]. The activity of LPL is regulated post-
translationally by numerous factors, many of which are produced in the liver, including 
several apolipoproteins. In addition, LPL activity is governed by several members of the 
family of Angiopoietin-like proteins: ANGPTL3, ANGPTL4, and ANGPTL8 [5,10–12]. 
ANGPTL3 is produced in the liver and cooperates with ANGPTL8 to inhibit LPL 
activity in peripheral tissues. The role of ANGPTL3/ANGPTL8 in LPL regulation is 
particularly important in the fed state [13]. By contrast, ANGPTL4 mainly plays a role 
in LPL regulation in the fasted state. Individuals who carry an inactive variant of 
ANGPTL4 exhibit lower levels of circulating triglycerides and have decreased odds of 
developing coronary heart disease [14,15]. In mice, overexpression of ANGPTL4 
potently represses LPL activity and leads to hypertriglyceridemia, whereas deletion of 
ANGPTL4 stimulates LPL activity and drastically reduces plasma triglyceride levels 
[16,17]. In contrast to ANGPTL3, which functions as an endocrine factor, ANGPTL4 
likely serves as a local regulator of LPL in tissues where LPL and ANGPTL4 are co-
produced, in particular in adipose tissue [18]. Inhibition of LPL is mediated by the N-
terminal coiled-coiled domain of ANGPTL4, leading to unfolding of LPL and 
conversion of the active LPL dimers into inactive monomers [19–21]. In adipocytes, 
ANGPTL4 promotes the cleavage and subsequent degradation of LPL, thereby 
preventing the delivery of LPL to the endothelial surface [22,23]. The important role of 
ANGPTL4 in governing plasma lipid levels in humans has made ANGPTL4 an attractive 
therapeutic target for correcting dyslipidemia and associated cardiovascular disorders. 
However, we and others showed that disabling ANGPTL4, either via monoclonal 
antibody-mediated or genetic inactivation, leads to a highly pro-inflammatory and 
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ultimately lethal phenotype in mice fed a high saturated fat diet. This marked phenotype 
includes mesenteric lymphadenopathy, characterized by the presence of lipid-laden 
Touton giant cells in mesenteric lymph nodes, as well as fibrinopurulent peritonitis, 
chylous ascites, and marked elevation of plasma levels of acute phase proteins, such as 
serum amyloid A and haptoglobin [24,25]. Accumulation of lipids in mesenteric lymph 
nodes was also observed in several female monkeys treated with an anti-ANGPTL4 
antibody [15]. Although there is so far no evidence pointing to the occurrence of 
abdominal lymphadenopathy in humans homozygous for an inactive ANGPTL4 variant, 
currently the therapeutic prospects of whole body ANGPLT4 inactivation are not very 
favourable. 
The mouse model that revealed the effect of ANGPTL4 inactivation on 
lymphadenopathy and other pathologies is a whole body ANGPTL4 knock-out model 
caused by the deletion of exons 2 and 3 and part of intron 1, leading to the absence of 
ANGPTL4 protein [26]. Whether other and milder forms of genetic ANGPTL4 
inactivation in mice provoke a similar phenotype upon feeding a high saturated fat diet 
is unclear. According, the first aim of our paper was to further investigate the role of 
ANGPTL4 in the aforementioned pathologies using Angptl4 hypomorphic mice. 
The deleterious effects of ANGPTL4 inactivation observed in mesenteric lymph nodes 
were previously attributed to the role of ANGPTL4 as LPL inhibitor in mesenteric lymph 
node macrophages, thereby preventing excessive fatty acid uptake and a concomitant 
pro-inflammatory response. It was shown that recombinant ANGPTL4 is able to limit 
lipid uptake into peritoneal macrophages incubated with chyle [24]. However, whether 
endogenous ANGPTL4 suppresses lipid uptake into macrophages was not addressed. 
Accordingly, the second aim of our paper was to examine the influence of endogenous 
ANGPTL4 on lipid uptake in macrophages.  
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Materials and Methods 
Animal studies 
Animal studies were performed in male purebred wild-type (WT), Angptl4hyp and 
Angptl4-/- mice on a C57Bl/6 background. The Angptl4hyp mice were a kind donation 
from Dr. Nguan Soon Tan (Nanyang Technological University, Singapore). These mice 
can also be classified as Angptl4 knockout-first mice [27], which upon stepwise crossing 
with mice expressing flippase recombinase and Cre recombinase can be used to generate 
a tissue-specific Angptl4 knockout mice model. 
High fat diet intervention: Eleven to 16-week-old mice (10 wild-type, 11 Angptl4hyp and 
8 Angptl4-/-) were fed a high fat diet that provided 45% energy percent as triglycerides 
(D12451, Research Diets Inc., New Brunswick, NJ). After week 2 and 4 of the 
intervention, blood samples were collected to measure plasma serum amyloid A (SAA). 
After 20 weeks, blood was collected via orbital puncture under isoflurane anaesthesia. 
Immediately thereafter, the mice were euthanized by cervical dislocation. Tissues were 
excised and immediately frozen in liquid nitrogen followed by storage at −80°C. The 
animal studies were approved by the Local Animal Ethics Committee of Wageningen 
University (AVD104002015236: 2016.W-0093.005, 2016.W-0093.007). 
Fasting intervention: Mice were fed a standard chow diet since weaning. Mice were 
either kept on chow or fasted for 24 hours and euthanized between 9.00 and 11.00 hours. 
Blood was collected via orbital puncture under isoflurane anaesthesia. Immediately 
thereafter, the mice were euthanized by cervical dislocation. Tissues were excised and 
immediately frozen in liquid nitrogen followed by storage at −80°C. 
Intraperitoneal glucose tolerance test: After 18 weeks of high fat diet, the mice were 
fasted for 5 hours prior to the glucose tolerance test. The mice were injected 
intraperitoneally with glucose (1g/kg body weight) (Baxter, Deerfield, IL, USA). Blood 
samples from tail vein bleeding were tested for glucose levels at different time points 
following glucose injection using a GLUCOFIX Tech glucometer and glucose sensor 
test strips (GLUCOFIX Tech, Menarini Diagnostics, Valkenswaard, The Netherlands). 
Histology 
Haematoxylin and eosin staining was performed on the mesenteric lymph nodes. During 
the mice sections, lymph nodes were isolated into plastic cassettes and immediately 
fixated in 4% paraformaldehyde. The tissues were processed and embedded into paraffin 
blocks. Thin sections of the blocks were made at 5 µM using a microtome and the placed 
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onto Superfrost glass slides followed by overnight incubation at 37oC. The tissues were 
stained in Mayer hematoxylin solution for 10 minutes and in eosin for 10 seconds at 
room temperature with intermediate washings in ethanol. The tissues were allowed to 
dry at room temperature followed by imaging using light microscope. 
Quantification of plasma parameters 
Blood samples were collected into EDTA-coated tubes and centrifuged at 4°C for 15 
min at 10,000 g. Plasma was collected and stored at -80°C. ELISA kits were used to 
measure plasma serum amyloid (SAA) (Tridelta Development Ltd, Ireland) and 
haptoglobin (Abcam, Cmabridge, UK) according to manufacturer’s protocol. 
Measurement of plasma levels of triglycerides, non-esterified fatty acids (NEFA) and 
glycerol were performed using kits from HUMAN Diagnostics (Wiesbaden, Germany) 
according to manufacturer’s protocol. Plasma levels of cholesterol and glucose were also 
measured using kits from Diasys Diagnostics Systems (Holzheim, Germany) according 
to manufacturer’s protocol. 
LPL activity measurements 
LPL activity levels in epididymal white adipose tissues were measured in triplicate with 
a [3H] triolein-labeled lipid emulsion as previously described [28]. Protein contents in 
homogenates of adipose tissue were measured using Markwell’s modified Lowry 
method [29]. 
Cell Culture 
Bone marrow cells were isolated from femurs of wild-type or Angptl4-/- mice following 
standard protocol and differentiated into macrophages (bone-marrow derived 
macrophages) during 6-8 days culturing in DMEM containing 10% FBS and 1% PS 
supplemented with 10% L929-conditioned medium (L929). After 6-8 days, non-
adherent cells were removed and adherent cells were washed and plated in 6-, 12-, or 48 
well plates in DMEM/FCS/PS + L929. After 24 hours, the cells were washed with PBS 
and treated. Peritoneal macrophages were obtained by infusion, and subsequent 
collection of ice-cold PBS from the abdominal cavity, and frozen directly or brought into 
culture in DMEM containing 10% FBS and 1% PS. RAW264.7 macrophages were 
cultured in DMEM containing 10% FBS and 1% P/S. All cells were maintained in a 
humidified incubator at 37OC with 5% CO2. 
Inguinal white adipose tissue from 3-4 WT, Angptl4hyp and Angptl4-/- mice was collected 
and placed in Dulbecco’s modified eagle’s medium (DMEM; Lonza, Verviers, Belgium) 
supplemented with 1% Penicillin/Streptomycin (PS) and 1% BSA (Sigma-Aldrich). 
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Material was minced with scissors and digested in collagenase-containing medium 
(DMEM with 3.2 mm CaCl2, 1.5 mg/ml collagenase type II (C6885, Sigma-Aldrich), 
10% foetal bovine serum (FBS), 0.5% BSA, and 15 mm HEPES) for 1 h at 37 °C, with 
occasional vortexing. Cells were filtered through a 100-μm cell strainer (Falcon) to 
remove remaining cell clumps and lymph nodes. The cell suspension subsequently was 
centrifuged at 1600 rpm for 10 min and the pellet was resuspended in erythrocyte lysis 
buffer (155 mm NH4Cl, 12 mm NaHCO3, 0.1 mm EDTA). Upon incubation for 2 min at 
room temperature, cells were centrifuged at 1200 rpm for 5 min and the pelleted cells 
were resuspended in DMEM + 10% FCS + 1% P/S and plated. Upon confluence, the 
cells were differentiated according to the protocol as described previously (14, 15). 
Briefly, confluent SVFs were plated in 1:1 surface ratio, differentiation was induced 2 
days afterwards by switching to an differentiation induction cocktail (DMEM containing 
10% FBS, 1% P/S, 0.5 mm isobutylmethylxanthine, 1 μM dexamethasone, 7 μg/ml 
insulin and 1 µM rosiglitazone) for 3 days. Subsequently, cells were maintained in 
DMEM supplemented with 10% FBS, 1% P/S, and 7 μg/ml insulin for 3-6 days and 
switched to DMEM with 10% FBS and 1% P/S for 3 days. Average rate of differentiation 
was at least 80% as determined by eye. 
Cell culture experiments and chemical treatments  
Bone marrow-derived macrophages and peritoneal macrophages were exposed to 1 mM 
intralipid or 500 µM oleic acid (Sigma-Aldrich) for 6 hours in DMEM/PS media. The 
oleic acid was conjugated to BSA at a ratio of about 2:1 (BSA:oleic acid). Bone-marrow 
derived macrophages were also treated with synthetic PPAR agonists; 1 µM Wy14643, 
1 µM rosiglitazone, 1 µM L165041, 1 µM GW501516 or vehicle control for 6 hours. All 
PPAR agonists were obtained from Sigma-Aldrich. Peritoneal macrophages and 
RAW264.7 cells were incubated for 6 hours with lymph (final triglyceride concentration 
of 2 mM, which was collected from rats provided with palm-oil based high fay diet 
overnight). Bone-marrow derived macrophages were co-incubated for 6 hours with 10 
µM orlistat (Sigma-Aldrich) and 1 mM intralipid. RAW264.7 macrophages treated with 
1 mM intralipid or lymph was incubated with or without 0.5 µg/mL recombinant 
ANGPTL4 (R&D Systems, Abingdon, UK). 
Oil red-O staining 
Oil red-O staining was performed in RAW264.7 cells incubated with intralipid or lymph 
in the presence or absence of recombinant ANGPTL4. A stock of oil red O (Sigma) was 
prepared by dissolving 0.5 g in 500 ml of isopropanol. Working concentrations were 
made by dissolving stock concentrations with water (3 stock:2 water) and filtered. 
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Treated cells were washed twice with PBS, followed by fixation with 4% formalin for 
30 min. The cells were then washed twice with PBS and incubated with oil red-O dye 
for 20 min. The stained cells were washed 3 times with ddH2O after which cells were 
visualised under a light microscope and pictures taken. 
Bodipy staining 
For visualization of lipid droplets, treated bone marrow-derived macrophages of wild-
type and Angptl4-/- mice were washed with PBS, fixated in 4% formalin and subsequently 
stained with 1 ng/mL bodipy (ThermoFisher Scientific, Landsmeer, The Netherlands).  
RNA isolation and quantitative real-time PCR 
Total RNA was isolated from tissues and cells by homogenizing in TRIzol (Thermo 
Fisher Scientific) either with a QIagen Tissue Lyser II (Qiagen, Venlo, The Netherlands) 
or by pipetting up and down. Reverse transcription was performed using the iScript™ 
cDNA Synthesis Kit (Biorad) according to the manufacturer’s protocol. Quantitative 
PCR amplifications were done on a CFX384 real-time PCR platform (Bio-Rad) with the 
SensiMix PCR mix from Bioline (GC Biotech, Alphen aan de Rijn, The Netherlands). 
Primer sequences of genes are provided in Supplemental Table 1. Expression of target 
genes was normalized to 36b4. 
Extracellular flux analysis 
Real-time oxygen consumption (OCR) and extracellular acidification rates (ECAR) of 
bone marrow-derived macrophages from wild-type and Angptl4-/- mice were assessed 
using XF-96 Extracellular Flux Analyzer (Seahorse, Bioscience, Santa Clara, CA, USA). 
Basal metabolic rates of bone marrow-derived macrophages seeded in quintuplicate were 
determined during three consecutive measurements in unbuffered Seahorse medium (8.3 
g DMEM powder, 0.016 g phenol red and 1.85 g NaCl in 1 L milli-Q, pH 7.4 at 37OC, 
sterile-filtered) conatining 25 mM glucose and 2 mM L-glutamine. After basal 
measurements, three consecutive measurements were made following addition of 1.5 
µM oligomycin, 1.5 mM carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone 
(FCCP) and combination of 2 µM antimycin and 1 µM rotenone. Pyruvate (1 mM) was 
added together with FCCP to fuel maximal respiration. All compounds used during the 
Seahorse runs were acquired from Merck. Signals were normalized to relative DNA 
content in the wells using the Quanti-iTTM dsDNA Assay kit (ThermoFisher). 
Western immunoblotting 
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To isolate protein, mouse fat pads, differentiated primary adipocytes, primary 
macrophages and whole adipose tissues were lysed in RIPA Lysis and Extraction Buffer 
(25 mm Tris-HCl, pH 7.6, 150 mm NaCl, 1% Nonidet P-40, and 0.1% SDS; Thermo 
Fisher Scientific) supplemented with protease and phosphatase inhibitors (Roche 
Diagnostics, Almere, The Netherlands). Following homogenization, lysates were placed 
on ice for 30 min and centrifuged 2–3 times at 13,000 rpm for 10 min at 4 °C to remove 
fat and cell debris. Concentration of protein lysates was determined by using a 
bicinchoninic acid assay (Thermo Fisher Scientific). For assessment of LPL release, 
bone marrow derrived macrophages were treated for 20 mins with 10 IU/mL heparin (# 
012866-08, LEO Pharma). For assessment of glycosylation of LPL, 2—30 µg of proteins 
was digested with endoglycosidase H (EndoH), (New England BioLabs) according to 
manufacturer’s protocol. Protein lysates (10–30 μg of protein/lane) were loaded onto 8–
16% or 10% Criterion gels (Bio-Rad, Veenendaal, The Netherlands). Next, proteins were 
transferred onto a polyvinylidene difluoride membrane using the Transblot Turbo 
System (Bio-Rad). Membranes were probed with a goat anti-mouse LPL antibody (28), 
a rabbit anti-mouse HSP90 antibody (#4874S, Cell signaling), a rat anti-mouse 
ANGPTL4 antibody (Kairos 142-2, Adipogen) and a rabbit anti-mouse ANGPTL4 
antibody (742) [30] at 1:5000 (mLPL), 1:2000 (HSP90), or 1:1000 (ANGPTL4) 
dilutions. Blocking and the incubation of primary and secondary antibodies were all done 
in TBS, pH 7.5, 0.1% Tween 20 (TBS-T), and 5% (w/v) skimmed milk at 1:5000. In 
between, membranes were washed in TBS-T. Quantification was performed with the 
ChemiDoc MP system (Bio-Rad) and Clarity ECL substrate (Bio-Rad). Equal loading 
of medium samples was verified with HSP90. 
Statistical Analysis 
Statistical analyses were performed using one-way ANOVA followed by Tukey HSD 
test. Data are presented as mean ± SEM (animal studies) or mean ± SD (cell culture 
studies). P < 0.05 was considered statistically significant. 
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Results 
Angptl4 expression is sensitive to lipids and regulates lipid uptake by macrophages 
We previously suggested that enhanced LPL-mediated lipid uptake in mesenteric lymph 
node macrophages may be at the basis of the pro-inflammatory phenotype in Angptl4-/- 
mice fed a high fat diet. To better understand the role of endogenous ANGPTL4 in lipid 
uptake in macrophages, we first studied the regulation of Angptl4 expression by lipids in 
macrophages. Treatment of peritoneal macrophages with oleic acid markedly increased 
Angptl4 mRNA (Fig. 1A).  
 
Figure 1. Angptl4 expression is induced in primary macrophages by lipid stimulation or 
PPAR agonists. (A) Angptl4 expression in peritoneal macrophages treated with 500 µM oleic 
acid for 6 hours. (B) Angptl4 expression in peritoneal macrophages (left) and bone marrow-
derived macrophages (right) treated for 6 hours with 0.5 mM intralipid. (C) Heatmap of top 10 
most upregulated and top 10 most downregulated genes in bone marrow-derived macrophages 
treated for 5 hours with 250 uM oleic acid or BSA (vehicle control) (GSE77104) [31]. (D) Angptl4 
expression in bone marrow-derived macrophages treated for 6 hours with 1 µM of PPAR agonists 
or control. mRNA expression was normalized to 36b4. Data are mean ± SD; *p < 0.05, **p < 0.01 
and ***p < 0.001 relative to vehicle control. 
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Similarly, treatment of peritoneal and bone-marrow derived macrophages with intralipid 
markedly induced Angptl4 mRNA (Fig. 1B). Interestingly, analysis of a publicly 
available transcriptomics dataset indicated that Angptl4 is the most highly induced gene 
in bone marrow-derived macrophages upon treatment with oleic acid (Fig. 1C) [31]. The 
effect of lipid treatment on Angptl4 expression is likely mediated by PPARδ and/or 
PPARγ, as Angptl4 is a well-established target of PPARs in other cell types and treatment 
with synthetic PPARδ and PPARγ agonists caused a pronounced increase in Angptl4 
mRNA (Fig. 1D). 
To study the effect of exogenous ANGPTL4 on lipid uptake in macrophages, RAW264.7 
macrophages were treated with intralipid in the presence or absence of recombinant 
ANGPTL4. ANGPTL4 clearly reduced lipid accumulation, as shown by decreased oil 
red O staining (Fig. 2A). Similar results were obtained in peritoneal macrophages 
incubated with lymph, an endogenous lipid source (Fig. 2B). Transcriptomics analysis 
of peritoneal macrophages treated with intralipid showed that the induction of lipid-
sensitive genes by intralipid was almost completely abolished in the presence of 
recombinant ANGPTL4 (Fig. 2C).  
To study the effect of endogenous ANGPTL4 on lipid uptake in macrophages, wild-type 
and Angptl4-/- macrophages were treated with intralipid. Lipid accumulation was 
distinctly higher in Angptl4-/- macrophages than in wild-type macrophages, as shown by 
Bodipy staining (Fig. 2D). This effect could be abolished by treatment with the LPL 
inhibitor orlistat (Fig. 2D). Consistent with enhanced lipid uptake in Angptl4-/- 
macrophages, the effect of intralipid on the expression of lipid-sensitive genes was much 
more pronounced in Angptl4-/- bone marrow-derived macrophages than in wild-type 
macrophages (Fig. 2E). Similar results were obtained in peritoneal wild-type and 
Angptl4-/- macrophages upon loading with lymph (Fig. 2F). Together, these data strongly 
suggest that ANGPTL4 deficiency leads to elevated lipid uptake in macrophages via 
regulation of LPL. 
ANGPTL4 deficiency has no effect on LPL protein and on fuel utilization in 
primary macrophages 
We previously showed in primary adipocytes that ANGPTL4 deficiency is paralleled by 
elevated LPL protein, indicating that ANGPTL4 regulates LPL protein levels [22]. To 
study the influence of ANGPTL4 on LPL protein in macrophages, we performed 
Western blot for LPL in bone marrow-derived macrophages from wild-type and Angptl4-
/- mice, with and without intralipid treatment.  
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Figure 2. ANGPTL4 deficiency promotes macrophage lipid uptake and magnifies the 
induction of lipid-sensitive genes. (A) Oil red O staining of lipid droplets in RAW264.7 
macrophages treated with 0.5 mM intralipid for 6 hours in the presence or absence of recombinant 
ANGPTL4 (0.5 µg/mL). (B) Oil red O staining of lipid droplets in peritoneal macrophages treated 
for 6 hours with lymph (final triglyceride concentration of 2 mM) in the presence or absence of 
recombinant ANGPTL4 (0.5 µg/mL). (C) Heatmap showing expression profile of lipid-sensitive 
genes in peritoneal macrophages treated for 6 hours with 0.5 mM intralipid in the presence or 
absence of recombinant ANGPTL4. (D) Bodipy staining of Angptl4+/+ and Angptl4-/- bone 
marrow-derived macrophages cultured with regular culture medium (Cntl), or for 6 hours with 0.5 
mM intralipid with or without orlistat . (E-F) mRNA expression of lipid sensitive genes in 
Angptl4+/+ and Angptl4-/- bone marrow-derived macrophages treated for 6 hours with 1 mM 
intralipid (E) or peritoneal macrophages treated for 6 hours with lymph (final triglyceride 
concentration of 2 mM) (F). mRNA expression was normalized to 36b4. Data are mean ± SD; *p 
< 0.05, **p < 0.01 and ***p < 0.001 relative to untreated wild-type; and #p < 0.05, ##p < 0.01 
and ###p < 0.001 relative to wild-type + intralipid/lymph. 
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In contrast to what was observed in adipocytes, ANGPTL4 deficiency did not have any 
effect on LPL protein in macrophages and did not alter the ratio between the active, 
endonuclease H-resistant form and the inactive, endonuclease-sensitive form of LPL 
(Fig. 3A).  
 
Figure 3. ANGPTL4 does not influence LPL processing and lipid oxidation in primary 
macrophages. (A) Immunoblot of LPL in Angptl4+/+ and Angptl4-/- bone marrow-derived 
macrophages treated for 6 hours with or without 0.5 mM intralipid in the presence or absence of 
endonuclease-H. (B) Immunoblot of LPL from culture medium of Angptl4+/+ and Angptl4-/- bone 
marrow-derived macrophages treated with or without heparin. HSP90 or Coomassie staining serve 
as loading control. (C) Real time changes in oxygen consumption rate (OCR) in Angptl4+/+ and 
Angptl4-/- bone marrow-derived macrophages treated with or without 0.5 mM intralipid for 6 
hours, assessed in unbuffered medium during sequential injections with Oligomycin, FCCP, and 
antimycin A + rotenone. (D) Basal extracellular acidification rate (ECAR) and oxygen 
consumption rate (OCR) of Angptl4+/+ and Angptl4-/- bone marrow-derived macrophages 
incubated with or without 0.5 mM intralipid for 6 hrours. Measurements were done in unbuffered 
medium. Data are mean ± SEM; *p < 0.05, **p < 0.01. 
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In addition, the amount of LPL that could be released into the medium by treatment of 
the macrophages with heparin did not differ between the two genotypes (Fig. 3B). These 
data suggest that in macrophages, ANGPTL4 does not inhibit LPL activity by promoting 
LPL degradation. 
To test if differences in lipid uptake are reflected in fuel utilization between the 
genotypes, we measured real time metabolic fluxes in bone marrow-derived 
macrophages using the Seahorse machine. No differences in basal and maximal 
oxidative phosphorylation were observed between wild-type and Angptl4-/- 
macrophages, both in the absence and in the presence of intralipid (Fig. 3C). Intralipid 
treatment increased glycolysis (ECAR) and oxidative phosphorylation (OCR) rates, 
which was not different between the wild-type and Angptl4-/- macrophages (Fig. 3D). 
These data suggest that the inhibitory effect of ANGPTL4 on LPL-mediated lipid uptake 
in macrophages does not have any influence on fuel utilization. 
Angptl4-hypomorphic mice show partial expression of N-terminal exons and 
truncated ANGPTL4 protein in adipose tissue and primary adipocytes 
The second objective of this paper was to investigate whether in addition to the Angptl4-
/- model, an alternative model of genetic Angptl4 inactivation also leads to a deleterious 
phenotype in mice fed a high saturated fat diet. To that end, we used Angptl4 knockout 
first mice. The Angptl4 knockout first allele contains a reading frame–independent LacZ 
gene trap cassette followed by a promoter-driven selection cassette in intron 3 (Fig. 4A). 
The Angptl4 knockout first allele was designed to create tissue-specific Angptl4-/- mice 
by subsequent crossing with mice expressing the FLP and Cre recombinase enzymes. 
Interestingly, based on sequence analysis, it can be predicted that when omitting the FLP 
and Cre recombinase reaction steps, the Angptl4 knockout first allele might lead to the 
production of a whole body mutant ANGPTL4 protein covering amino acid residues 1-
186, followed by 51 amino acids originating from the EN2a splice acceptor site, internal 
ribosome entry site, and part of LacZ (Fig. 4B). Accordingly, we hypothesized that the 
Angptl4 knockout first allele may give rise to a truncated ANGPTL4 protein that contains 
the N-terminal domain responsible for LPL inhibition. In the remainder of the paper, we 
will refer to the ANGPTL4 knockout first mice as Angptl4hyp mice, as explained below. 
To carefully characterize the Angptl4hyp mice, we performed qPCR for Angptl4 using 
cDNA obtained from adipose tissue and primary adipocytes of wild-type, Angptl4hyp and 
Angptl4-/- mice. Primers were designed to amplify parts of the cDNA encoded by specific 
exons.  
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Figure 4. Hypomorphic ANGPTL4 mice show reduced ANGPTL4 expression and reduced 
regulation on LPL. (A) Schematic map of the Angptl4 locus by knockout first-allele strategy.  
(B) Full ANGPTL4 protein (upper scheme) and predicted sequence of truncated ANGPTL4 
(lower scheme) based on sequence analysis of the knockout first-allele mice. mRNA expression 
of all 7 exons of Angptl4 in epididymal adipose tissue (C) and primary adipocytes (D) of Angptl4-
/- and Angptl4hyp mice relative to wild-type mice. Western blot showing full-length and N-terminal 
ANGPTL4, and LPL in adipose tissue (E) and primary adipocytes (F) of the Angptl4-/-, Angptl4hyp 
and wild-type mice. mRNA expression was normalized to 36b4. N = 7 to 11 mice/group. Data are 
mean ± SEM. 
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Remarkably, whereas no Angptl4 expression using any of the primers could be detected 
in adipose tissue and adipocytes of Angptl4-/- mice, substantial Angptl4 expression 
(approx. 30-50% of wild-type level) for exon 1-3 was found in the Angptl4hyp mice (Fig. 
4C, D). By contrast, no amplification was observed in the Angptl4hyp mice using primers 
directed against parts of the cDNA encoded by exons 4-7 (Fig. 4C,D). A similar 
expression profile of the Angptl4 exons was observed in the mouse livers (Supplemental 
Fig. 1). These data indicate that the Angptl4hyp mice produce a truncated cDNA that may 
lead to the production of a truncated ANGPTL4 protein. 
To verify this notion, we performed Western blot on adipose tissue of the three types of 
mice using a monoclonal antibody directed against mouse ANGPTL4. A strong 
ANGPTL4 band at 50 kD was observed in the wild-type mice (Fig. 4E). At this position, 
a weak band was observed in the Angptl4hyp and Angptl4-/- mice, which is likely non-
specific. Interestingly, a band around 32kD was observed in the Angptl4hyp mice but not 
in the Angptl4-/- mice (Fig. 4E). This band migrates at a molecular weight that is slightly 
higher than would be predicted for the ANGPTL4 fragment based on primary sequence. 
To verify that the designated bands indeed represent ANGPTL4, we used the same 
samples to perform Western blot using a polyclonal antibody directed against an epitope 
close to the N-terminus of ANGPTL4. Similar results were obtained (Fig. 4E). These 
analyses confirm that the Angptl4hyp mice produce a truncated ANGPTL4 protein 
containing the LPL inhibitory domain, at levels that are far below the levels in wild-type 
mice. Accordingly, the Angptl4hyp mice represent a hypomorph. In line with previous 
studies, we found that LPL protein levels are increased in adipose tissue of Angptl4-/- 
mice (Fig. 4E) [22,23]. LPL protein levels were also increased in Angptl4hyp mice (Fig. 
4E). Similarly, primary adipocytes of Angptl4hyp mice expressed low levels of a truncated 
N-terminal ANGPTL4 protein (Fig. 4F). LPL protein levels in Angptl4hyp adipocytes 
were markedly lower than in Angptl4-/- adipocytes, yet higher than in wild-type 
adipocytes (Fig. 4F). 
Angptl4hyp and Angptl4-/- mice show similar regulation on plasma metabolites and 
LPL after 24-hour fast 
In line with the alternative name fasting-induced adipose factor, the effects of Angptl4 
inactivation or overexpression on lipid metabolism are most prominent in the fasted 
state. Accordingly, we measured basic plasma parameters in the three types of mice in 
the fasted and fed state. Fasting plasma levels of triglycerides, cholesterol, and non-
esterified fatty acids were remarkably similar between the Angptl4hyp and Angptl4-/- mice, 
and were significantly lower compared to the wild-type mice (Fig. 5A). These data 
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suggest that Angptl4hyp and Angptl4-/- mice are highly similar and that the low levels of 
N-terminal ANGPTL4 protein in the Angptl4hyp mice have no discernible impact on 
plasma lipid parameters. 
 
Figure 5. Similar regulation on plasma metabolites and LPL between Angptl4hyp and 
Angptl4-/- mice after 24-hour fast. (A) Plasma levels of triglycerides, glucose, cholesterol, non-
esterified fatty acids (NEFA) and β-hydroxybutyrate in fed (closed bars) and fasted (opened bars) 
mice. (B) Representative mRNA expression from N-terminal (left column) and C-terminal (right 
column) regions of Angptl4 in epididymal adipose tissues of fed (closed bars) and fasted (opened) 
mice. (C) Western blot of LPL and ANGPTL4 in epididymal adipose tissues from the 3 groups of 
mice in fed and fasted state. Coomassie staining represent loading control. mRNA expression was 
normalized to 36b4. N = 7 to 11 mice/group. Data are mean ± SEM; *p < 0.05, **p < 0.01 and 
***p < 0.001 represent significance in fasted group relative to wild-type fasted mice;  #p < 0.05 
represent significance in fed group relative to wild-type fed mice; and §§p < 0.01 relative to wild-
type fed mice. 
Consistent with previous studies [28,32], Angptl4 mRNA in adipose tissue was 
significantly increased by fasting (Fig. 5B). Interestingly, fasting did not influence 
Angptl4 mRNA in the Angptl4hyp mice. In line with these data and fitting with previous 
studies [23,33], ANGPTL4 protein levels in wild-type adipose tissue were increased by 
fasting, whereas LPL protein levels were reduced by fasting (Fig. 5C). By contrast, levels 
of truncated ANGPTL4 protein were modestly reduced by fasting in the Angptl4hyp mice, 
concomitant with an increase in LPL protein. 
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As previously shown [23], LPL protein was higher in Angptl4-/- mice compared with 
wild-type mice (Fig. 5C). Importantly, the decrease in LPL protein upon fasting was 
abrogated in Angptl4-/- mice, indicating that the increase in ANGPTL4 mediates the 
reduction in LPL protein upon fasting. Interestingly, in the fed state, LPL protein levels 
were lower in Angptl4hyp than Angptl4-/- mice, whereas in the fasted, LPL protein levels 
were similar in Angptl4hyp and Angptl4-/- mice (Fig. 5C). These data suggest that small 
amounts of N-terminal ANGPTL4 in adipose tissue can decrease LPL protein levels, 
presumably by promoting LPL degradation, specifically in the fed and not the fasted 
state. 
Angptl4hyp mice show attenuated chylous ascites and acute inflammation but similar 
levels of lymphadenopathy as Angptl4-/- mice 
We have previously shown that Angptl4-/- mice respond poorly to high saturated fat diet 
characterised by the formation of lipid-laden Touton giant cells in mesenteric lymph 
nodes, accumulation of chylous ascites in peritoneum and acute inflammation [25]. To 
determine the influence of low levels of N-terminal ANGPTL4 on the development of 
lymphadenopathy, chylous ascites and other pathologies, the three groups of mice were 
fed a standard high fat diet rich in saturated fat for 20 weeks. Whereas the Angptl4-/- mice 
showed a rapid and marked increase in serum amyloid A levels upon high fat feeding, 
serum amyloid A levels in the Angptl4hyp mice only went up after 20 weeks of high fat 
feeding (Fig. 6A). At this time point, hepatic expression of several acute phase proteins 
in Angptl4hyp mice was significantly lower than or approximating the levels in Angptl4-/- 
mice (Fig. 6B). Besides a delayed increase in serum amyloid A, the development of 
chylous ascites was much reduced in the Angptl4hyp mice compared to the Angptl4-/- 
mice. Whereas 90% of the Angptl4-/- mice show very pronounced ascites several weeks 
after starting the high fed diet, leading to premature death [25], at the end of the 20 weeks 
of high fat feeding only 12% of the Angptl4hyp mice showed any sign of ascites, which 
was also much milder (Fig. 6C). The mesenteric adipose tissue of the mice with ascites 
showed the characteristic mesenteric panniculitis (Fig. 6D). Of note, the frequency rate 
and severity of ascites in the Angptl4hyp mice remained unchanged when extending the 
high fat feeding to 36 weeks (data not shown). Despite the much milder ascites and 
slower progression of the inflammatory phenotype, after 20 weeks of high fat feeding 
nearly all mesenteric lymph nodes in the Angptl4hyp mice contained multiple lipid-laden 
Touton giant cells (Fig. 6E). 
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Figure 6. Angptl4hyp mice have less severe pathological phenotypes in response to 20-weeks 
of high fat diet compared to Angptl4-/- mice. (A) Plasma levels of serum amyloid A after 2, 4 
and 20 weeks of high fat diet. (B) Relative hepatic expression of pro-inflammatory markers in 
three groups of mice. (C) Pictures showing levels of ascites formation in the peritoneum of 
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Angptl4hyp mice. (D) Images depicting mesenteric panniculitis in Angptl4hyp mice. (E) Images 
showing Touton giant cells in the mesenteric lymph nodes of Angptl4hyp and Angptl4-/- mice but 
not wildtype mice. Images are 200x magnification; insert is 400x magnification. mRNA 
expression was normalized to 36b4. N = 7 to 11 mice/group. Data are mean ± SEM; *p < 0.05, 
**p < 0.01 and ***p < 0.001 relative to wild-type. 
Angptl4hyp mice show increased LPL activity and improved glucose tolerance 
compared to wild-type mice 
Consistent with the role of ANGPTL4 as LPL inhibitor, after 20 weeks of high fat 
feeding, adipose tissue LPL activity was significantly higher in Angptl4hyp mice than in 
wild-type mice (Fig. 7A). By contrast, adipose tissue LPL activity was not increased in 
Angptl4-/- mice, which is likely related to the steatitis in these animals [24]. Interestingly, 
whereas plasma levels of triglycerides and cholesterol were significantly lower in both 
Angptl4hyp and Angptl4-/- mice than in wild-type mice, plasma glycerol and non-esterified 
fatty acid levels were only lower in the Angptl4hyp mice, which again may be related to 
the steatitic phenotype of the Angptl4-/- adipose tissue (Fig. 7B). To study the impact of 
ANGPTL4 deficiency on glucose homeostasis, we measured plasma glucose and 
performed a glucose tolerance test. Plasma glucose levels were significantly lower in 
Angptl4-/- mice than in wild-type and Angptl4hyp mice (Fig. 7C), while glucose tolerance 
was dramatically or modestly improved in Angptl4-/- and Angptl4hyp mice, respectively, 
compared with wild-type mice (Fig. 7D). Overall, the LPL activity and plasma 
metabolites levels in Angptl4hyp mice are consistent with the known role of ANGPTL4 
in intra- and extracellular lipolysis. By contrast, LPL activity and plasma metabolite 
levels in Angptl4-/- mice fed a high fat diet likely partly reflect the severe inflammatory 
phenotype in these animals. 
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Figure 7. Increased LPL activity and improved glucose tolerance in Angptl4hyp mice after 20 
week of high fat diet. (A) LPL activity in epididymal adipose tissue of Angptl4hyp, Angptl4-/- and 
wild-type mice (B) Plasma concentrations of triglycerides, cholesterol, glycerol and non-esterified 
fatty acids (NEFA) in the 3 groups of mice. Plasma glucose levels (C) and glucose tolerance test 
(D) in the 3 groups of mice. N = 7 to 11 mice/group. Data are mean ± SEM; *p < 0.05, **p < 0.01 
and ***p < 0.001 relative to wild-type. No statistical analysis could be done on glucose tolerance 
in Angptl4-/- mice due to the use of different time points. 
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Discussion 
In this paper we addressed two independent questions relevant to the inflammatory 
phenotype in ANGPTL4-deficient mice fed a high fat diet: 1) what is the influence of 
endogenous ANGPTL4 on lipid uptake in macrophages, and 2) what is the role of N-
terminal ANGPTL4 in the development of the inflammatory phenotype. Previously, we 
showed that Angplt4-/- mice fed a diet rich in saturated fat develop an inflammatory and 
ultimately lethal phenotype characterized by the formation of Touton giant cells in 
mesenteric lymph nodes, chylous ascites, and fibrinopurulent peritonitis [24,25]. By 
comparing Angplt4-/- mice with an Angptl4-hypomorphic model, here we show that a 
low level expression of a truncated N-terminal ANGPTL4 does not prevent Touton giant 
cell formation, yet drastically mitigates the acute phase response and the development of 
chylous ascites upon high fat feeding. Importantly, the development of fibrinopurulent 
peritonitis and the death of the animals is completely prevented by the expression of the 
truncated ANGPTL4. Although the severity of the clinical phenotype was attenuated, 
activation of the acute phase response and chylous ascites were still observed in a 
substantial number of Angptl4hyp mice. These data also indicate that the deleterious 
phenotype in Angplt4-/- mice fed a high fat diet is caused by the absence of the N-terminal 
portion of ANGPTL4, which is involved in LPL inhibition, and is not related to the 
absence of the C-terminal fragment of ANGPTL4. 
Our observation that partial deficiency of ANGPTL4 leads to undesirable clinical 
consequences in mice suggests that therapeutic approaches that only partially inactivate 
ANGPTL4 and/or are aimed at whole body inactivation of ANGPTL4 may still carry the 
risk of major side effects in humans. By contrast, tissue-specific inactivation, in 
particular adipose tissue-specific and possibly liver-specific inactivation of ANGPTL4, 
hold considerably more promise for improving dyslipidemia and reducing coronary 
artery disease risk without leading to deleterious side-effects [33]. 
In line with a predominant role of ANGPTL4 in lipid metabolism during fasting, plasma 
levels of triglycerides, cholesterol and non-esterified fatty acids were lower in Angptl4-/- 
mice compared with wild-type mice specifically in the fasted but not the fed state. 
Interestingly, in the fasted state, plasma triglyceride, cholesterol, and non-esterified fatty 
acid levels were similar in Angptl4hyp and Angptl4-/- mice, which was accompanied by 
similar levels of LPL protein in the adipose tissue. Accordingly, the expression of low 
levels of N-terminal ANGPTL4 does not influence LPL protein levels in the fasted state. 
By contrast, in the fed state, LPL protein levels in adipose tissue were lower in Angptl4hyp 
mice than in Angptl4-/- mice, suggesting that a low level of N-terminal ANGPTL4 
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decreases LPL protein, likely by promoting LPL degradation. The reason why N-
terminal ANGPTL4 in Angptl4hyp mice has a more pronounced effect on LPL in the fed 
state than in the fasted state could be related to the decrease in N-terminal ANGPTL4 
during fasting. This decrease in N-terminal ANGPTL4 in Angptl4hyp mice by fasting 
likely accounts for the parallel increase in LPL protein. Why N-terminal ANGPTL4 is 
suppressed by fasting in Angptl4hyp mice is unclear but does not seem to be mediated at 
the transcriptional level. 
In addition to regulating plasma lipid levels, recent reports also suggest a role of 
ANGPTL4 in glucose homeostasis [34–36]. Using different models, ANGPTL4 
deficiency in mice was found to lead to improved glucose tolerance. Consistent with the 
study by Gusarova et al [37], we found that Angptl4-/- mice chronically fed a high fat diet 
have drastically lower basal plasma glucose levels and improved glucose tolerance. 
However, these mice have numerous clinical abnormalities, which prohibits any 
conclusion on the direct effect of ANGPTL4 deficiency on glucose homeostasis. 
Angptl4hyp mice fed a high fat diet showed a much milder clinical phenotype, 
concomitant with a more modest yet statistically significant improvement in glucose 
tolerance, yet acute phase protein levels were still elevated compared with wild-type 
mice. This observation again makes it difficult to derive a solid conclusion on the direct 
effect of ANGPTL4 deficiency on glucose homeostasis. We previously found that 
Angptl4-/- mice fed a diet high in unsaturated fat, which does not exhibit any clinical 
complications, were more glucose tolerant than wild-type mice fed the same diet [35]. 
In addition, it was shown that adipocyte-specific ANGPTL4-deficient mice have 
markedly improved glucose and insulin tolerance after one month and to a lesser extent 
five months of high fat feeding, which was suggested to be due to LPL-mediated 
redistribution of ectopic fat stores to adipose tissue [34]. While growing evidence thus 
connects ANGPTL4 with glucose homeostasis, further studies are necessary to 
determine how ANGPTL4 may influence glucose homeostasis. 
An interesting question concerns the significance of the lipid-laden Touton giant cells 
for the onset of the debilitating side-effects after high fat feeding. A causal role had been 
previously questioned by the observation that Angptl4-/- mice fed a high trans-fat diet 
develop Touton cells but do not show elevated systemic inflammation or ascites and 
survive the intervention [25]. Here we find that Angptl4hyp mice fed a high fat diet, 
despite showing a much milder inflammation and ascites than Angptl4-/- mice, carry 
similar numbers of Touton giant cells in their mesenteric lymph nodes. These data 
reinforce the notion that the formation of lipid-laden Touton giant cells is uncoupled 
from activation of an acute-phase response and chylous ascites [25]. 
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Our study confirms previous data indicating that Angptl4 expression in macrophages is 
highly induced by lipids [24,38,39]. This regulation is likely mediated by PPARδ and/or 
PPARγ, as shown by the marked induction of Angptl4 mRNA by PPARδ and PPARγ 
agonists in bone marrow-derived macrophages. Importantly, the present study shows that 
not only external ANGPTL4 but also endogenously produced ANGPTL4 inhibits lipid 
uptake in macrophages. The elevated lipid uptake in Angptl4-/- macrophages increases 
the expression of various lipid-sensitive genes involved in inflammation and ER stress, 
such as Hilpda, Ddit3, Ptgs2 and Cxcl2. The absence of ANGPTL4 in bone marrow-
derived macrophages did not influence respiration and fuel utilization, indicating that the 
influence of ANGPTL4 deficiency on inflammation is likely not due to changes in 
intracellular metabolism. Together, our findings solidify the important role of ANGPTL4 
in protecting macrophages from the deleterious effects of excessive lipid uptake. 
It is well established that ANGPTL4 inactivates LPL by promoting LPL unfolding 
[19,40]. Recently, we demonstrated a local role of action for ANGPTL4 in promoting 
the intracellular cleavage and subsequent degradation of LPL in adipocytes [22]. In stark 
contrast, ANGPTL4 deficiency in macrophages does not lead to the accumulation of full 
length, rapidly-releasable LPL, while the cleaved, N-terminal LPL portion is generally 
not detectable in our hands. These data suggest that the inhibitory effect of ANGPTL4 
on LPL activity in macrophages does not involve enhanced LPL degradation. The 
cellular factors explaining the difference in ANGPTL4 action between adipocytes and 
macrophages remain to be identified. Overall, these findings suggest that the location 
and cellular mechanism of LPL inactivation by ANGPTL4 may be different in different 
tissues. 
In conclusion, we find that ANGPTL4 deficiency enhances lipid uptake into 
macrophages. Furthermore, in comparison to Angptl4-/- mice, mice expressing low levels 
of N-terminal ANGPTL4 show a reduced acute phase response and milder chylous 
ascites following high fat feeding. These findings have significant clinical implications 
since any therapeutic strategy would likely reduce but not completely inactivate 
ANGPTL4. 
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Supplemental Material 
 
Supplemental Figure 1: Relative mRNA expression of all 7 exons of Angptl4 in the liver Angptl4-/-, Angptl4mut 
and wild-type mice. mRNA expression was normalized to 36b4. N=7-11 mice/group. Data are mean ± SEM. 
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Supplemental Table 1: Primer sequences of genes  
Genes  Forward primer   Reverse primer    
m36B4     ATGGGTACAAGCGCGTCCTG   GCCTTGACCTTTTCAGTAAG 
mAngptl4     GTTTGCAGACTCAGCTCAAGG CCAAGAGGTCTATCTGGCTCTG 
mHilpda     GCACGACCTGGTGTGACTGT  CCAGCACATAGAGGTTCAGCAT   
mDdit3     CTGGAAGCCTGGTATGAGGAT  CAGGGTCAAGAGTAGTGAAGGT   
mXbp1s    AAACAGAGTAGCAGCGCAGACTGC        GGATCTCTAAAACTAGAGGCTTGGTG 
mCxcl2 CCAACCACCAGGCTACAGG  GCGTCACACTCAAGCTCTG   
mErn1  ACACCGACCACCGTATCTCA  CTCAGGATAATGGTAGCCATGTC 
mPlin2 CTTGTGTCCTCCGCTTATGTC  GCAGAGGTCACGGTCTTCAC 
mCxcl1  CTGGGATTCACCTCAAGAACATC CAGGGTCAAGGCAAGCCTC 
mCcr1  CTCATGCAGCATAGGAGGCTT  ACATGGCATCACCAAAAATCCA 
mPtgs2  TTCAACACACTCTATCACTGGC  AGAAGCGTTTGCGGTACTCAT 
mCd14    CACACTCACTCAACTTTTCCT  GCTGAGATCAGTCCTCTCTCG 
mGdf15   CTGGCAATGCCTGAACAACG  GGTCGGGACTTGGTTCTGAG 
mAngtpl4 Exon1  CTTTGCATCCTGGGACGAGATG GACAAGCGTTACCACAGGCAG  
mAngtpl4 Exon2   GCTCAAGGCTCAAAACAGCAA TGATAGGTATCTCTGCTGCTGG 
mAngtpl4 Exon3  CCCACGCACCTAGACAATGG TGGGAGTCAAGCCAATGAGC 
mAngtpl4 Exon4  GGGACTGCCAGGAACTCTTC AATGGTGGAGACCCCAGAGG 
mAngtpl4 Exon5  GAGGCTGGACAGTGATTCAGAGA GGGATCTCCGAAGCCATCCTT 
mAngtpl4 Exon6  ACGGCCAATGAGCTGGG  GGGCAGGGAAAGGCCA 
mAngtpl4  Exon7  CGCTACTATCCTCTGCAGGC CCCTCGAGCCCATGTTTTCT 
mSaa2    GCGAGCCTACACTGACATGA  TTTTCTCAGCAGCCCAGACT 
mHp     GCTATGTGGAGCACTTGGTTC  CACCCATTGCTTCTCGTCGTT 
mLcn2     TGGAAGAACCAAGGAGCTGT  GGTGGGGACAGAGAAGATGA 
Orm2     CAACATCACCATAGGCGACCC  ATTTCCTGCCGGTAATCAGGG 
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Abstract 
Aims/hypothesis Obesity is associated with a state of chronic low-grade inflammation 
that is believed to contribute to the development of skeletal muscle insulin resistance. 
However, the extent to which local and systemic elevation of cytokines, such as 
monocyte chemoattractant protein 1 (MCP-1), interferes with the action of insulin and 
promotes insulin resistance and glucose intolerance in muscle remains unclear. Here, 
we aim to investigate the effect of muscle-specific overexpression of MCP-1 on insulin 
sensitivity and glucose tolerance in lean and obese mice.  
Methods We used Mck–Mcp-1 transgenic (Tg) mice characterised by muscle-specific 
overexpression of Mcp-1 (also known as Ccl2) and elevated plasma MCP-1 levels. Mice 
were fed either chow or high-fat diet for 10 weeks. Numerous metabolic variables were 
measured, including glucose and insulin tolerance tests, muscle insulin signalling and 
plasma NEFA, triacylglycerol, cholesterol, glucose and insulin.  
Results Despite clearly promoting skeletal muscle inflammation, muscle-specific 
overexpression of Mcp-1 did not influence glucose tolerance or insulin sensitivity in 
either lean chow-fed or diet-induced obese mice. In addition, plasma NEFA, 
triacylglycerol, cholesterol, glucose and insulin were not affected by MCP-1 
overexpression. Finally, in vivo insulin-induced Akt phosphorylation in skeletal muscle 
did not differ between Mcp-1-Tg and wild-type mice.  
Conclusions/interpretation We show that increased MCP- 1 production in skeletal 
muscle and concomitant elevated MCP-1 levels in plasma promote inflammation in 
skeletal muscle but do not influence insulin signalling and have no effect on insulin 
resistance and glucose tolerance in lean and obese mice. Overall, our data argue against 
MCP-1 promoting insulin resistance in skeletal muscle and raise questions about the 
impact of inflammation on insulin sensitivity in muscle. 
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Introduction 
Over recent decades, the global prevalence of obesity has been increasing steadily, 
concurrent with major changes in diet and lifestyle. Obesity is often accompanied by a 
number of metabolic perturbations, including insulin resistance, hyperinsulinaemia, 
dyslipidaemia and hypertension, which together substantially increase the risk for type 
2 diabetes and cardiovascular disease [1–4]. Development of insulin resistance is 
generally considered as an early event that drives many of the metabolic disturbances 
associated with obesity. Since insulin resistance was first recognised several decades 
ago, a number of ideas have been put forward to try and explain the link between excess 
adiposity and reduced tissue sensitivity to insulin. Currently, major emphasis is placed 
on the detrimental effect of fat stored outside the adipose compartment. Additionally 
and alternatively, inflammation is increasingly believed to play a pivotal role in the 
development of insulin resistance and type 2 diabetes (reviewed in [5]). According to 
this so-called inflammatory hypothesis, obesity is characterised by expansion of the 
adipose depot, giving rise to adipocyte hypertrophy, hypoxia and endoplasmic reticulum 
(ER) stress, which in turn causes enhanced production of cytokines and chemokines [6–
8]. Cytokines such as TNFα, IL-1β, IL-6, IL-8 and monocyte chemoattractant protein 1 
(MCP-1) promote the attraction of different immune cells in obese adipose tissue, 
including proinflammatory macrophages and B cells, whereas regulatory T cells, natural 
killer T cells and eosinophils become less abundant [9]. These immune cells are 
producers of a host of different cytokines/chemokines and together with the 
hypertrophic adipocytes contribute to a state of chronic low-grade inflammation. In vitro 
studies abound indicating that proinflammatory cytokines are able to inhibit insulin 
signalling and thus promote the development of insulin resistance in fat cells and muscle 
cells. For example, Eckel and colleagues found that the chemokine MCP-1 impaired 
insulin signalling and reduced insulin-stimulated glucose uptake in muscle cells, 
suggesting that MCP-1 may represent a molecular link in the negative crosstalk between 
adipose tissue and skeletal muscle [10]. What is less clear is whether the obesity-induced 
adipose tissue inflammation leads to the increments in cytokine levels in blood plasma 
necessary to interfere with the action of insulin and to cause insulin resistance in muscle 
in vivo. This is particularly relevant since it has been calculated that approximately 80% 
of insulin-induced glucose disposal is accounted for by skeletal muscle glucose uptake. 
Studies performed using mice characterised by fat-specific overexpression of Mcp-1 
(also known as Ccl2) or expression of a dominant-negative mutant of Mcp-1 suggest 
that fat-derived MCP-1 reduces glucose tolerance and insulin sensitivity and blunts 
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insulin-mediated signalling [11,12]. However, the full scope of the role of adipose tissue 
inflammation and the impact of specific cytokines such as MCP-1 on whole-body 
glucose tolerance and insulin’s action in skeletal muscle remains ambiguous. 
Importantly, recent studies indicate that elevated MCP-1 expression not only occurs 
during obesity but is also a feature of physical exercise. Specifically, levels of MCP-1 
mRNA in skeletal muscle and levels of MCP-1 protein in plasma were found to be 
increased upon acute exercise, leading to the classification of MCP-1 as a myokine or 
exercise factor [13–17]. In skeletal muscle, MCP-1 is known to promote macrophage 
infiltration after (severe) tissue damage [18,19]. In contrast, chronic exercise results in 
a decrease in MCP-1 plasma levels [20,21]. The features of MCP-1 are reminiscent of 
IL-6. Production of IL-6 in adipose tissue has been shown to be increased during obesity 
and contributes to obesity-associated low-grade inflammation (reviewed in [22]). At the 
same time, production of IL-6 in skeletal muscle and plasma IL-6 levels are increased 
in response to acute exercise and have been suggested to potentially confer a positive 
effect on insulin signalling and insulin sensitivity in skeletal muscle [23], although 
recent data argue against that notion [24]. How inflammatory mediators may have a 
beneficial role in the context of physical exercise yet promote insulin resistance during 
obesity represents somewhat of a conundrum.  
The aim of the present study was to assess the extent to which elevation of MCP-1 
production in muscle and elevated MCP-1 levels in plasma may be able to interfere with 
insulin signalling in skeletal muscle and promote insulin resistance. To this end, we took 
advantage of Mck–Mcp-1 transgenic (Tg) mice, which specifically overexpress Mcp-1 
in skeletal muscle. Our studies indicate that elevation of MCP-1 production in skeletal 
muscle and elevated MCP-1 levels in plasma promote inflammation in skeletal muscle 
but do not influence insulin signalling in skeletal muscle and have no effect on insulin 
resistance and glucose tolerance in lean and obese mice. 
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Materials and Methods 
Animals 
Animal studies were carried out using wild-type (WT) and Mck–Mcp-1 Tg mice, all on 
a C57Bl/6J background [25]. The mice were kindly donated by D. Patsouris (Université 
Claude Bernard Lyon 1, France). Only male mice were used. Mice were kept in 
temperature-controlled rooms (21±1°C) on a 12 h light–dark cycle. For the studies using 
chow-fed mice, 16 WT and 19 Mcp-1-Tg mice were fed regular chow (RMH-B Arie 
Blok, Woerden, the Netherlands). At 14–17 weeks of age, eight mice per group were 
subjected to an intraperitoneal glucose tolerance test and a week later to an 
intraperitoneal insulin tolerance test. Mice were euthanised at 17–20 weeks of age after 
a 6 h fast at zeitgeber time (ZT)7–ZT9. Before being euthanised, eight mice of each 
genotype received an intraperitoneal injection of insulin (2 U/kg body weight in 100 μl 
saline [154 mmol/l NaCl], n=4 per genotype) or saline (100 μl, n=4 per genotype) 
followed by euthanasia exactly 5 min later by cervical dislocation. For the remaining 
mice, blood was collected by orbital puncture under isoflurane anaesthesia and mice 
were euthanised by cervical dislocation. For the high-fat feeding study, 12 WT and 12 
Mcp-1-Tg mice were fed regular chow (RMH-B Arie Blok) after weaning. At 12–16 
weeks of age, mice were switched to a high-fat diet (HFD) containing 60 energy% fat 
(D12492; Research Diets Inc., New Brunswick, NJ, USA). Food intake and body 
weights were registered weekly. After 8 weeks of high-fat feeding, mice were subjected 
to an intraperitoneal glucose tolerance test and a week later to an intraperitoneal insulin 
tolerance test. Mice were euthanised after 10 weeks of high-fat feeding after a 6 h fast 
at ZT7–ZT9. Before being euthanised, four mice of each genotype received an 
intraperitoneal injection of insulin (2 U/kg body weight in 100 μl saline, n=2 per 
genotype) or saline (100 μl, n=2 per genotype) followed by euthanasia exactly 5 min 
later by cervical dislocation. For the remainder of the mice, blood was collected by 
orbital puncture under isoflurane anaesthesia and mice were euthanised by cervical 
dislocation. Tissues were excised and immediately frozen in liquid nitro- gen followed 
by storage at −80°C. All experiments were blind to group and outcome assessment. All 
animal experiments were authorised by the animal welfare committee of Wageningen 
University. 
Intraperitoneal glucose tolerance test 
After a 6 h fast mice were injected intraperitoneally with glucose (1.2 g/kg body weight 
for mice on chow, 0.8 g/kg body weight for mice on HFD). Blood was collected by tail 
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bleeding after 0, 15, 30, 60, 90 and 120 min, and glucose was measured using an Accu-
Chek compact (Roche Diagnostics, Almere, the Netherlands). 
Intraperitoneal insulin tolerance test 
After a 6 h fast mice were injected intraperitoneally with insulin (0.75 U/kg body 
weight). Blood was collected by tail bleeding after 0, 15, 30, 45, 60 and 90 min, and 
glucose was measured using an Accu-Chek compact (Roche Diagnostics). 
Histological stainings 
Histological analysis of musculus gastrocnemius morphology and macrophage 
infiltration was done using hematoxylin and eosin (H&E) staining. On the day of 
euthanasia, samples were frozen in isopentane mixed with dry ice and stored at −80°C. 
Tissue was embedded in Tissue-Tek O.C.T. Compound (Sakura Finetek, Alpen aan de 
Rijn, the Netherlands), sectioned at 10 μm in a cryostat chamber, fixed on a Superfrost 
glassslide, left to dry for 30 min and stored at −20°C. Samples were stained at room 
temperature in Mayer hematoxylin solution for 10 min and in eosin Y solution for 30 
sec. 
Measurement of plasma variables 
Blood was collected into EDTA-coated tubes. Blood samples were placed on ice and 
centrifuged at 4°C for 10 min at 10,000g. Plasma was collected and stored at −80°C. To 
measure plasma MCP-1 concentration a DuoSet ELISA Development kit against mouse 
MCP-1 was used (R&D Systems, Minneapolis, MN, USA). For insulin measurements 
an ultra-sensitive mouse insulin ELISA kit was used (Crystal chemicals, Downers 
Grove, IL, USA). For the other plasma measurements, the following kits were used: 
NEFA Reagent set, Triglycerides Liquicolor, Cholesterol Liquicolor (all Instruchemie, 
Delfzijl, the Netherlands) and Glucose GOD FS (DiaSys, Holzheim, Germany). All 
measurements were performed according to the manufacturers’ protocols. 
Affymetrix microarray 
Microarray analysis was performed on RNA of the musculus gastrocnemius. The RNA 
of 8 WT mice and 8 Tg mice was extracted using TRIzol reagent (Invitrogen, Carlsbad, 
CA, USA) and a Tissuelyser II (Qiagen, Germantown, MD, USA), purified using the 
RNeasy Micro Kit (Qiagen) and the integrity were verified with the RNA 6000 Nano 
assay on the Agilent 2100 Bioanalyzer (Agilent Technologies, Amsterdam, the 
Netherlands). Hybridization, washing, and scanning of the Affymetrix GeneChip Mouse 
Gene 1.1 ST Array were performed on Affymetrix GeneTitan. Scans of the Affymetrix 
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arrays were processed using packages from the Bioconductor project [26]. Arrays were 
normalized and raw signal intensities were obtained using the Robust Multiarray 
Average method [27,28]. Probe sets were defined according to Dai et al. [29]. In this 
method probes are assigned to Entrez IDs as a unique gene identifier. The P values were 
calculated using an Intensity-Based Moderated T-statistic (IBMT) [30]. The microarray 
data were submitted to the Gene Expression Omnibus (accession number pending). 
Gene set enrichment analysis (GSEA) was used to find enriched gene sets in the induced 
or suppressed genes [31]. Genes were ranked based on the IBMT-statistic and 
subsequently analyzed for over- or underrepresentation in predefined gene sets derived 
from Gene Ontology, KEGG, National Cancer Institute, PFAM, Biocarta, Reactome 
and WikiPathways pathway databases. Only gene sets consisting of more than 15 and 
fewer than 500 genes were taken into account. Statistical significance of GSEA results 
was determined using 1,000 permutation. 
RNA isolation and quantitative real-time PCR 
Total RNA was extracted from different mouse tissues using TRIzol reagent 
(Invitrogen, Bleiswijk, the Netherlands) and a Tissuelyser II (Qiagen, Venlo, the 
Netherlands). Reverse transcription was performed using Superscript II and oligo(dT) 
primers (Invitrogen). PCR-amplifications were carried out using iQ SYBR Green 
Supermix on a CFX384 Touch real-time PCR detection system (Bio-Rad, Hercules, CA, 
USA). The sequences of the primers used for quantitative real-time PCR (qPCR) are 
shown in Supplemental Table 1. All genes were normalised to 36b4. Primer efficiencies 
were determined using LinRegPCR v11.1 (http://LinRegPCR.nl) [32]. Relative 
expression of the transcript levels was calculated as described previously [33]. 
Western blotting 
Total protein extracts were obtained from musculus gastrocnemius to detect MCP-1. 
Tissue was homogenised using a Tissuelyser II (Qiagen) in protein extraction buffer 
without bromophenol blue (62.5 mmol/l Tris HCl, pH 6.8, 2% SDS, 10% glycerol and 
10 mmol/l dithiothreitol) and protein concentration was measured using Bradford 
protein assay. Protein (50 μg) was boiled, subjected to SDS- PAGE and proteins 
transferred to nitrocellulose membrane (Immobilon; Millipore, Billerica, MA, USA). 
Membranes were blocked and incubated with anti-MCP-1 (R17; Santa Cruz, Dallas, 
TX, USA) and anti-Actin (Sigma Aldrich, St Louis, MO, USA). To obtain total protein 
extracts from musculus gastrocnemius to detect phospho-Akt, tissue was homogenised 
using a Tissuelyser II (Qiagen) in protein extraction buffer with phosphatase inhibitors 
(50 mmol/l Tris HCl, pH 4.7, 1 mmol/l EDTA, 150 mmol/l NaCl, 1% NP40, 0.25% 
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sodium deoxycholate, 2 mmol/l sodium orthovanadate and 5 mmol/l sodium fluoride, 
containing freshly added protease inhibitor cocktail [Roche Applied Science, Penzberg, 
Germany]). After being centrifuged at 20,800g for 10 min at 4°C, supernatant fractions 
were collected and 50 μg of protein was boiled with Laemmli sample buffer. The protein 
was subjected to SDS-PAGE and transferred to a polyvinylidene difluoride membrane 
(Immobilon; Millipore). Membranes were blocked and incubated with anti-Akt (in 
house), anti-phospho-Akt (Ser473) (Cell Signalling Technology, Danvers, MA, USA) 
and anti-Actin (Sigma Aldrich). Quantification was carried out using ImageJ 1.49m 
(http://imagej.nih.gov). 
Statistical analysis 
For statistical analysis Student’s t test was used. Data are means ± SEM and p<0.05 is 
considered statistically significant. One mouse from the WT group, fed HFD, was 
excluded from subsequent analysis because it was mistakenly injected with a higher 
dose of insulin during the insulin tolerance test. Some qPCR data on gene expression 
were excluded from the results section because the genes were expressed at a low level, 
with Ct values greater than 32 in both the WT and Mcp-1-Tg mice. 
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Results 
Skeletal muscle-specific overexpression of MCP-1 results in a local inflammatory 
response 
To assess the impact of muscle-specific overexpression of MCP-1 on whole-body 
glucose homeostasis and insulin sensitivity, we used Tg mice that overexpress Mcp-1 
under the control of the Mck promotor [25].  
 
Figure 1: Skeletal muscle-specific overexpression of MCP-1 provokes inflammation. (a) 
Relative gene expression of Mcp-1 measured by qPCR; n=8 (WT mice) or n=11 (Mcp-1-Tg 
mice). (b) Representative western blot analysis of MCP-1 overexpression in Mcp-1-Tg mice. (c) 
Plasma concentration of MCP-1; n=8 (WT mice) or n=11 (Mcp-1-Tg mice). (d) H&E staining of 
representative sections of musculus gastrocnemius of WT and Mcp-1-Tg mice (magnification 
×200). Arrowheads indicate macrophage infiltration. Insert: H&E staining of musculus vastus 
(magnification ×1,000), showing immune cell infiltrate. e–g: Relative gene expression of Il6, 
Il1b, F4/80 and Cd68 in gastrocnemius (e), liver (f) and WAT (g) measured by qPCR; n=8 (WT 
mice) or n=11 (Mcp-1-Tg mice). White bars, WT mice; black bars, Mcp-1-Tg mice. Data are 
means ±SEM; *p<0.05 and ***p<0.001 according to Student’s t test for WT vs Mcp-1-Tg mice 
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The marked overexpression of Mcp-1 in the transgenic mice was confirmed at the 
mRNA level in the musculus gastrocnemius, vastus and soleus, whereas Mcp-1 was 
only weakly induced or not induced in the liver and white adipose tissue (WAT), 
respectively (Figure 1a). Since the overexpression of Mcp-1 was most pronounced in 
the gastrocnemius muscle, we used the gastrocnemius in all follow-up experiments. 
Overexpression of Mcp-1 in the gastrocnemius of the Mcp-1-Tg mice was confirmed at 
the protein level (Figure 1b). Furthermore, the plasma concentration of MCP-1 in the 
Mcp-1-Tg mice was increased approximately 4.4-fold compared with WT mice, 
indicating that MCP-1 is secreted from skeletal muscle (Figure 1c). H&E staining 
indicated enhanced inflammation in the gastrocnemius of the Mcp-1-Tg mice as 
compared with WT mice, as illustrated by infiltration of macrophages between the 
muscle fibres (Figure 1d). In addition, mRNA levels of Il1b and the macrophage 
markers F4/80 and Cd68 were significantly increased in the gastrocnemius of the Mcp-
1-Tg mice (Figure 1e). In contrast, expression of the same inflammatory markers in liver 
(Figure 1f) and WAT (Figure 1g) did not reveal any differences between WT and Mcp-
1-Tg mice.  
Next, we performed microarray analysis on the gastrocnemius of eight WT mice and 
eight Mcp-1-Tg mice to study the overall effect of MCP-1 overexpression on gene 
expression in skeletal muscle. Overexpression of MCP-1 caused a clear inflammatory 
gene expression signature (Figure 2a). The 25 most highly induced genes were all 
involved in inflammation and/or immunity, including the genes encoding lysozyme 
(Lyz1), the immune cells surface markers Cd52 and Cd180, and the secreted protein 
Retnla. Interestingly, the most highly induced gene was Mcp-1 (99-fold), followed by 
its receptor Ccr2. Gene set enrichment analysis (GSEA) corroborated the pronounced 
induction of inflammation and immune-related pathways. Specifically, the top 20 of 
most highly enriched pathways are all linked to inflammation, including chemokine 
signalling, T cell receptor signalling, phagocytosis and inflammatory disease-related 
pathways (Figure 2b). The complete list of significantly regulated genes (q value<0.05) 
is presented in Supplemental Table 2. Taken together, these data indicate that MCP-1 
overexpression promotes inflammation in skeletal muscle. 
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Figure 2: MCP-1 overexpression induces an inflammatory gene expression profile. (a) Gene 
expression changes in gastrocnemius muscle, illustrated by a heatmap of the 25 most highly 
induced genes in Mcp-1-Tg mice compared with WT mice. FC, fold change. (b) Gene sets 
positively enriched in the gastrocnemius of Mcp-1-Tg mice ranked according to normalised 
enrichment score (GSEA). The enrichment score reflects the degree to which a gene set is over-
represented at the top or bottom of a ranked list of genes. Normalisation accounts for differences 
in gene set size and in correlations between gene sets and the expression dataset. 
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No metabolic phenotype can be observed in mice overexpressing MCP-1 in skeletal 
muscle when fed a normal chow diet 
To test whether skeletal muscle-specific overexpression of MCP-1 and associated 
inflammation may also influence glucose homeostasis and insulin sensitivity, Mcp-1-
Tg mice and their WT littermates were subjected to detailed metabolic characterisation. 
Mcp-1-Tg and WT mice had similar weights of musculus gastrocnemius, musculus 
vastus, liver and WAT (Figure 3a).  
 
Figure 3: No metabolic phenotype is observed in mice overexpressing Mcp-1 in skeletal 
muscle under normal chow diet. (a) Tissue weights of musculus gastrocnemius (Gastroc.), 
musculus vastus, liver and WAT; n=8 (WT mice) or n=11 (Mcp-1-Tg mice). (b, c) Blood glucose 
level during insulin tolerance test (b) and glucose tolerance test (c); n=8 (WT and Mcp-1-Tg 
mice). (d) Representative western blot showing phosphorylation levels of Akt in gastrocnemius 
of WT and Mcp-1-Tg mice upon insulin injection. Bar graph shows quantification of p-Akt/Akt 
ratio performed in four mice per treatment group and normalised to WT mice without insulin. (e–
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i) Plasma concentration of NEFA (e), triacylglycerol (f), cholesterol (g), glucose (h) and insulin 
(i); n=8 (WT mice) or n=11 (Mcp-1-Tg mice). White bars and squares, WT mice; black bars and 
squares, Mcp-1-Tg mice. Data are means ± SEM; *p<0.05 according to Student’s t test for 
insulin-treated mice vs control-treated mice (d). 
Intriguingly, the results of an intraperitoneal insulin tolerance test (Figure 3b) and 
intraperitoneal glucose tolerance test (Figure 3c) did not differ between Mcp-1-Tg and 
WT mice. In addition, we analysed the effect of muscle-specific MCP-1 overexpression 
on the sensitivity of muscle to i.p. injection of insulin, using phosphorylation of Akt as 
a readout. Insulin injection markedly stimulated Akt phosphorylation in the 
gastrocnemius muscle (Figure 3d). However, no significant difference in phospho-Akt 
could be observed between WT and Mcp-1-Tg mice, indicating that MCP-1 
overexpression does not alter insulin-dependent signalling in skeletal muscle. Finally, 
the Mcp-1-Tg mice did not show any changes in plasma concentrations of NEFA, 
triacylglycerol, cholesterol, glucose or insulin when compared with WT mice (Figure 
3e–i). Taken together, our results indicate a lack of an effect of muscle-specific MCP-1 
overexpression on insulin sensitivity and glucose homeostasis in mice fed a normal 
chow diet. 
HFD feeding does not result in metabolic alterations in muscle-specific Mcp-1-Tg 
mice 
One possible explanation for the lack of effect of MCP-1 overexpression on variables 
associated with insulin sensitivity is related to the fact that the mice were fed normal 
chow and were therefore lean. To determine the impact of muscle-specific 
overexpression of MCP-1 on glucose homeostasis and insulin sensitivity in the context 
of obesity and insulin resistance, muscle-specific Mcp-1-Tg and WT littermates were 
rendered obese and insulin resistant by chronic high-fat feeding. The muscle- specific 
overexpression of Mcp-1 in the Mcp-1-Tg mice was maintained after HFD (Figure 4a), 
accompanied by a 10.9-fold increase in plasma MCP-1 levels (Figure 4b) . H&E staining 
showed more pronounced macrophage infiltration in the gastrocnemius of the Mcp-1-
Tg mice compared with WT mice (Figure 4c). In addition, mRNA levels of Il1b and the 
macrophage markers F4/80 and Cd68 were significantly increased in the gastrocnemius 
of the Mcp-1-Tg mice (Figure 4d). In contrast, expression of inflammatory markers 
remained unchanged in liver and adipose tissue of the Mcp-1-Tg mice, with the 
exception of macrophage marker F4/80 and alternatively-activated macrophage marker 
Cd206, which were both significantly reduced in liver of Mcp-1-Tg mice (Supplemental 
Figure 1). 
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Figure 4: Characterisation of muscle-specific Mcp-1-Tg mice fed an HFD. (a) Relative gene 
expression of Mcp-1 measured by qPCR. (b) Blood concentration of MCP-1. (c) H&E staining 
of representative sections of gastrocnemius of WT and Mcp-1-Tg mice (magnification ×200); 
Arrowheads indicate macrophage infiltration. (d) Relative gene expression of Il6, Il1b, F4/80 and 
Cd68 measured by qPCR. (e): Body weight changes in the WT and Mcp-1-Tg mice. (f) Average 
food intake from week 2 to week 8. (g) Tissue weights of musculus gastrocnemius (Gastroc.), 
musculus vastus, liver and WAT. White bars and squares, WT mice; black bars and squares, Mcp-
1-Tg mice. Data are means ± SEM; n=11 (WT mice) or n=12 (Mcp-1-Tg mice); **p<0.01 and 
***p<0.001 according to Student’s t test for WT vs Mcp-1-Tg mice. 
Whole-body weight (Figure 4e) and food intake (Figure 4f) did not differ between Mcp-
1-Tg mice and WT mice on HFD, and there was no difference in weights of the 
musculus gastrocnemius, musculus vastus, liver and WAT (Figure 4g). An 
intraperitoneal insulin tolerance test and glucose tolerance test revealed decreased 
glucose tolerance in mice fed HFD compared with chow.  
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Figure 5: HFD feeding does not result in metabolic alterations in muscle- specific Mcp-1-Tg 
mice. (a, b) Plasma glucose level during insulin tolerance test (a) and glucose tolerance test (b); 
n=11 (WT mice) or n=12 (Mcp-1-Tg mice). (c) Representative western blot showing 
phosphorylation levels of Akt in gastrocnemius of WT and Mcp-1-Tg mice upon injection of 
insulin. Bar graph shows quantification of p-Akt/Akt ratio performed on two mice per treatment 
group and normalised to WT mice without insulin. (d–h) Plasma concentration of NEFA (d), 
triacylglycerol (e), cholesterol (f), glucose (g) and insulin (h); n=7 (WT mice) or n=8 (Mcp-1-Tg 
mice). (i) Relative gene expression of Gk, Srebp1c, Acc1 and Pepck in liver measured by qPCR; 
n=12 (for WT and Mcp-1-Tg mice). White bars and squares, WT mice; black bars and squares, 
Mcp-1-Tg mice. Data are means±SEM; †p=0.08, ‡p=0.03 according to Student’s t test for insulin-
treated mice vs control-treated mice (c). 
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However, no differences in insulin and glucose tolerance were detected when 
comparing diet-induced obese Mcp-1-Tg mice with WT mice (Figure 5a, b). As 
observed in chow-fed mice, insulin-induced Akt phosphorylation was similar in the 
gastrocnemius of HFD-fed Mcp-1-Tg mice compared with HFD-fed WT mice (Figure 
5c). In addition, none of the plasma metabolites measured was significantly changed in 
the Mcp-1-Tg mice compared with WT mice. (Figure 5d–h). Finally, hepatic expression 
of insulin-sensitive genes Gk, Srebp1c (also known as Srebf1), Acc1 (Acaca), and Pepck 
(Pck1) was unaffected by muscle-specific MCP-1 over-expression (Figure 5i). Taken 
together, muscle-specific overexpression of MCP-1 did not affect insulin sensitivity and 
glucose homeostasis in obese insulin-resistant mice.  
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Discussion 
The aim of the present study was to assess to what extent elevation of MCP-1 production 
in muscle and elevated MCP-1 levels in plasma interfere with insulin signalling in 
skeletal muscle and promote insulin resistance. To this end, an Mck-Mcp-1-Tg mouse 
model that specifically overexpresses MCP-1 in skeletal muscle was used. We show 
that muscle-specific overexpression of MCP-1 promotes inflammation in skeletal 
muscle but does not influence insulin signalling in skeletal muscle and has no effect on 
whole-body insulin sensitivity and glucose tolerance in either lean or obese mice. These 
findings therefore indicate that muscle inflammation by itself is not sufficient to evoke 
whole-body insulin resistance.  
Studies to date have not been consistent in establishing a causal relation between 
muscle-specific stimulation or repression of inflammatory molecules and alterations in 
insulin sensitivity. On the one hand, it has been shown that over- production of 
constitutively activated c-Jun N-terminal kinase in skeletal muscle impairs insulin 
signalling in mice by modulating serine and threonine phosphorylation of Akt and IRS-
1 [34]. On the other hand, muscle-specific ablation of IκB kinase 2, resulting in reduced 
activation of the transcription factor nuclear factor-κB (NF-κB), had no effect on 
obesity-induced insulin resistance and on insulin signalling in muscle [35]. Similarly, 
muscle-specific ablation of signal transducer and activator of transcription 3 (STAT3), 
another transcription factor activated by proinflammatory cytokines, showed no effect 
on obesity-induced insulin resistance, as assessed by glucose tolerance test, clamp 
studies and measurement of 2-deoxyglucose uptake [36]. Our study indicates that local 
activation of inflammation in muscle via MCP-1 overexpression does not affect insulin 
sensitivity and insulin action. Along the same lines, overexpression of NF-κB subunit 
p65 and IκBKβ in single muscles of rats using in vivo electrotransfer had no effect on 
glucose disposal in muscle under hyperinsulinaemic–euglycaemic clamp conditions, 
suggesting that activation of the IκBKβ–NF-κB pathway in muscle does not seem to be 
an important local mediator of insulin resistance [37].  
Presently, it is difficult to merge the diverse findings into a coherent and consistent 
picture describing the role and impact of inflammatory signalling in muscle on local 
insulin resistance. A provocative conclusion emerging from our study and other 
‘negative’ studies is that obesity-induced insulin resistance in muscle, the primary organ 
accounting for insulin-mediated glucose disposal, is not dependent on inflammatory 
signalling in muscle itself; this in turn can be extrapolated to suggest that development 
of insulin resistance in muscle during obesity does not require inflammatory mediators 
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that affect skeletal muscle. In future studies, more attention should be accorded to 
clarification of the role of inflammatory signalling from adipose tissue to muscle in the 
development of insulin resistance.  
In contrast to our findings, Patsouris et al observed modest whole-body and muscle 
insulin resistance and mildly elevated plasma glucose levels in Mck–Mcp-1-Tg mice 
[25]. One of the potential reasons for the discrepancy between our data and those of 
Patsouris is the composition of the background diet, as our chow diet and HFD are 
different from the diets used by Patsouris et al. Another important difference between 
our study and the study by Patsouris and colleagues is that we measured plasma 
metabolic variables (i.e. insulin, glucose, triacylglycerol) in 6 h-fasted mice, whereas 
Patsouris assessed the same variables in fed mice. Unfortunately, additional relevant 
experimental details (number of mice used, sex of the mice, time of euthanasia) are not 
mentioned in the Patsouris paper, which would have allowed for a more detailed 
comparison between the two studies [25].  
In contrast to the present study in mice with muscle-specific overexpression of MCP1, 
studies performed in mice with adipose tissue-specific overexpression of MCP-1 or 
expression of a dominant-negative mutant of MCP-1 show that adipose tissue-derived 
MCP-1 reduces glucose tolerance and insulin sensitivity and blunts insulin-mediated 
signalling in skeletal muscle [11, 12]. Also, in vitro treatment of human skeletal muscle 
cells or the C2C12 muscle cell line with recombinant MCP-1 protein results in decreased 
Akt phosphorylation upon insulin stimulation [10, 11]. This raises the question why 
MCP-1 secreted from adipose tissue is able to alter whole-body and muscle insulin 
sensitivity whereas MCP-1 secreted from the muscle is not, especially since the levels 
of plasma MCP-1 were comparable in both transgenic mouse models [11, 12]. One 
explanation may be that circulating MCP-1 only plays a minor role in regulating whole-
body insulin sensitivity and that local MCP-1 concentrations predominantly determine 
the metabolic outcome: raising MCP-1 levels in muscle only results in local 
inflammation, while increased MCP-1 expression in adipose tissue starts a cascade of 
events including altered adipose-resident immune cell profiles and altered output of 
adipokines and metabolites, ultimately resulting in impaired whole-body insulin 
sensitivity. It should be noted, however, that acute or chronic elevation of circulating 
MCP-1 by injection results in insulin resistance [38]. Accordingly, a possible alternative 
explanation is that circulating MCP-1 is able to affect insulin sensitivity but that the 
form secreted by adipose tissue is different from the form secreted by muscle tissue. It 
is known that MCP-1 exists in an unglycosylated (8–12 kDa) and in a glycosylated form 
(17– 30 kDa) [39–41] and it has been suggested that the glycosylated form can bind to 
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cell membranes, increasing the local MCP-1 expression, while unglycosylated MCP-1 
is more easily diffusible and able to form a potent chemotactic gradient [42]. The MCP-
1 protein detected by western blotting in this study has a molecular mass of 
approximately 18 kDa, which suggests that the MCP-1 expressed in skeletal muscle is 
glycosylated. Furthermore, in vitro treatment of muscle cells with MCP-1 and acute or 
chronic elevation of MCP-1 by injection in vivo, which both resulted in insulin 
resistance, were all performed with unglycosylated recombinant MCP-1 protein 
produced in E. coli [10,11,38]. More research is therefore needed to investigate the 
glycosylation status of MCP-1 originating from different tissues. Moreover, it would be 
interesting to determine whether MCP-1 glycosylation status influences insulin 
signalling in insulin-sensitive tissues.  
By acting as a myokine and as an inflammatory mediator, MCP-1 displays 
characteristics similar to those of IL-6, the most studied and discussed myokine 
(reviewed in [22]). It has been suggested that IL-6 produced by skeletal muscle has a 
stimulatory influence on insulin sensitivity in skeletal muscle, whereas opposite effects 
have been shown for elevated IL-6 levels in adipose tissue and liver [23,43–45]. 
Accordingly, the effect of both MCP-1 and IL-6 on insulin sensitivity seems to be very 
tissue-specific and may also depend on whether they are induced acutely or chronically 
[22]. Examining the parallels between MCP-1 and IL-6 may help unravel the underlying 
mechanism accounting for the tissue-specific actions of these two dual-faced regulators 
of glucose homeostasis.  
A limitation of our study is that we only assessed muscle-specific insulin signalling at 
the level of Akt phosphorylation and did not examine other insulin-sensitive targets or 
perform clamp studies. Another limitation is that we cannot rule out that (obesity-
induced) overexpression of MCP-1 specifically during adulthood has a different effect 
on insulin action than permanent MCP-1 overexpression in muscle starting during 
embryonic development. Future studies using inducible Mcp-1-Tg mice are necessary 
to clarify this issue.  
In conclusion, elevation of MCP-1 production in skeletal muscle and concomitant 
elevation of plasma MCP-1 lead to enhanced inflammation in skeletal muscle but have 
no effect on insulin resistance and glucose tolerance in lean and obese mice and do not 
affect insulin-mediated signalling in skeletal muscle. 
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Supplemental Material 
 
Supplemental Figure 1: Relative gene expression of selected genes in liver and white 
adipose tissue  measured by RT-PCR; n = 12 [WT], 12 [Mcp-1-Tg]. Data are means ± 
SEM; * = p < 0.05 
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Supplemental Table 1:  Primer sequences of genes 
Genes  Forward primer   Reverse primer    
m36B4     AGCGCGTCCTGGCATTGTCTGTGG GGGCAGCAGTGGTGGCAGCAGC 
mCd68     CCAATTCAGGGTGGAAGAAA  CTCGGGCTCTGATGTAGGTC 
mF4/80     CTTTGGCTATGGGCTTCCAGTC   GCAAGGAGGACAGAGTTTATCGTG 
mIl-1b     CAGGCAGGCAGTATCACTCA  AGGTGCTCATGTCCTCATCC   
mIl-6     CTTCCATCCAGTTGCCTTCTTG  AATTAAGCCTCCGACTTGTGAAG  
mLy6c     GCAGTGCTACGAGTGCTATGG  ACTGACGGGTCTTTAGTTTCCTT 
mCd206     CTCTGTTCAGCTATTGGACGC  CGGAATTTCTGGGATTCAGCTTC 
mSrebp1c    GGAGCCATGGATTGCACATT  CCTGTCTCACCCCCAGCATA   
mGk      AGGAGGCCAGTGTAAAGATGT  CTCCCAGGTCTAAGGAGAGAAA 
mAcc       GCCATTGGTATTGGGGCTTACC CCCGACCAAGGACTTTGTTG 
mPepck      CAGGATCGAAAAGCAAGACAGT AAGTCCTCTTCCGACATCCAG 
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Supplemental Table 2: Genes significantly altered between gastrocnemius of WT 
and Mcp-1-Tg mice (q<0.05) 
Entrez ID Gene Fold q value Description 
 name change    
20296 Ccl2 99.11 0.00E+00 chemokine (C-C motif) ligand 2 
12772 Ccr2 6.90 2.09E-10 chemokine (C-C motif) receptor 2 
17110 Lyz1 5.76 5.22E-10 lysozyme 1 
57262 Retnla 5.73 6.48E-08 resistin like alpha 
14961 H2-Ab1 5.34 2.33E-10 histocompatibility 2, class II antigen A, beta 1 
13587 Ear2 5.08 2.10E-05 eosinophil-associated, ribonuclease A family, member 2 
14960 H2-Aa 4.88 2.55E-09 histocompatibility 2, class II antigen A, alpha 
16149 Cd74 4.79 3.58E-10 CD74 antigen (invariant polypeptide ofMHC, class II antigen-
associated) 
14969 H2-Eb1 4.74 5.85E-09 histocompatibility 2, class II antigen E beta 
23833 Cd52 4.31 8.65E-09 CD52 antigen 
68169 Ndnf 4.17 1.17E-09 neuron-derived neurotrophic factor 
80891 Fcrls 3.87 1.23E-07 Fc receptor-like S, scavenger receptor 
17079 Cd180 3.81 6.87E-10 CD180 antigen 
98365 Slamf9 3.80 5.23E-09 SLAM family member 9 
17476 Mpeg1 3.58 1.22E-07 macrophage expressed gene 1 
14999 H2-DMb1 3.43 2.14E-03 histocompatibility 2, class II, locus Mb1 
14998 H2-DMa 3.36 1.64E-08 histocompatibility 2, class II, locus DMa 
17084 Ly86 3.32 1.80E-06 lymphocyte antigen 86 
12982 Csf2ra 3.24 6.48E-08 colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-
macrophage) 
16792 Laptm5 3.22 2.55E-09 lysosomal-associated protein transmembrane 5 
11658 Alcam 3.21 4.03E-04 activated leukocyte cell adhesion molecule 
241633 Atp8b4 3.15 1.98E-07 ATPase, class I, type 8B, member 4 
19264 Ptprc 3.12 4.85E-08 protein tyrosine phosphatase, receptor type, C 
17105 Lyz2 3.07 1.82E-06 lysozyme 2 
231805 Pilra 3.02 1.22E-07 paired immunoglobin-like type 2 receptor alpha 
12523 Cd84 2.99 1.82E-06 CD84 antigen 
213391 Rassf4 2.98 4.85E-08 Ras association (RalGDS/AF-6) domain family member 4 
13723 Emb 2.98 5.93E-06 embigin 
12508 Cd53 2.91 2.77E-07 CD53 antigen 
227929 Cytip 2.88 1.52E-06 cytohesin 1 interacting protein 
104759 Pld4 2.88 9.84E-08 phospholipase D family, member 4 
216864 Mgl2 2.85 3.28E-08 macrophage galactose N-acetyl-galactosamine specific lectin 2 
225825 Cd226 2.84 1.29E-06 CD226 antigen 
213002 Ifitm6 2.81 8.04E-06 interferon induced transmembrane protein 6 
17381 Mmp12 2.75 2.52E-06 matrix metallopeptidase 12 
20345 Selplg 2.75 2.37E-07 selectin, platelet (p-selectin) ligand 
217305 Cd300ld 2.73 1.92E-05 CD300 molecule-like family member d 
72318 Cyth4 2.73 5.85E-09 cytohesin 4 
16414 Itgb2 2.72 4.85E-08 integrin beta 2 
18726 Lilra6 2.70 6.53E-04 leukocyte immunoglobulin-like receptor, subfamily A (with TM 
domain), member 6 
94176 Dock2 2.70 1.25E-07 dedicator of cyto-kinesis 2 
216984 Evi2b 2.68 1.52E-06 ecotropic viral integration site 2b 
16409 Itgam 2.66 6.60E-07 integrin alpha M 
100038909 Gm14548 2.64 1.01E-03 predicted gene 14548 
20375 Spi1 2.64 8.65E-09 spleen focus forming virus (SFFV) proviral integration oncogene 
12721 Coro1a 2.59 2.37E-07 coronin, actin binding protein 1A 
414084 Tnip3 2.58 1.42E-07 TNFAIP3 interacting protein 3 
14728 Lilrb4 2.58 1.29E-06 leukocyte immunoglobulin-like receptor, subfamily B, member 4 
19260 Ptpn22 2.55 1.25E-07 protein tyrosine phosphatase, non-receptor type 22 (lymphoid) 
14727 Gp49a 2.55 5.40E-05 glycoprotein 49 A 
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319446 Dpep2 2.54 1.70E-06 dipeptidase 2 
627984 Nlrp1c-ps 2.54 1.13E-05 NLR family, pyrin domain containing 1C, pseudogene 
20308 Ccl9 2.52 8.11E-06 chemokine (C-C motif) ligand 9 
13058 Cybb 2.50 1.44E-06 cytochrome b-245, beta polypeptide 
394432 Ugt1a7c 2.49 2.60E-04 UDP glucuronosyltransferase 1 family, polypeptide A7C 
11690 Alox5ap 2.48 2.04E-06 arachidonate 5-lipoxygenase activating protein 
20305 Ccl6 2.48 7.78E-05 chemokine (C-C motif) ligand 6 
13040 Ctss 2.46 5.68E-06 cathepsin S 
18636 Cfp 2.46 1.80E-06 complement factor properdin 
74039 Nfam1 2.45 5.98E-07 Nfat activating molecule with ITAM motif 1 
11501 Adam8 2.43 6.23E-09 a disintegrin and metallopeptidase domain 8 
69810 Clec4b1 2.43 3.50E-03 C-type lectin domain family 4, member b1 
232413 Clec12a 2.43 1.00E-05 C-type lectin domain family 12, member a 
66815 Ccdc109b 2.40 8.55E-07 coiled-coil domain containing 109B 
230787 Themis2 2.37 1.52E-06 thymocyte selection associated family member 2 
18830 Pltp 2.37 1.15E-08 phospholipid transfer protein 
14127 Fcer1g 2.35 6.48E-08 Fc receptor, IgE, high affinity I, gamma polypeptide 
16822 Lcp2 2.33 4.33E-07 lymphocyte cytosolic protein 2 
56644 Clec7a 2.31 3.86E-05 C-type lectin domain family 7, member a 
13449 Dok2 2.28 1.71E-06 docking protein 2 
21391 Tbxas1 2.27 3.45E-07 thromboxane A synthase 1, platelet 
107684 Coro2a 2.24 2.12E-05 coronin, actin binding protein 2A 
12265 Ciita 2.24 1.37E-06 class II transactivator 
15000 H2-DMb2 2.23 6.28E-04 histocompatibility 2, class II, locus Mb2 
19204 Ptafr 2.21 3.73E-06 platelet-activating factor receptor 
18826 Lcp1 2.20 4.02E-05 lymphocyte cytosolic protein 1 
19277 Ptpro 2.18 1.01E-02 protein tyrosine phosphatase, receptor type, O 
72042 Cotl1 2.17 2.71E-08 coactosin-like 1 (Dictyostelium) 
100038363 RIKEN 2.16 1.44E-03 RIKEN cDNA F630028O10 gene 
12514 Cd68 2.15 4.84E-05 CD68 antigen 
75345 Slamf7 2.11 1.03E-05 SLAM family member 7 
105855 Nckap1l 2.11 2.18E-07 NCK associated protein 1 like 
18301 Fxyd5 2.10 1.37E-05 FXYD domain-containing ion transport regulator 5 
212937 Tifab 2.10 6.98E-06 TRAF-interacting protein with forkhead-associated domain, family 
member B 
12481 Cd2 2.09 1.82E-06 CD2 antigen 
18796 Plcb2 2.08 7.80E-05 phospholipase C, beta 2 
16854 Lgals3 2.06 7.78E-05 lectin, galactose binding, soluble 3 
12260 C1qb 2.05 8.60E-06 complement component 1, q subcomponent, beta polypeptide 
22177 Tyrobp 2.05 6.02E-04 TYRO protein tyrosine kinase binding protein 
73149 Clec4a3 2.04 1.03E-04 C-type lectin domain family 4, member a3 
12493 Cd37 2.02 1.00E-05 CD37 antigen 
19354 Rac2 2.01 1.54E-03 RAS-related C3 botulinum substrate 2 
503550 Klri1 1.95 1.66E-04 killer cell lectin-like receptor family I member 1 
56792 Stap1 1.95 1.00E-05 signal transducing adaptor family member 1 
20491 Sla 1.94 2.10E-05 src-like adaptor 
26904 Sh2d1b1 1.94 4.48E-03 SH2 domain protein 1B1 
226652 Arhgap30 1.92 2.69E-05 Rho GTPase activating protein 30 
76088 Dock8 1.91 1.29E-06 dedicator of cytokinesis 8 
98496 Pid1 1.89 1.15E-06 phosphotyrosine interaction domain containing 1 
12506 Cd48 1.89 2.82E-05 CD48 antigen 
54445 Unc93b1 1.89 3.12E-05 unc-93 homolog B1 (C. elegans) 
668218 Bin2 1.89 1.07E-03 bridging integrator 2 
22778 Ikzf1 1.89 2.30E-05 IKAROS family zinc finger 1 
20351 Sema4a 1.89 2.83E-05 Semaphorin 4A 
17969 Ncf1 1.88 8.81E-05 neutrophil cytosolic factor 1 
58861 Cysltr1 1.87 7.30E-04 cysteinyl leukotriene receptor 1 
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19267 Ptpre 1.87 5.72E-05 protein tyrosine phosphatase, receptor type, E 
52614 Emr4 1.87 2.71E-03 EGF-like module containing, mucin-like, hormone receptor-like 
sequence 4 
78416 Rnase6 1.87 2.30E-05 ribonuclease, RNase A family, 6 
17345 Mki67 1.86 1.51E-03 antigen identified by monoclonal antibody Ki 67 
26411 Map4k1 1.86 1.37E-05 mitogen-activated protein kinase kinase kinase kinase 1 
56177 Olfm1 1.85 1.78E-02 olfactomedin 1 
14421 B4galnt1 1.84 1.25E-03 beta-1,4-N-acetyl-galactosaminyl transferase 1 
73723 Sh3bgrl3 1.84 2.83E-05 SH3 domain binding glutamic acid-rich protein-like 3 
64381 Ms4a8a 1.83 1.50E-03 membrane-spanning 4-domains, subfamily A, member 8A 
239217 Kctd12 1.82 5.93E-06 potassium channel tetramerisation domain containing 12 
320139 Ptpn7 1.81 1.39E-03 protein tyrosine phosphatase, non-receptor type 7 
14130 Fcgr2b 1.80 1.61E-04 Fc receptor, IgG, low affinity IIb 
16364 Irf4 1.79 2.80E-02 interferon regulatory factor 4 
18718 Pip4k2a 1.79 6.47E-05 phosphatidylinositol-5-phosphate 4-kinase, type II, alpha 
80719 Igsf6 1.79 4.62E-04 immunoglobulin superfamily, member 6 
17916 Myo1f 1.79 7.78E-05 myosin IF 
545030 Wdfy4 1.79 2.10E-04 WD repeat and FYVE domain containing 4 
14131 Fcgr3 1.79 3.37E-03 Fc receptor, IgG, low affinity III 
81897 Tlr9 1.78 6.31E-05 toll-like receptor 9 
65963 Tmem176b 1.78 2.35E-05 transmembrane protein 176B 
14017 Evi2a 1.77 2.55E-04 ecotropic viral integration site 2a 
11810 Apobec1 1.77 1.37E-05 apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1 
246177 Myo1g 1.77 1.16E-04 myosin IG 
668139 Gm8995 1.77 1.38E-04 predicted gene 8995 
20963 Syk 1.77 8.16E-04 spleen tyrosine kinase 
71653 RIKEN 1.76 1.08E-04 RIKEN cDNA 4930506M07 gene 
17082 Il1rl1 1.76 5.03E-04 interleukin 1 receptor-like 1 
67111 Naaa 1.75 7.41E-07 N-acylethanolamine acid amidase 
19261 Sirpa 1.75 6.28E-04 signal-regulatory protein alpha 
20198 S100a4 1.73 9.85E-03 S100 calcium binding protein A4 
170786 Cd209a 1.72 7.73E-03 CD209a antigen 
210293 Dock10 1.71 4.24E-04 dedicator of cytokinesis 10 
236312 Pyhin1 1.71 2.10E-04 pyrin and HIN domain family, member 1 
269799 Clec4a1 1.71 4.91E-04 C-type lectin domain family 4, member a1 
64214 Rgs18 1.71 1.00E-03 regulator of G-protein signaling 18 
12229 Btk 1.70 3.35E-03 Bruton agammaglobulinemia tyrosine kinase 
18173 Slc11a1 1.70 5.40E-05 solute carrier family 11 (proton-coupled divalent metal ion 
transporters), member 1 
26888 Clec4a2 1.70 1.88E-03 C-type lectin domain family 4, member a2 
69993 Chn2 1.70 2.22E-02 chimerin 2 
234779 Plcg2 1.70 5.30E-04 phospholipase C, gamma 2 
21844 Tiam1 1.70 2.60E-04 T cell lymphoma invasion and metastasis 1 
57781 Cd200r1 1.70 1.54E-03 CD200 receptor 1 
13732 Emp3 1.70 2.64E-05 epithelial membrane protein 3 
22228 Ucp2 1.70 6.82E-04 uncoupling protein 2 (mitochondrial, proton carrier) 
217304 Cd300lb 1.70 2.35E-04 CD300 antigen like family member B 
16541 Napsa 1.69 6.67E-03 napsin A aspartic peptidase 
12505 Cd44 1.69 1.52E-04 CD44 antigen 
17444 Grap2 1.69 6.22E-05 GRB2-related adaptor protein 2 
170744 Tlr8 1.68 8.45E-03 toll-like receptor 8 
13733 Emr1 1.68 8.12E-03 EGF-like module containing, mucin-like, hormone receptor-like 
sequence 1 
100504464 RIKEN 1.68 3.16E-04 RIKEN cDNA E230016K23 gene 
72461 Prcp 1.67 6.22E-05 prolylcarboxypeptidase (angiotensinase C) 
210029 Metrnl 1.67 1.59E-03 meteorin, glial cell differentiation regulator-like 
14667 Gm2a 1.66 6.05E-06 GM2 ganglioside activator protein 
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14457 Gas7 1.66 6.22E-05 growth arrest specific 7 
14191 Fgr 1.66 2.38E-05 Gardner-Rasheed feline sarcoma viral (Fgr) oncogene homolog 
83490 Pik3ap1 1.66 1.96E-04 phosphoinositide-3-kinase adaptor protein 1 
16331 Inpp5d 1.66 1.34E-04 inositol polyphosphate-5-phosphatase D 
108101 Fermt3 1.65 1.17E-03 fermitin family homolog 3 (Drosophila) 
16534 Kcnn4 1.65 2.07E-04 potassium intermediate/small conductance Ca-activ. channel, subfam 
N, member 4 
66058 Tmem176a 1.65 7.78E-05 transmembrane protein 176A 
15170 Ptpn6 1.65 2.56E-04 protein tyrosine phosphatase, non-receptor type 6 
22350 Ezr 1.64 4.28E-05 ezrin 
224829 Trerf1 1.63 5.29E-05 transcriptional regulating factor 1 
224109 Nrros 1.62 4.92E-03 negative regulator of reactive oxygen species 
74131 Sash3 1.61 3.11E-03 SAM and SH3 domain containing 3 
19271 Ptprj 1.61 2.12E-05 protein tyrosine phosphatase, receptor type, J 
12267 C3ar1 1.60 1.34E-03 complement component 3a receptor 1 
238875 Gapt 1.59 7.38E-03 Grb2-binding adaptor, transmembrane 
13057 Cyba 1.59 7.10E-03 cytochrome b-245, alpha polypeptide 
70719 Hmha1 1.59 4.60E-03 histocompatibility (minor) HA-1 
16154 Il10ra 1.58 4.03E-03 interleukin 10 receptor, alpha 
75767 Rab11fip1 1.58 2.14E-03 RAB11 family interacting protein 1 (class I) 
56470 Rgs19 1.58 1.58E-04 regulator of G-protein signaling 19 
67742 Samsn1 1.57 3.52E-03 SAM domain, SH3 domain and nuclear localization signals, 1 
320181 Fndc7 1.56 1.88E-05 fibronectin type III domain containing 7 
382062 AB124611 1.56 2.51E-02 cDNA sequence AB124611 
170741 Pilrb1 1.56 5.22E-03 paired immunoglobin-like type 2 receptor beta 1 
72828 Ubash3b 1.55 6.61E-03 ubiquitin associated and SH3 domain containing, B 
73690 Glipr1 1.55 2.50E-03 GLI pathogenesis-related 1 (glioma) 
12978 Csf1r 1.54 1.80E-03 colony stimulating factor 1 receptor 
239081 Tlr11 1.54 7.38E-03 toll-like receptor 11 
14268 Fn1 1.54 1.15E-03 fibronectin 1 
227541 Camk1d 1.54 8.16E-04 calcium/calmodulin-dependent protein kinase ID 
74127 Krt80 1.54 1.24E-02 keratin 80 
76117 Arhgap15 1.54 1.38E-04 Rho GTPase activating protein 15 
72925 March1 1.53 8.45E-03 membrane-associated ring finger (C3HC4) 1 
107373 Fam111a 1.53 1.65E-02 family with sequence similarity 111, member A 
70536 Qpct 1.53 5.03E-04 glutaminyl-peptide cyclotransferase (glutaminyl cyclase) 
211228 Lrrc25 1.53 7.46E-04 leucine rich repeat containing 25 
64095 Gpr35 1.53 1.77E-04 G protein-coupled receptor 35 
27056 Irf5 1.53 5.66E-03 interferon regulatory factor 5 
225471 Ticam2 1.53 1.23E-02 toll-like receptor adaptor molecule 2 
22324 Vav1 1.53 1.56E-02 vav 1 oncogene 
64380 Ms4a4c 1.52 1.47E-02 membrane-spanning 4-domains, subfamily A, member 4C 
69769 Tnfaip8l2 1.52 2.24E-04 tumor necrosis factor, alpha-induced protein 8-like 2 
16970 Lrmp 1.52 6.02E-04 lymphoid-restricted membrane protein 
16985 Lsp1 1.52 1.59E-03 lymphocyte specific 1 
637515 Nlrp1b 1.52 1.69E-03 NLR family, pyrin domain containing 1B 
320664 Cass4 1.51 1.05E-02 Cas scaffolding protein family member 4 
19229 Ptk2b 1.51 2.02E-02 PTK2 protein tyrosine kinase 2 beta 
64008 Aqp9 1.51 3.96E-04 aquaporin 9 
27405 Abcg3 1.50 5.03E-03 ATP-binding cassette, sub-family G (WHITE), member 3 
21810 Tgfbi 1.50 1.16E-04 transforming growth factor, beta induced 
227659 Slc2a6 1.50 5.92E-03 solute carrier family 2 (facilitated glucose transporter), member 6 
27984 Efhd2 1.50 4.66E-04 EF hand domain containing 2 
14255 Flt3 1.49 1.45E-02 FMS-like tyrosine kinase 3 
20970 Sdc3 1.49 2.92E-03 syndecan 3 
11857 Arhgdib 1.49 4.91E-04 Rho, GDP dissociation inhibitor (GDI) beta 
70785 Dennd1c 1.49 1.05E-02 DENN/MADD domain containing 1C 
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107321 Lpxn 1.48 2.83E-02 leupaxin 
67865 Rgs10 1.48 2.89E-02 regulator of G-protein signalling 10 
19735 Rgs2 1.48 4.85E-02 regulator of G-protein signaling 2 
20556 Slfn2 1.48 8.03E-04 schlafen 2 
320207 Pik3r5 1.48 1.54E-02 phosphoinositide-3-kinase, regulatory subunit 5, p101 
215653 Rassf2 1.48 4.54E-02 Ras association (RalGDS/AF-6) domain family member 2 
54135 Lsr 1.48 4.00E-03 lipolysis stimulated lipoprotein receptor 
27007 Klrk1 1.48 5.03E-03 killer cell lectin-like receptor subfamily K, member 1 
54519 Apbb1ip 1.47 1.91E-02 amyloid beta (A4) precursor protein-binding, family B, member 1 
interacting protein 
75766 Dcstamp 1.47 2.66E-02 dentrocyte expressed seven transmembrane protein 
12475 Cd14 1.47 1.32E-02 CD14 antigen 
56743 Lat2 1.47 5.66E-03 linker for activation of T cells family, member 2 
17970 Ncf2 1.47 3.76E-02 neutrophil cytosolic factor 2 
74748 Slamf8 1.47 1.13E-02 SLAM family member 8 
26382 Fgd2 1.46 1.47E-02 FYVE, RhoGEF and PH domain containing 2 
17952 Naip6 1.46 5.03E-03 NLR family, apoptosis inhibitory protein 6 
68870 Ak8 1.46 6.61E-03 adenylate kinase 8 
233046 Rasgrp4 1.45 4.58E-02 RAS guanyl releasing protein 4 
544963 Iqgap2 1.45 1.44E-03 IQ motif containing GTPase activating protein 2 
15163 Hcls1 1.45 9.46E-03 hematopoietic cell specific Lyn substrate 1 
71607 Snx20 1.45 2.22E-02 sorting nexin 20 
16633 Klra2 1.44 2.56E-04 killer cell lectin-like receptor, subfamily A, member 2 
16411 Itgax 1.44 8.03E-04 integrin alpha X 
102595 Plekho2 1.44 9.51E-04 pleckstrin homology domain containing, family O member 2 
330177 Taok3 1.43 1.23E-03 TAO kinase 3 
16194 Il6ra 1.43 1.29E-02 interleukin 6 receptor, alpha 
101202 Hepacam2 1.43 1.25E-02 HEPACAM family member 2 
21934 Tnfrsf11a 1.43 1.52E-02 tumor necrosis factor receptor superfamily, member 11a 
11867 Arpc1b 1.43 7.38E-03 actin related protein 2/3 complex, subunit 1B 
14269 Fnbp1 1.42 3.89E-02 formin binding protein 1 
56193 Plek 1.42 6.61E-03 pleckstrin 
23880 Fyb 1.42 1.28E-03 FYN binding protein 
21803 Tgfb1 1.41 1.72E-02 transforming growth factor, beta 1 
17095 Lyl1 1.41 2.29E-02 lymphoblastomic leukemia 1 
29875 Iqgap1 1.41 4.71E-04 IQ motif containing GTPase activating protein 1 
108686 Ccdc88a 1.41 4.74E-02 coiled coil domain containing 88A 
57442 Kcne3 1.41 4.70E-03 potassium voltage-gated channel, Isk-related subfamily, gene 3 
114644 Slc13a3 1.41 1.27E-02 solute carrier family 13 (sodium-dependent dicarboxylate transporter), 
member 3 
242248 Bank1 1.41 1.26E-02 B cell scaffold protein with ankyrin repeats 1 
380732 Milr1 1.41 4.54E-02 mast cell immunoglobulin like receptor 1 
214854 Neurl3 1.41 1.16E-02 neuralized homolog 3 homolog (Drosophila) 
19241 Tmsb4x 1.40 5.14E-04 thymosin, beta 4, X chromosome 
383619 Aim2 1.40 4.13E-03 absent in melanoma 2 
16535 Kcnq1 1.40 4.39E-02 potassium voltage-gated channel, subfamily Q, member 1 
100182 Akna 1.40 1.94E-03 AT-hook transcription factor 
72054 Cyp4f18 1.40 1.16E-02 cytochrome P450, family 4, subfamily f, polypeptide 18 
18106 Cd244 1.39 4.31E-03 CD244 natural killer cell receptor 2B4 
11513 Adcy7 1.39 6.06E-03 adenylate cyclase 7 
233571 P2ry6 1.38 2.75E-02 pyrimidinergic receptor P2Y, G-protein coupled, 6 
20868 Stk10 1.38 2.63E-02 serine/threonine kinase 10 
54354 Rassf5 1.38 3.11E-02 Ras association (RalGDS/AF-6) domain family member 5 
226421 RIKEN 1.38 5.08E-03 RIKEN cDNA 5430435G22 gene 
12331 Cap1 1.38 7.96E-04 CAP, adenylate cyclase-associated protein 1 (yeast) 
11630 Aim1 1.37 2.29E-02 absent in melanoma 1 
233406 Prc1 1.37 1.32E-02 protein regulator of cytokinesis 1 
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56356 Gltp 1.37 8.46E-04 glycolipid transfer protein 
12193 Zfp36l2 1.37 1.38E-02 zinc finger protein 36, C3H type-like 2 
22376 Was 1.37 1.00E-03 Wiskott-Aldrich syndrome homolog (human) 
23790 Coro1c 1.37 2.74E-04 coronin, actin binding protein 1C 
57257 Vav3 1.36 4.48E-03 vav 3 oncogene 
74735 Trim14 1.36 1.41E-02 tripartite motif-containing 14 
13860 Eps8 1.36 5.27E-03 epidermal growth factor receptor pathway substrate 8 
215632 Psd4 1.36 5.09E-02 pleckstrin and Sec7 domain containing 4 
226101 Myof 1.35 2.20E-02 myoferlin 
12798 Cnn2 1.34 6.53E-03 calponin 2 
66494 Prelid1 1.34 3.43E-02 PRELI domain containing 1 
107766 Haao 1.34 1.27E-02 3-hydroxyanthranilate 3,4-dioxygenase 
223753 Cerk 1.34 4.07E-02 ceramide kinase 
17972 Ncf4 1.34 4.67E-02 neutrophil cytosolic factor 4 
56318 Acpp 1.34 4.78E-02 acid phosphatase, prostate 
217203 Tmem106a 1.33 2.75E-02 transmembrane protein 106A 
11461 Actb 1.32 7.13E-04 actin, beta 
328660 Bex6 1.31 4.49E-02 brain expressed gene 6 
12442 Ccnb2 1.31 3.59E-02 cyclin B2 
12259 C1qa 1.31 4.93E-02 complement component 1, q subcomponent, alpha polypeptide 
241197 Serpinb10 1.31 3.88E-02 serine (or cysteine) peptidase inhibitor, clade B (ovalbumin), member 
10 
71279 Slc29a3 1.29 8.22E-03 solute carrier family 29 (nucleoside transporters), member 3 
16889 Lipa 1.28 3.89E-02 lysosomal acid lipase A 
13710 Elf3 1.28 9.88E-03 E74-like factor 3 
110835 Chrna5 1.28 3.10E-02 cholinergic receptor, nicotinic, alpha polypeptide 5 
16643 Klrd1 1.27 2.97E-02 killer cell lectin-like receptor, subfamily D, member 1 
330460 Tmem150b 1.27 4.44E-02 transmembrane protein 150B 
223666 Arhgap39 1.27 4.00E-02 Rho GTPase activating protein 39 
12489 Cd33 1.27 2.80E-02 CD33 antigen 
244209 Cyp2r1 1.26 3.06E-02 cytochrome P450, family 2, subfamily r, polypeptide 1 
238377 Gpr68 1.25 3.64E-02 G protein-coupled receptor 68 
12306 Anxa2 1.24 2.38E-02 annexin A2 
18438 P2rx4 1.23 2.75E-02 purinergic receptor P2X, ligand-gated ion channel 4 
68598 Dnajc8 -1.23 2.29E-02 DnaJ (Hsp40) homolog, subfamily C, member 8 
381816 RIKEN -1.23 3.48E-02 RIKEN cDNA 4922502D21 gene 
11529 Adh7 -1.24 4.66E-02 alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide 
70385 Spdl1 -1.25 2.12E-02 spindle apparatus coiled-coil protein 1 
213006 Mfsd4 -1.27 3.44E-02 major facilitator superfamily domain containing 4 
244329 Mcph1 -1.27 4.33E-02 microcephaly, primary autosomal recessive 1 
105083 Pelo -1.28 3.79E-02 pelota homolog (Drosophila) 
67390 Rnmtl1 -1.29 2.73E-02 RNA methyltransferase like 1 
12971 Crym -1.31 2.13E-02 crystallin, mu 
52653 Nudcd2 -1.33 4.82E-02 NudC domain containing 2 
74096 Hvcn1 -1.34 2.86E-02 hydrogen voltage-gated channel 1 
242519 Ifna12 -1.37 1.97E-02 interferon alpha 12 
17300 Foxc1 -1.38 2.29E-02 forkhead box C1 
18782 Pla2g2d -1.53 2.52E-02 phospholipase A2, group IID 
114332 Lyve1 -1.68 1.01E-02 lymphatic vessel endothelial hyaluronan receptor 1 
276891 Timd4 -1.74 7.08E-04 T cell immunoglobulin and mucin domain containing 4 
14276 Folr2 -1.82 1.65E-02 folate receptor 2 (fetal) 
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The importance of lipids to the sustenance of life cannot be over-emphasized. Lipids are 
a diverse group of biomolecules with different physiological effects. While some forms 
of lipids carry health and therapeutic benefits, others have been suggested to contribute 
to cardiometabolic diseases such as hyperlipidaemia, insulin resistance, non-alcoholic 
fatty liver disease (NAFLD), diabetes, and coronary heart disease. How different types 
of lipids influence the risk of these diseases has been poorly characterized. Accordingly, 
there is need for a deeper understanding of the molecular mechanisms regulating lipid 
metabolism.  
The general objective of this thesis was to investigate the regulation of cellular lipid 
metabolism by trans fatty acids and the lipid-sensitive ANGPTL4 protein. The first aim 
was to investigate the cellular and molecular mechanisms that underlie the deleterious 
effects of trans fatty acids on cardiometabolic health using animal and cell culture 
models. The second aim was to further characterize the role of ANGPTL4 in lipid 
metabolism, again using animal and cell culture models. Lastly, this thesis examined the 
effects of muscle-specific inflammation on systemic insulin sensitivity in mice.   
The major outcomes of this thesis are that: 
 In Chapter 2, we provide an overview of the literature on the molecular effects 
of trans fatty acids. 
 In Chapter 3, we show that a diet enriched in industrial trans fatty acids 
promotes non-alcoholic fatty liver disease in mice. We also show that the 
industrial trans fatty acid elaidic acid induces cholesterol synthesis by 
activating the SREBP signalling pathway. 
 In Chapter 4, we demonstrate that ANGPTL4-deficient mice respond more 
favourably to a diet rich in trans fatty acids than to a diet rich in saturated fatty 
acids. Furthermore, we show that saturated fatty acids but not trans fatty acids 
induce inflammation and ER stress in murine macrophages. 
 In Chapter 5, using ANGPTL4-hypomorphic mice, we show that a low level 
of expression of N-terminal ANGPTL4 reduces but does not fully prevent the 
rise in plasma acute phase proteins and the development of chylous ascites 
upon high fat feeding. We also show that ANGPTL4 limits lipid uptake and 
subsequent formation of foam cells in macrophages. 
 In Chapter 6, we show that skeletal muscle-specific inflammation via over-
expression of the chemokine MCP-1 does not affect systemic insulin 
sensitivity in mice. 
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Industrial trans fatty acids and cardiometabolic disorders 
Epidemiological studies have found a positive association between markers of trans fatty 
acid intake and the development of NAFLD [1,2]. In chapter 3 of this thesis, we find that 
a high fat diet enriched in industrial trans fatty acid diet promotes NAFLD in mice. 
Specifically, we found that feeding C57Bl/6 wild-type mice a diet enriched in industrial 
trans fatty acids promoted liver steatosis and fibrosis along with an increase in liver 
damage, inflammation and hepatic content of triglycerides and cholesterol, in 
comparison to diets enriched with saturated or cis-unsaturated fatty acids. In agreement 
with our study outcome, similar studies have shown that feeding mice diets enriched 
with industrial trans fatty acids enhances non-alcoholic steatohepatitis (NASH) [3–6]. 
Hence, both epidemiological studies and studies in mice suggest a stimulatory effect of 
industrial trans fatty acids on the development of NAFLD. 
In addition to NALFD, human studies have also shown a positive association between 
the intake of industrial trans fatty acids and the development of coronary artery disease 
[7–10]. This association is likely due to an increase in total and LDL cholesterol and a 
decrease in HDL cholesterol following intake of foods rich in industrial trans fatty acids 
[11–13]. In our mice study, we did not see any differences in plasma levels of total 
cholesterol between the mice fed the various diets. The lack of difference in plasma 
cholesterol between the various diets may be related to the fact that lipoprotein 
metabolism is rather different between mice and humans. 
In wild-type mice, cholesterol is contained mainly in anti-atherosclerotic HDL, whereas 
in humans, most of the cholesterol is carried by the pro-atherosclerotic LDL [14]. The 
difference in lipoprotein metabolism between mice and humans partly stems from the 
lack of the cholesteryl-ester transfer protein (CETP) in mice [15,16]. CETP transfers 
cholesterol ester from HDL to apoB-containing lipoprotein particles such as VLDL and 
LDL [16], and has been implicated in the development of atherosclerosis in humans [17–
19]. Additionally, humans and mice have differences in their lipoproteome [20]. As a 
result, wild-type mice do not develop spontaneous atherosclerosis, unlike humans. To 
overcome this limitation, so-called “humanized” mice models have been developed, 
including ApoE-deficient, LDLr-deficient and APOE*3-Leiden.CETP mice. These mice 
have similar lipoprotein profiles as humans and develop spontaneous atherosclerosis, 
making them attractive models to study the molecular mechanisms involved in the 
development of atherosclerosis, as well as the influence of specific drugs or dietary 
factors on atherosclerosis [21–23]. Indeed, few studies in LDLr-knockout mice have 
shown that industrial trans fatty acids increase atherosclerotic plaque formation in the 
aorta, along with increased plasma levels of total and LDL cholesterol [24], and oxidised 
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LDL cholesterol [25]. As indicated above, the absence of an effect of the trans fatty acid 
diet on plasma cholesterol in our study is likely due to the use of regular C57Bl/6 wild-
type mice, which contrasts with the reported effects of industrial trans fatty acids on 
levels of plasma lipoproteins in humans [26]. 
Interestingly, several studies have reported a positive association between NAFLD and 
coronary artery disease [27–29]. Currently, however, there is no consensus on a causal 
relationship between NAFLD and cardiovascular diseases [30,31]. This is largely 
because NAFLD often co-exists with several other abnormalities such as dyslipidaemia, 
insulin resistance, and type 2 diabetes, which confounds the association between 
NAFLD and cardiovascular diseases [32,33]. As indicated above, there is compelling 
evidence that intake of industrial trans fatty acids promotes NAFLD. Accordingly, it can 
be speculated that NAFLD may be involved in mediating the positive association 
between intake of trans fatty acids and coronary artery disease. 
Molecular effects between industrial and natural trans fatty acids 
Trans fatty acids can be divided into two main groups; industrial trans fatty acids and 
natural trans fatty acids. Industrial trans fatty acids are produced artificially by partial 
hydrogenation of vegetable oils and are contained in snacks and fast food products. 
Natural trans fatty acids are produced in the gut of ruminant animals by bacterial 
fermentation of non-degradable fibres and are contained in meat and dairy products [34].  
The concentration of trans fatty acids in industrially produced partially hydrogenated 
vegetable oil can be as high as 60%, with elaidic acid (t18:1n-9) taking up the highest 
proportion. Meanwhile, the maximum content of trans fatty acids in ruminant fat is 
approximately 6%. Important natural trans fatty acids include trans vaccenic acid 
(t18:1n-11), palmitelaidic acid, and the conjugated linoleic acids (CLAs) [35–38]. 
There is an ongoing debate as to whether industrially produced and naturally produced 
trans fatty acids exert the same effects on cardiovascular health. A couple of human 
studies have reported that the harmful effects of trans fatty acids is exclusive to industrial 
trans fatty acids [34,35,39], whereas natural trans fatty acids are reported to be innocuous 
or even beneficial to cardiovascular health [40–42]. In contrast, other epidemiological 
and clinical studies have reported that natural trans fatty acids are equally culpable as 
industrial trans fatty acids in promoting cardiovascular diseases [43–46]. 
As part of this thesis, we investigated the molecular effects of industrial and natural trans 
fatty acids in cell culture experiments to gain mechanistic understanding between these 
groups of trans fatty acids. In Chapter 4, we showed that compared to untreated controls, 
elaidic acid did not significantly stimulate inflammatory markers nor ER stress markers 
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in RAW264.7 macrophages. In order to determine if the effect of elaidic acid was 
representative of a broad group of other trans fatty acids, we tested several other natural 
trans fatty acids. Similar to the elaidic acid effect, trans vaccenic acid, palmitelaidic acid, 
CLA 9Z,11E and CLA 10E,12Z did not significantly induce expression of inflammatory 
and ER stress markers in RAW264.7 cells. This result supports the argument that 
industrial and natural trans fatty acids have similar molecular and cellular effects, at least 
with respect to their effects on ER stress and inflammation. However, in RAW264.7 
macrophages, elaidic acid promoted the expression of genes involved in cholesterol 
biosynthesis. In Chapter 3, we explored this effect in detail and observed that elaidic acid 
is cholesterogenic partly because of its ability to stimulate the SREBP/SCAP signalling 
pathway. Besides increasing the mRNA expression of Srebp2, elaidic acid lowered the 
levels of intracellular cholesterol and decreased the sensitivity of SCAP to cholesterol. 
These effects likely underlie the cholesterogenic effects of elaidic acid. Here also, we 
compared the effects of elaidic acid to natural trans fatty acids. However, the 
cholesterogenic effects of elaidic acid was not recapitulated by any of the natural trans 
fatty acids such as trans-vaccenic acid, palmitelaidic acid, CLA 9Z,11E and CLA 
10E,12Z. This result supports the claim that industrial and natural trans fatty acids have 
different molecular and cellular effects. 
In conclusion, the outcome of this thesis demonstrates that whereas industrial and  
natural trans fatty acids share similar molecular effects on ER stress and inflammation, 
these two types of trans fatty acids have different effects on cholesterogenesis. 
Molecular effects between trans-unsaturated and saturated fatty acids 
Saturated and trans-unsaturated fatty acids share common physicochemical properties. 
The presence of a trans double bond in fatty acids generates a straight chain tertiary 
structure similar to saturated fatty acids [47,48]. Additionally, trans-unsaturated and 
saturated fatty acids have relatively high melting temperatures that make them solid at 
room temperature [49]. Beyond these physicochemical similarities, diets that are high in 
saturated and trans-unsaturated fatty acids have been reported to negatively alter plasma 
lipoprotein profiles in humans, characterised by increased levels of total and LDL 
cholesterol, which is predicted to promote atherosclerosis and coronary artery disease 
[11,50]. Based on these considerations, saturated and trans-unsaturated fatty acids are 
predicted to have similar effects at the cellular and molecular level. 
The studies contained in Chapters 3 and 4 of this thesis highlight the molecular effects 
of saturated and trans-unsaturated fatty acids and demonstrate that these two types of 
fatty acids potentially trigger different molecular processes to achieve their 
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pathophysiological effects. In Chapter 3, we show in wild-type C57Bl/6 mice that a diet 
rich in industrial trans-unsaturated fatty acids from partially hydrogenated soy oil 
promotes NAFLD to a greater extent than a diet rich in saturated fatty acids from cocoa 
butter. At the cellular level, elaidic acid but not palmitic acid strongly induced 
cholesterogenesis in murine adipocyte and hepatocyte cell lines. In Chapter 4, Angptl4-/- 
mice were used to investigate the pro-inflammatory effects of different types of dietary 
fatty acids. Due to its high sensitivity, Angptl4-/- mice are an excellent model to 
investigate the presumably subtle differences between trans-unsaturated and saturated 
fatty acids. However, against our expectations, and contrary to the reported harmfulness 
of industrial trans fatty acids, Angptl4-/- mice survived 7 weeks of feeding the diet 
enriched in trans fatty acids, whereas 75% of the mice (6 out of 8 mice) fed the diet 
enriched in saturated fatty acids became severely ill and died of deleterious pro-
inflammatory complications. Complementary in vitro experiments in RAW264.7 
macrophages showed that palmitic acid strongly induced ER stress and inflammation, 
whereas elaidic acid did not. It is important to reiterate that the effects of all other trans 
fatty acids on ER stress and inflammation were similar to elaidic acid, while the effect 
of all other saturated fatty acids on ER stress and inflammation were similar to palmitic 
acid. In conclusion, although trans fatty acids and saturated fatty acids share a similar 
structure and are believed to have similar effects, the studies in wild-type and Angptl4-/- 
mice and the in vitro experiments revealed pronounced differences between saturated 
and trans fatty acids. 
Molecular effects between trans- and cis-unsaturated fatty acids 
The hydrogenation process that converts PUFAs into trans fatty acids not only leads to 
differences in physical and structural properties between the cis and trans isomers but 
also results in profound differences in physiological effects. A number of studies have 
shown opposing effects between trans and cis-unsaturated fatty acids. In simple terms, 
cis-unsaturated fatty acids are generally beneficial to health, whereas trans-unsaturated 
fatty acids are generally harmful. In humans, cis-unsaturated fatty acid diets have been 
shown to reduce levels of total and LDL-cholesterol, whilst trans-unsaturated fatty acids 
increase total and LDL-cholesterol [11,50–53]. In a mice study in LDL-receptor 
knockout mice, a diet containing trans-unsaturated fatty acids increased atherosclerosis 
development and plaque formation in aorta, whereas a diet containing cis-unsaturated 
fatty acids showed a protective effect [24]. 
In Chapter 3 of this thesis, we showed that feeding C57Bl/6 mice a diet rich in industrial 
trans-unsaturated fatty acids leads to more pronounced NAFLD as compared to a diet 
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rich in cis-unsaturated fatty acids. Using cell culture experiments, we further 
demonstrated that elaidic acid is cholesterogenic due to enhanced expression and activity 
of SREBP2 in murine Hepa1-6 cells. In contrast, oleic acid suppressed expression and 
activity of SREBP2, leading to strong downregulation of cholesterogenic genes. We 
recapitulated the differential effects of oleic and elaidic acids in other cells, including 
murine 3T3-L1 adipocytes and human hepatoma Huh7 cells. Our study corroborates 
earlier findings from studies in human HepG2 [54] and Huh7 [55] cells, showing 
prominent induction of cholesterogenesis by elaidic acid, whereas oleic acid had the 
opposite effect. In Chapter 4 of this thesis, we also showed that the diet enriched with 
trans-unsaturated fatty acids resulted in formation of giant Touton foam cells in 
mesenteric lymph nodes of Angptl4-/- mice, whereas the diet enriched in cis-unsaturated 
fatty acid did not. In deciphering the mechanistic insights, we demonstrated in 
RAW264.7 macrophages that compared to oleic acid, elaidic acid modestly induced 
inflammation and ER stress.  
In our in vitro studies, oleic acid and elaidic acid served as model cis- and trans-
unsaturated fatty acids, respectively, because they each represent the most abundant fatty 
acid in their respective groups. Oleic and elaidic acid are 9-octadecenoic acid isomers 
that differ only by the geometric isomerisation at carbon 9 of their fatty acyl chain [56]. 
However, the geometric isomerisation confers structural differences between these fatty 
acids, with oleic acid having a bent and flexible structure, whilst elaidic acid is straighter 
and rigid [48]. Apparently, this seemingly small structural difference greatly impacts the 
extent to which these fatty acids are sensed and metabolised, leading to important 
physiological differences. A number of studies have shown that in comparison to the cis 
isoforms, incorporation of trans fatty acids into cell membranes alters the membrane 
composition, leading to a pro-inflammatory response and a dysfunction to endothelial 
cells [57–59]. Till date, it is still unclear how the cis-trans configuration and the 
accompanying structural differences affect their metabolism. It is not unimaginable that 
the cis-trans configuration influences the extent to which these fatty acids can be 
assembled into triglycerides or hydrolysed into free fatty acids when contained in 
triglyceride-rich lipoprotein. The structural differences conferred by the cis-trans 
configuration could impact the efficiency by which enzymes such as lipoprotein lipase 
access and hydrolyse circulating triglycerides enriched in either cis- or trans-unsaturated 
fatty acids. Indeed, it has been reported that the cholesterol-ester synthesizing enzyme, 
acyl coenzyme A:cholesterol-O-acyltransferase (ACAT) discriminates strongly between 
cis- and trans-unsaturated fatty acids in the formation of cholesterol esters, with a 
preference for cis-unsaturated fatty acids [60]. 
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Mesenteric lymphadenopathy is uncoupled from acute inflammation and 
chylous ascites in Angptl4-/- mice 
ANGPTL4 inactivation is clinically beneficial since carrier status of ANGPTL4-
inactivation mutation is associated with reduced levels of circulating triglycerides and 
decreased risks of coronary artery disease [61,62]. We have previously shown that 
Angptl4-/- mice that were fed a high fat diet enriched with saturated fatty acids develop 
severe pathological complications that ultimately lead to the death of the animals [63]. 
The high saturated fat diet generates chylomicron particles which are secreted through 
the lymphatic system before onward secretion into the blood. The lymphatic system 
contains mesenteric lymph nodes that are rich in resident macrophages that express 
relatively high amounts of both Lpl and Angptl4  [64–66]. Due to deficiency of 
ANGPTL4, the macrophage LPL activity is unhindered, leading to increased hydrolysis 
of the triglyceride content of the chylomicron particles. It is believed that the resulting 
free saturated fatty acids are taken up by the macrophages, resulting in the formation of 
foam cells that aggregate into a ring-like structure called Touton giant cells. These 
activated macrophages secrete cytokines that stimulate a pro-inflammatory phenotype 
through the portal circulation. In response, the liver secretes acute phase markers, 
including serum amyloid A, haptoglobin and lipocalin. Eventually, chylous ascites and 
fibrinopurulent peritonitis ensue, that ultimately caused the death of the mice. In our 
original publication, the formation of Touton giant cells in the mesenteric lymph nodes 
was presented as the likely initiator of the pro-inflammatory complications in Angptl4-/- 
mice [63].  
In Chapter 4, we showed that Angptl4-/-mice fed a diet rich in industrial trans fatty acids 
from partially hydrogenated soy oil develop Touton giant cells in mesenteric lymph 
nodes to a similar extent as the Angptl4-/- mice fed the saturated fat diet. However, 
contrary to the saturated fat diet, the trans fat diet did not result in subsequent activation 
of the acute phase response or chylous ascites, and all the mice survived. Therefore, one 
major outcome of this thesis is that lymphadenopathy in Angptl4-/- mice can be 
uncoupled from the lethal effects of fibrinopurulent peritonitis and ascites development. 
This study also affirms that the development of lethal phenotypes in Angptl4-/- mice is 
diet-dependent. The differential effect between the trans and saturated fat diets in vivo 
was partly explained by in vitro experiments. Specifically, palmitic acid and other 
saturated fatty acids induced a pro-inflammatory phenotype in RAW264.7 macrophages, 
whereas elaidic acid and other trans-unsaturated fatty acids did not. This suggests that in 
addition to formation of foam cells, the pro-inflammatory property of the constituent 
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fatty acids in the mice diets was important in activating the inflammatory cascade in the 
Angptl4-/- mice.  
Even though we learned that mere formation of foam cells in the mesenteric lymph nodes 
is not enough to activate the pro-inflammatory complications, it is still unclear why the 
cis-unsaturated fat diet does not lead to formation of Touton giant cells. A possible 
explanation is that LPL active on the surface of Angptl4-deficient macrophages had 
different affinities for triglycerides containing different fatty acids. Alternatively, the 
lipid storage may not only require the provision of substrate but also the presence of a 
pro-inflammatory stimulus. Saturated fatty acids may carry both properties, while cis-
unsaturated fatty acids may only serve as substrate. Another possibility is that different 
fatty acids are differentially taken up by the mesenteric lymph node macrophages.  
In conclusion, in light of a clinical study that showed that loss-of-function mutations in 
ANGPTL4 are seemingly not associated with lymphadenopathies in humans [62], our 
pre-clinical study suggests that lymphadenopathy could be benign and clinically silent, 
and therefore downgrades the relevance of this potential side effect of ANGPTL4 
inactivation. This observation increases the therapeutic prospect of targeting ANGPTL4 
for correcting cardiometabolic abnormalities. Moreover, it can be hypothesized that 
individuals who will benefit from therapeutic targeting of ANGPTL4 could potentially 
further reduce the risk of side effects by cutting down the intake of foods rich in saturated 
fatty acids in favour of foods rich in cis-unsaturated fatty acids. 
Clinical relevance of ANGPTL4 based on study in Angptl4-hypomorphic mice 
As highlighted earlier, ANGPTL4 inactivation reduces circulating levels of triglycerides 
primarily due to enhanced LPL activity, and this is associated with decreased odds of 
developing coronary artery disease. However, as discussed above, pre-clinical studies in 
mice revealed damning and ultimately lethal side-effects in whole body Angptl4-/- mice 
fed a high fat diet enriched with saturated fatty acids. This observation hampers the 
putative prospects of ANGPTL4 targeting in humans. 
In Chapter 5, we make use of Angptl4-hypomorphic mice to further characterize the 
clinical importance of ANGPTL4. The Angptl4-hypomorphs are characterised by the 
complete deletion of the C-terminal domain of ANGPTL4, and a partial expression of 
the N-terminal LPL-inhibiting domain. Compared to wild-type mice, the hypomorphs 
showed a similar reduction in plasma triglycerides as the whole body Angptl4-/- mice 
after a 24-hour fast and after 20 weeks of high saturated fat diet. Additionally, the 
hypomorphs exhibited greater resistance to a chronic high saturated fat diet by surviving 
over 36 weeks of feeding, while the Angptl4-/- mice developed pro-inflammatory 
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complications and died over the course of the intervention. Only about 12% of the 
Angptl4-hypomorphic mice developed chylous ascites, which is markedly lower than the 
80% in the Angptl4-/- mice. Additionally, acute inflammation was significantly lower and 
delayed in the Angptl4-hypomorphs compared to the Angptl4-/- mice. However, both the 
hypomorphs and the Angptl4-/- mice showed similar levels of Touton giant cell formation 
in their mesenteric lymph nodes. Since therapeutic targeting of ANGPTL4 will likely 
reduce instead of completely inactivate ANGPTL4, our hypomorphic model and the 
outcome of this study are closely applicable to the clinical situation in human. 
A number of inferences can be drawn from this study. First, we re-affirm that the 
formation of Touton giant cells can be uncoupled from fibrinopurulent peritonitis and 
chylous ascites. We also re-affirm that Touton giant cell formation in mesenteric lymph 
node macrophages is seemingly benign with little to no clinical impact. Secondly, we 
demonstrate that clinical targeting of ANGPTL4 with minimal side-effects could 
potentially be achieved by employing conservative approaches that partially repress 
instead of completely inactivate ANGPTL4. The modest side-effects in the Angptl4-
hypomorphs suggests that cardiovascular disease patients who will benefit from 
ANGPTL4 targeting should have first exhausted other clinical treatments with 
potentially less side-effects. Our findings in the Angptl4-hypomorphs also indicate that 
the therapeutic potential of ANGPTL4 targeting can be further fine-tuned to amplify its 
benefits and downsize its side-effects. This will require a collaborative effort between 
pre-clinical and clinical studies. 
Role of ANGPTL4 in glucose homeostasis and type-2-diabetes 
Recently, several studies have implicated ANGPTL4 in systemic glucose homeostasis 
and type-2-diabetes. This is not surprising, given that ANGPTL4 is involved in 
dyslipidaemia, and dyslipidaemia has been positively associated with dysregulated 
glucose metabolism and incidence of type-2-diabetes [67,68]. Two recent studies have 
reported that plasma levels of ANGPTL4 are increased in type 2 diabetics [69,70] whilst 
another study showed that carriers of the E40K loss-of-function mutation in ANGPTL4 
have lower odds of developing type 2 diabetes [71]. Using mice models, Gusarova and 
Janssen have demonstrated in separate studies that Angptl4-/- mice have lower levels of 
plasma glucose and improved tolerance compared to wild-type mice [71,72]. In chapter 
5 of this thesis, we showed that plasma levels of glucose were significantly lower in 
Angptl4-/- mice compared to wild-type mice after 24 hours of fasting or 20 weeks of high 
fat diet. We also demonstrated by an intra-peritoneal glucose tolerance test that Angptl4-
/- mice were more glucose tolerant compared to wild-type mice, while the Angptl4-
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hyopmorphs showed intermediate glucose tolerance between the Angptl4-/- and wild-type 
mice. Although these reports support additional therapeutic benefits of ANGPTL4 
inactivation, the mechanism by which ANGPTL4 affects glucose homeostasis is unclear. 
It is possible that the effect of ANGPTL4 on glucose homeostasis is indirect and 
secondary to its effect on lipid metabolism. This is likely because the inactivation of 
ANGPTL4 corrects dyslipidaemia, leading to a more efficient glucose utilisation. 
However, we cannot rule out the possibility of a direct effect of ANGPTL4 on glucose 
metabolism. Therefore, further studies will be required to provide mechanistic insights 
on how ANGPTL4 affects glucose metabolism. 
Skeletal muscle inflammation and systemic insulin insensitivity 
Insulin sensitivity is central to diabetes. Accordingly, a detailed understanding of cellular 
processes that promote insulin insensitivity is vital to enable the identification of 
molecular targets against diabetes. In light of evidences that inflammatory cytokines 
interfere with insulin signalling to promote insulin resistance [73,74], the objective of 
Chapter 6 of this thesis was to investigate the extent to which skeletal muscle 
inflammation promotes insulin resistance. Using mice that over-express MCP-1 in the 
skeletal muscle, we demonstrated that skeletal muscle inflammation did not have an 
effect on systemic insulin sensitivity in both lean and diet induced obese mice. As 
discussed in Chapter 6, one of the explanations for the differences in tissue-specific 
inflammatory effect of MCP-1 is glycosylation status of the MCP-1 protein. 
Additionally, previous studies have shown that adipose-tissue specific inflammation via 
MCP-1 overexpression reduces whole-body insulin sensitivity and impairs insulin-
signalling in skeletal muscle of mice [75,76], suggesting that the global effect of 
inflammation on systemic insulin sensitivity may be tissue dependent. However, due to 
the important role of skeletal muscles in glucose disposal in the post-prandial state, the 
outcome of our study is unexpected and challenges the over-emphasized role of 
inflammation in systemic glucose homeostasis. Because inflammation is a component of 
the innate immune system, it is fundamental to many cellular and physiological events. 
For instance, increased levels of  IL-6 and MCP-1 occur in skeletal muscle and plasma 
during acute exercise [77], and also occurs during chronic low-grade inflammation in 
obesity [78]. However, existing evidence suggests that these two inflammatory situations 
can have different and even opposing effects on insulin sensitivity [79,80]. Therefore the 
implication of the “inflammatory hypothesis” as underlying factor of several 
pathological events must be carefully arrived at based on stronger and compelling 
evidence. 
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Conclusion 
In this thesis, we have extended our understanding of the molecular effects of trans-
unsaturated fatty acids. We demonstrated that compared to diets enriched with cis-
unsaturated and saturated fatty acids, diets rich in industrial trans fatty acids promote 
non-alcoholic fatty liver disease characterised by aggravated liver steatosis and fibrosis. 
At the molecular level, we showed that elaidic acid promotes cholesterogenesis by 
stimulating the SREBP signalling pathway, which was evident by induced expression of 
SREBP2 and target genes involved in cholesterol synthesis in a number of cell models 
including Hepa1-6, Huh7, 3T3-L1 and RAW264.7 cell lines. We also demonstrated that 
trans fatty acids have molecular effects that are distinct from saturated fatty acids even 
though these two types of fatty acids share similar physicochemical properties. 
Additionally, this thesis has demonstrated that in Angptl4-/- mice, enhanced LPL activity 
increases hydrolysis of triglyceride-rich lipoproteins leading to enhanced uptake of lipids 
by resident macrophages and a subsequent formation of foam cells in the mesenteric 
lymph nodes. These foam cells were formed in mice that were fed trans and saturated 
fatty acid diets, but not cis-unsaturated fatty acid diet. Intriguingly, whereas the 
formation of foam cells led to inflammation and death in the mice fed the saturated fat 
diet, there was no further repercussions pertaining to the foam cell formation in the mice 
fed the trans fat diet. Therefore, we conclude that the formation of foam cells in the 
mesenteric lymph nodes per se is inadequate to induce inflammation and death, but could 
be dependent on the properties of fatty acids that generate the foam cells. We have further 
shown in this thesis that Angptl4-hypomorphic mice characterised by reduced expression 
of N-terminal exons and complete absence of C-terminal exons of ANGPTL4 survive 
over 20 weeks of high saturated fat diets. The hypomorphic mice also showed  
significantly reduced and delayed forms of the lethal phenotypes exhibited in the 
Angptl4-/-  mice. The outcome of this study has implications for targeting ANGPTL4 as 
a measure to reduce the risk of coronary heart disease in humans.  
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Cardiovascular disorders are among the leading causes of death worldwide. Several 
factors contribute to the risks, onset and progression of cardiovascular diseases, 
including age, lifestyle, genetics and nutrition. In most instances, a complex 
interrelationship between two or more of such predisposing risk factors mediate 
cardiovascular diseases. In this thesis, we have investigated specific aspects of the 
nutritional and genetic factors, using animal and in vitro models. It is well known that a 
coordinated regulation of lipid metabolism is important in maintaining cardiometabolic 
health, since a dysregulation in lipid metabolism is implicated in hyperlipidaemia, 
insulin resistance, non-alcoholic fatty liver disease (NAFLD), diabetes mellitus and 
coronary artery disease. Therefore, the aim of this thesis was to investigate the regulation 
of lipid metabolism with specific focus on trans fatty acids and the lipid-sensitive 
angiopoietin-like 4 (ANGTPL4) protein. 
Epidemiological studies have shown a positive association between the intake of 
industrial trans fatty acids and cardiovascular diseases. Clinical studies have shown that 
industrial trans fatty acids perturb plasma lipoprotein metabolism by raising the levels 
of total and LDL cholesterol, and reducing the levels of HDL cholesterol. This abnormal 
lipoprotein profile is suggested to mediate the pro-atherogenicity of industrial trans fatty 
acids. However, only few studies have examined the molecular and cellular mechanisms 
that underlie the harmful effects of trans fatty acids. Chapter 2 of this thesis is a literature 
review of the studies that examined potential molecular mechanisms of trans fatty acids, 
mostly in animal and in vitro models. In summary, a number of these studies demonstrate 
that the harmful effects of trans fatty acids may lie in their negative effect on cellular 
pathways involved in cellular lipid metabolism, inflammation, autophagy, ER stress and 
oxidative stress. 
In Chapter 3, we showed that C57Bl/6 wild-type mice developed pronounced NAFLD 
after 7-weeks on a high fat diet enriched with industrial trans-unsaturated fatty acids 
from hydrogenated soy oil compared to mice fed on cis-unsaturated or saturated fatty 
acid diets from canola oil and cocoa butter respectively. NAFLD is a liver disease that 
progresses from a benign state of liver steatosis to non-alcoholic steatohepatitis which is 
characterised by increased liver inflammation. In the advanced stages of NAFLD, the 
liver becomes fibrotic leading to liver cirrhosis and hepatocellular carcinoma. In Chapter 
3, we showed that the trans-unsaturated fatty acid diet led to pronounced liver steatosis 
and fibrosis, increased hepatic inflammation and increased liver damage compared to the 
mice on the cis-unsaturated and saturated fatty acid diets. Also, in Chapter 3, in vitro 
studies in murine and human hepatocytes showed that the industrial trans fatty acid, 
elaidic acid is cholesterogenic. Compared to the cis-unsaturated oleic acid and the 
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saturated palmitic acid, elaidic acid increased the mRNA expression and activity of sterol 
regulatory element binding protein 2 (SREBP2), a transcriptional regulator of 
cholesterogenic genes. This resulted in an upregulation of important cholesterol-
synthesis genes including HMG-CoA reductase. This distinct anabolic property of 
elaidic acid is a potential contributing mediator to the negative effects of industrial trans 
fatty acids on cardiometabolic disorders.  
The second part of this thesis investigated the role of ANGPTL4 in lipid metabolism. 
ANGPTL4 is a ubiquitously expressed protein composed of an N-terminal coiled-coiled 
domain and a C-terminal fibrinogen-like domain. The N-terminal domain of ANGPTL4 
is an inhibitor of the extracellular lipase, lipoprotein lipase (LPL). Therefore, ANGPTL4 
indirectly elevates plasma triglycerides, which has been shown to be an independent risk 
factor for cardiovascular diseases. Clinical studies have shown that human carriers of 
ANGPTL4 variants have reduced odds of developing coronary artery disease. Therefore, 
ANGPTL4 inactivation is a therapeutic potential for correcting dyslipidaemia and 
associated cardiovascular diseases. However, we and others have shown that in response 
to high saturated fatty acid diet, Angptl4-/- mice develop lethal phenotypes characterised 
by formation of Touton giant cells in mesenteric lymph nodes, chylous ascites and 
peritonitis, that ultimately led to death. These deleterious phenotypes are potential side-
effects of ANGPTL4 inactivation that hamper the prospect of ANGPTL4 targeting. Due 
to the reported similarities between trans-unsaturated and saturated fatty acids, we 
hypothesized in Chapter 4 that Angptl4-/- mice will respond similarly to high fat diets 
enriched in either trans-unsaturated or saturated fatty acids. Contrary to our hypothesis, 
the Angptl4-/- mice on the saturated fat diet got severely ill and died, while the mice on 
the trans fat diet survived the intervention with no physical signs of ill-health. The 
saturated fat diet led to the formation of Touton giant cells, chylous ascites and acute 
inflammation as was previously observed, whereas the mice on the trans fat diet showed 
no signs of acute inflammation or peritonitis. However, the trans fat diet resulted in 
formation of Touton giant cells in the mesenteric lymph nodes to similar levels as the 
saturated fat diet. We had previously suggested that the formation of Touton giant cells 
is coupled to acute inflammation and chylous ascites. However, this observation in the 
trans fat fed Angptl4-/- mice led to an important finding and two conclusions: (1) the 
formation of Touton giant cells can be uncoupled from acute inflammation and chylous 
ascites and (2) mesenteric lymphadenopathy can be clinically silent. Complementary in 
vitro experiments in RAW264.7 macrophage-like cells showed induction in gene 
markers of inflammation and ER stress by palmitic acid but not elaidic acid, further 
revealing molecular differences between saturated and trans-unsaturated fatty acids.  
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In Chapter 5, we further investigated the clinical potential of targeting ANGPTL4 by 
using an Angptl4-hypomorphic mice model that had a complete deletion of the C-
terminal domain of ANGPTL4, and a partial expression of the N-terminal LPL-inhibiting 
domain. Compared to wild-type mice, the hypomorphs showed only about 30-50% 
mRNA expression of exons 1 to 3 which contains the N-terminal domain of ANGPTL4, 
leading to a truncated ANGPTL4 protein. We compared physiological response of the 
hypomorphs to Angptl4-/- and wild-type mice after 20-weeks of high fat diet and after 
24-hours of fasting. Both Angptl4-hypomorphic and Angptl4-/- mice showed similar 
levels of reduced plasma triglycerides in comparison to the wild-types after 24-hour fast 
or 20-weeks on high fat diet. While the high fat diet intervention expectedly resulted in 
pronounced formation of chylous ascites in about 85% of the Angptl4-/- mice, chylous 
ascites formed in appreciably lower volumes, and in only about 12% of the Angptl4-
hypomorphic mice. Additionally, there was delayed onset and significantly reduced 
acute inflammation in the Angptl4-hypomorphic mice compared to the Angptl4-/- mice. 
However, both the hypomorphs and the Angptl4-/- mice showed similar formation of 
lipid-laden Touton giant cells in mesenteric lymph nodes. These findings are of clinical 
importance, since therapeutic targeting will potentially reduce but not completely 
inactivate ANGPTL4. Also in Chapter 4, we showed that increased LPL activity due to 
ANGPTL4-deficiency in primary macrophages, promoted foam cell formation and 
induced the expression of gene markers of ER stress and inflammation after incubation 
of the ANGPTL4-deficient macrophages with triglyceride-rich lipid particles. 
 In Chapter 6, we explored the effect of muscle-specific inflammation on systemic 
insulin sensitivity in mice. Insulin insensitivity underlies diabetes mellitus. Previous 
studies showed that adipose tissue-specific inflammation promote systemic insulin 
resistance and generated abnormal glucose homeostasis. Due to the important role of 
skeletal muscle in glucose disposal in the post-prandial state, we hypothesized that 
skeletal muscle-inflammation will promote insulin resistance. Using a transgenic mice 
model that over-expressed the chemokine MCP-1 under the creatinine kinase promoter, 
we showed that muscle specific over-expression of Mcp-1 strongly induced local 
inflammation in the skeletal muscles in both lean and diet-induced obese mice. However, 
both lean and diet-induced obese mice showed no differences in systemic glucose and 
insulin sensitivity measured by an intraperitoneal glucose and insulin tolerance tests 
respectively. This led to the conclusion that skeletal-muscle inflammation via Mcp-1 
overexpression has no effect on systemic insulin sensitivity in mice. 
In conclusion, the studies performed in this thesis have increased our understanding of 
the molecular effects of trans fatty acids and the regulatory effects of ANGPTL4 in lipid 
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metabolism. We have demonstrated that an industrial trans fatty acid diet promotes 
NAFLD in mice. We have also shown that trans fatty acids have distinct physiological 
and molecular effects from saturated fatty acids. Based on in vitro studies, we have 
demonstrated that saturated fatty acids promote ER stress and inflammation whereas 
industrial trans fatty acids have a cholesterogenic property. Response by ANGPTL4-
deficient mice to trans fat diet has revealed that chylous ascites and acute inflammation 
can be uncoupled from mesenteric lymphadenopathy. And by characterizing the 
physiological response of an Angptl4-hypomorphic mice to high fat diet and fasting, we 
have demonstrated that potential side-effects of ANGPTL4 targeting could be reduced 
significantly but not completely by clinical strategies that will partially repress instead 
of strategies that will completely inactivate ANGPTL4.  
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